

**EUROPEAN
CENTRE FOR
GUIDELINES
DEVELOPMENT**



**European
Dermatology
Forum**



***EUROGUIDERM GUIDELINE FOR THE SYSTEMIC
TREATMENT OF PSORIASIS VULGARIS***

September 2023, revised version March 2024 *

A Nast, PI Spuls, C Dressler, Z Bata-Csörgö, I Bogdanov, H Boonen,
EMGJ De Jong, I Garcia-Doval, P Gisondi, D Kaur-Knudsen, S Mahil,
T Mälkönen, JT Maul, S Mburu, L Mercieca, U Mrowietz, A Pennitz,
E Remenyik, D Rigopoulos, PG Sator, M Schmitt-Egenolf, M Sikora, K Strömer,
O Sundnes, I Vader, G Van Der Kraaij, N Yawalkar, C Zeyen, C Smith.

* chapter on “Viral hepatitis” under re-review



Overview of changes

Chapter title	Last updated	Changes
General chapters		
Introduction, scoping, population and targeted users	09/2023	Editorial changes
Disease severity and treatment goals	09/2023	No changes
Methods and evidence section	09/2023	Editorial changes
Main Recommendations and Decision Grid	09/2023	Deucravacitinib was added
Implementation Slides	09/2023	New data added
IFPA Guideline	09/2023	Deucravacitinib was added
Drug chapters		
Acitretin	03/2023	No changes
Ciclosporin	03/2023	Reference added
Fumarates	03/2023	No changes
Methotrexate	03/2023	New data added
Adalimumab	03/2023	No changes
Apremilast	03/2023	New data added
Bimekizumab	09/2023	New data added
Brodalumab	09/2023	New data added
Certolizumab – pegol	09/2023	No changes
Deucravacitinib	03/2024	Editorial changes
Etanercept	03/2023	No changes
Guselkumab	03/2023	No changes
Infliximab	03/2023	No changes
Ixekizumab	09/2023	New data added
Risankizumab	09/2023	New data added
Secukinumab	09/2023	New data added
Tildrakizumab	03/2023	No changes
Ustekinumab	03/2023	No changes
Biosimilars	09/2023	New data added
Newly approved medications and treatments in the pipeline	10/2021	No changes
Specific clinical and comorbid situations		
Psoriatic arthritis	03/2023	New data added, recommendations changed
Inflammatory bowel disease	10/2021	Recommendation concerning bimekizumab added



Chapter title	Last updated	Changes
Cancer	09/2023	New data added
Depression	09/2023	New data added
Diabetes mellitus	09/2023	New data added, recommendations changed
Heart disease	03/2023	New data added
Kidney disease	03/2023	New data added
Neurological diseases	09/2023	New data added
Viral hepatitis	01/2024	Chapter under review
Tuberculosis: screening	09/2023	Editorial changes
Tuberculosis: management	09/2023	Editorial changes
Wish for child / pregnancy	10/2021	Time until pregnancy added for bimekizumab
Vaccinations	03/2023	Completely new written
Immunogenicity	10/2021	No changes

Overview of main recommendations (flow chart) and recommendations for specific treatment circumstances (decision grid I +II)




Figure 1: Overview of treatment options for plaque type psoriasis arranged by the label as approved by European Medical Agency.



Table 1: Overview of ‘conventional’ treatment options and the expert assessment of their suitability in specific treatment circumstances (decision grid I)

Therapy Specific circumstances	Conventional systemic agents			
	Acitretin	Ciclosporin	Fumarates	Methotrexate
Concomitant psoriatic arthritis				↑ first line peripheral active joint involvement
Chronic inflammatory bowel disease: Crohn's Disease	↑ especially cases with mild paradoxical psoriasis			↑ 2nd choice oral treatment
Chronic inflammatory bowel disease: Ulcerative colitis	↑ especially cases with mild paradoxical psoriasis	↑ 2nd choice oral treatment		
Diabetes mel./ metabolic syndrome		consider alternatives		consider alternatives
Dyslipidaemia	↓			
Advanced heart failure	↑	↓		↑
Heart Disease: Ischemic heart disease	↓			↑
Concomitant latent / treated TB	↑		↑	
Pregnancy	↓↓	↑ preferred conventional	↓	↓↓



Symbols	Implications ¹
↑↑	We believe that all or almost all informed people would make that choice.
↑	We believe that most informed people would make that choice, but a substantial number would not.
-	See background text and specific recommendations
↓	We believe that most informed people would make a choice against that intervention, but a substantial number would not.
↓↓	We believe that all or almost all informed people would make a choice against that choice.

¹ Adapted from GRADE



Table 2: Overview of treatment options with ‘biologics’ and ‘small molecules’ and the expert assessment of their suitability in specific treatment circumstances (decision grid II)

Therapy / Specific circumstances			TNF inhibitors				anti-IL12/23	anti-IL17				anti-IL23		
	Apremilast	Deucravacitinib	Etanercept	Infliximab	Adalimumab	Certolizumab	Ustekinumab	Secukinumab	Ixekizumab	Brodalumab	Bimekizumab	Guselkumab	Tildrakizumab	Risankizumab
Concomitant psoriatic arthritis	↑		↑↑								has been approved for PsA 06/23, evaluation pending	↑↑		↑↑
Chronic inflammatory bowel disease: Crohn's Disease				↑↑ 1st choice				↓				↑ 2nd choice if TNFi not suitable		
Chronic inflammatory bowel disease: Ulcerative colitis	↑ 2nd choice oral treatment			↑↑ 1st choice			↑↑ 1st choice	↓				↑ 2nd choice if TNFi not suitable		



Therapy / Specific circumstances	Apremilast / Deucravacitinib		TNF inhibitors				anti-IL12/23	anti-IL17				anti-IL23		
	Apremilast	Deucravacitinib	Etanercept	Infliximab	Adalimumab	Certolizumab	Ustekinumab	Secukinumab	Ixekizumab	Brodalumab	Bimekizumab	Guselkumab	Tildrakizumab	Risankizumab
Diabetes mel./ metabolic syndrome														
Dyslipidaemia														
Advanced heart failure	↑		↓↓					↑				↑		
Heart Disease: Ischemic heart disease							↑							
Concomitant latent / treated TB	↑		↓↓					↑				↑		
Pregnancy	↓	↓				↑ preferred choice biologic								



Symbols	Implications ¹
↑↑	We believe that all or almost all informed people would make that choice.
↑	We believe that most informed people would make that choice, but a substantial number would not.
	See background text and specific recommendations
↓	We believe that most informed people would make a choice against that intervention, but a substantial number would not.
↓↓	We believe that all or almost all informed people would make a choice against that choice.

¹ Adapted from GRADE



Members of the EuroGuiDerm Psoriasis guideline development group

Title	First name	Last name	Institution	Role
Prof.	Zsuzsanna	Bata-Csörgő	University of Szeged	Co-author
Prof.	Ivan	Bogdanov	Tokuda Hospital Sofia	Co-author
Dr.	Hugo	Boonen	Geel	Co-author
Prof.	Elke	de Jong	Radboud University	Co-author
Dr.	Ignacio	Garcia-Doval	Unidad de Investigación. Fundación Piel Sana AEDV	Co-author
Prof.	Paolo	Gisoni	University of Verona	Co-author
Dr.	Diljit	Kaur-Knudsen	University hospital Copenhagen	Co-author
Dr.	Satveer	Mahil	Guy's and St Thomas' NHS Foundation Trust, London, UK	Co-author
Dr.	Tarja	Mälkönen	Helsinki University Central Hospital	Co-author
Dr.	Julia-Tatjana	Maul	Department of Dermatology, University Hospital of Zürich	Co-author
	Sicily	Mburu	International Federation of Psoriasis Associations (IFPA); patient representative	Patient rep.
Dr.	Liam	Mercieca	Department of Dermatology at Mater Dei Hospital	Co-author
Prof.	Ulrich	Mrowietz	Universitätsklinikum Schleswig-Holstein	Co-author
Prof.	Alexander	Nast	Charité - Universitätsmedizin Berlin	Coordinator, co-authored chapters
Prof.	Kristian	Reich	Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf	Co-author until 2020
Prof.	Eva	Remenyik	University of Debrecen	Co-author
Prof.	Dimitris	Rigopoulos	University of Athens	Co-author
Dr.	Kirsten Marthine	Rønholt Stausholm	Aarhus University Hospital	Co-author until 2022
Dr.	Paul-Gunther	Sator	Municipal Hospital Hietzing, Vienna	Co-author
Prof.	Marcus	Schmitt-Egenolf	Umeå university	Co-author
Dr.	Mariusz	Sikora	Department of Dermatology, Medical University of Warsaw	Co-author
Prof.	Catherine	Smith	St John's Institute of Dermatology	Co-author
Prof.	Phyllis I.	Spuls	Academic Medical Centre Amsterdam	Co-author
Dr.	Klaus	Strömer	Mönchengladbach	Co-author
Dr.	Olav	Sundnes	Oslo University Hospital	Co-author
	David	Trigos	IFPA, patient representative	Patient rep. until 2022
	Gayle	van der Kraaij	Academic Medical Centre Amsterdam	Co-author
Prof.	Nikhil	Yawalkar	Inselspital Uni Bern	Co-author
	Gabriela	Avila Valle	Charité - Universitätsmedizin Berlin	Methodologist
	Martin	Dittmann	Charité - Universitätsmedizin Berlin	Team Support; Information Specialist
Dr.	Corinna	Dressler	Charité - Universitätsmedizin Berlin	Methodologist: GL development & Cochrane Review
Dr.	Maria	Kinberger	Charité - Universitätsmedizin Berlin	Methodologist



Title	First name	Last name	Institution	Role
	Antonia	Pennitz	Charité - Universitätsmedizin Berlin	Methodologist
	Isabell	Vader	Charité - Universitätsmedizin Berlin	Methodologist
	Christoph	Zeyen	Charité - Universitätsmedizin Berlin	Methodologist



Table of contents

I.	Notes on use/Disclaimer	18
II.	Accompanying documents:	19
III.	Funding	19
IV.	Scope and purpose of this guideline	19
V.	Population and health questions covered by the guideline	20
VI.	Targeted users of this guideline	21
VII.	Disease severity and treatment goals	25
	i. Measuring disease severity	25
	ii. Defining disease severity	25
	iii. Treatment goals	26
VIII.	Methods Section	29
IX.	Recommendations	43
	Initiation and selection of a systemic treatment	43
X.	Guideline text and recommendations	52
1.	Conventional systemic therapy	52
1.1.	Acitretin	52
	1.1.1. Instructions for use	52
	1.1.2. Recommendations for lab controls ^{18,36,37}	53
	1.1.3. Adverse drug reactions ^{38,39}	54
	1.1.4. Special consideration during treatment ⁴⁰	54
	1.1.5. Important contraindications ⁴¹	54
	1.1.6. Drug interactions ⁴²	55
1.2.	Ciclosporin	56
	1.2.1. Instructions for use ^{18,36}	56
	1.2.2. Recommendations for lab controls ^{18,36,37,43}	57
	1.2.3. Adverse drug reactions ³⁹	58
	1.2.4. Special consideration during treatment ⁴⁰	59
	1.2.5. Important contraindications ⁴⁴	60
	1.2.6. Drug interactions ^{41,42}	61
1.3.	Fumarates	63
	1.3.1. Instructions for use	63
	1.3.2. Recommendations for lab controls	64



1.3.3.	Adverse drug reactions.....	64
1.3.4.	Special consideration during treatment.....	65
1.3.5.	Important contraindications	65
1.3.6.	Drug interactions.....	65
1.4.	Methotrexate (MTX).....	66
1.4.1.	Instructions for use.....	66
1.4.2.	Recommendations for lab controls	67
1.4.3.	Adverse drug reactions.....	68
1.4.4.	Special consideration during treatment.....	68
1.4.5.	Important contraindications	69
1.4.6.	Drug interactions.....	70
2.	Biological therapy and small molecules	72
2.1.	Adalimumab	72
2.1.1.	Instructions for use.....	72
2.1.2.	Recommendations for lab controls	73
2.1.3.	Adverse drug reactions.....	74
2.1.4.	Special consideration during treatment.....	75
2.1.5.	Important contraindications	75
2.1.6.	Drug interactions.....	76
2.2.	Apremilast	77
2.2.1.	Instructions for use.....	77
2.2.2.	Recommendations for lab controls	78
2.2.3.	Adverse drug reactions ^{66,67}	78
2.2.4.	Special consideration during treatment.....	79
2.2.5.	Important contraindications	80
2.2.6.	Drug interactions.....	80
2.3.	Bimekizumab	81
2.3.1.	Instructions for use.....	81
2.3.2.	Recommendations for lab controls	82
2.3.3.	Adverse drug reactions.....	82
2.3.4.	Special consideration during treatment.....	84
2.3.5.	Important contraindications	84
2.3.6.	Drug interactions.....	84
2.4.	Brodalumab	85



2.4.1.	Instructions for use.....	85
2.4.2.	Recommendations for lab controls	86
2.4.3.	Adverse drug reactions.....	86
2.4.4.	Special consideration during treatment.....	88
2.4.5.	Important contraindications	89
2.4.6.	Drug interactions.....	89
2.5.	Certolizumab – pegol	90
2.5.1.	Instructions for use.....	90
2.5.2.	Recommendations for lab controls	91
2.5.3.	Adverse drug reactions.....	92
2.5.4.	Special consideration during treatment.....	93
2.5.5.	Important contraindications	94
2.5.6.	Drug interactions.....	94
2.6.	Deucravacitinib.....	95
2.6.1.	Instructions for use.....	95
2.6.2.	Recommendations for lab controls ⁹⁵	97
2.6.3.	Adverse drug reactions ⁹⁶⁻⁹⁹	97
2.6.4.	Special consideration during treatment ⁹⁸⁻¹⁰¹	99
2.6.5.	Important contraindications ⁹⁶⁻⁹⁸	100
2.6.6.	Drug interactions ^{98,102}	100
2.7.	Etanercept	102
2.7.1.	Instructions for use.....	102
2.7.2.	Recommendations for lab controls	103
2.7.3.	Adverse drug reactions.....	103
2.7.4.	Special consideration during treatment.....	105
2.7.5.	Important contraindications	105
2.7.6.	Drug interactions.....	106
2.8.	Guselkumab.....	107
2.8.1.	Instructions for use.....	107
2.8.2.	Recommendations for lab controls	108
2.8.3.	Adverse drug reactions.....	108
2.8.4.	Special consideration during treatment.....	108
2.8.5.	Important contraindications	109
2.8.6.	Drug interactions.....	109



2.9.	Infliximab	110
2.9.1.	Instructions for use.....	110
2.9.2.	Recommendations for lab controls	111
2.9.3.	Adverse drug reactions.....	112
2.9.4.	Special consideration during treatment.....	114
2.9.5.	Important contraindications	114
2.9.6.	Drug interactions.....	115
2.10.	Ixekizumab.....	116
2.10.1.	Instructions for use.....	116
2.10.2.	Recommendations for lab controls	117
2.10.3.	Adverse drug reactions.....	117
2.10.4.	Special consideration during treatment.....	119
2.10.5.	Important contraindications	119
2.10.6.	Drug interactions.....	120
2.11.	Risankizumab.....	121
2.11.1.	Instructions for use.....	121
2.11.2.	Recommendations for lab controls	122
2.11.3.	Adverse drug reactions.....	122
2.11.4.	Special consideration during treatment.....	123
2.11.5.	Important contraindications	123
2.11.6.	Drug interactions.....	123
2.12.	Secukinumab	125
2.12.1.	Instructions for use.....	125
2.12.2.	Recommendations for lab controls	126
2.12.3.	Adverse drug reactions ^{118,119}	126
2.12.4.	Special consideration during treatment.....	128
2.12.5.	Important contraindications	128
2.12.6.	Drug interactions.....	128
2.13.	Tildrakizumab	130
2.13.1.	Instructions for use.....	130
2.13.2.	Recommendations for lab controls	131
2.13.3.	Adverse drug reactions.....	131
2.13.4.	Special consideration during treatment.....	131
2.13.5.	Important contraindications	132



2.13.6.	Drug interactions.....	132
2.14.	Ustekinumab	133
2.14.1.	Instructions for use.....	133
2.14.2.	Recommendations for lab controls.....	134
2.14.3.	Adverse drug reactions.....	134
2.14.4.	Special consideration during treatment.....	134
2.14.5.	Important contraindications	135
2.14.6.	Drug interactions.....	135
2.15.	Biosimilars	136
2.16.	Newly approved medications and treatments in the pipeline.....	138
3.	Guidance for specific clinical and comorbid situations.....	139
3.1.	Psoriatic arthritis: How should psoriasis patients with concomitant psoriatic arthritis be managed?.....	139
3.2.	Inflammatory bowel disease: How should psoriasis patients be managed with concomitant inflammatory bowel disease? (last update: 10/2021).....	144
3.3.	Cancer: How should psoriasis patients with a history of malignancies be managed? 147	
3.4.	Depression: How should psoriasis patients with a history of depression and/or suicidal ideation be managed?.....	152
3.5.	Diabetes: How should psoriasis patients with diabetes mellitus be managed?	155
3.6.	Heart disease: How should psoriasis patients with ischaemic heart disease and/or congestive heart failure be managed?.....	159
3.7.	Kidney disease: How should psoriasis patients with kidney failure / renal impairment be managed?.....	168
3.8.	Neurological diseases: Which treatments are appropriate for psoriasis patients with neurological diseases?.....	172
3.9.	Viral hepatitis: When and how should psoriasis patients be screened for viral hepatitis and how should patients who test positive be managed?	177
3.10.	Tuberculosis: How to screen for tuberculosis before and during biologic treatment?	178
3.11.	Tuberculosis: How to manage psoriasis in patients with positive tuberculosis test results? 182	
3.12.	Wish for child / pregnancy: How should psoriasis patients with a wish for pregnancy in the near future or who are pregnant be managed? (under review; last update: 10/2021) 187	
3.13.	Vaccinations: How should vaccinations in psoriasis patients on systemic treatment be managed?.....	196



3.14.	Immunogenicity of targeted therapies in psoriasis (last update: 10/2021).....	198
XI.	Strengths and limitations	199
XII.	References.....	200
XIII.	Abbreviations	232



I. Notes on use/Disclaimer

The EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris was developed in accordance with the EuroGuiDerm Methods Manual v1.3, which can be found on the website of the European Dermatology Forum (EDF), subsection EuroGuiDerm/EDF Guidelines <https://www.guidelines.edf.one/guideline-methods>.

This work is licensed under the Creative Commons Attribution-NonCommercial- 4.0. For further information on copyright in case of translation, adaptation, commercial use etcetera, see EDF website. Copyright © European Dermatology Forum.

These evidence- and consensus-based guidelines contain recommendations that were developed to assist clinicians in the care of patients in specific clinical conditions. The recommendations are based on the available evidence and their development followed a pre-specified, standardized process. Nevertheless, guidelines do not replace the clinicians' knowledge and skills, since guidelines never encompass therapy specifications for all medical decision-making situations. Guidelines should not be deemed inclusive of all proper methods of care nor exclusive of other methods of care reasonably directed to obtaining the same results. Deviation from the recommendations may be justified or inevitable in specific situations. The ultimate judgment regarding patient care must be individualized and must be made by the physician and patient in the light of all presenting circumstances.

Safety aspects that were considered within these guidelines do not represent a comprehensive assessment of all available safety information for the included interventions. They are limited to those aspects chosen for evaluation and the information available in the included clinical trials. Readers must carefully check the information in these guidelines and determine whether the recommendations (e.g. regarding dose, dosing regimens, contraindications, or drug interactions) are complete, correct, up-to-date and appropriate.

European guidelines are intended to be adapted to national or regional circumstances (regulatory approval and availability of treatments, health care provider and insurance systems). Particularly, the approval situation/availability/reimbursement of the different treatment options has to be adapted to the national situation. Thus, the national medical societies associated adopting European Guidelines will be responsible for the adoption and implementation of the guidelines on a national level.



II. Accompanying documents:

The EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Methods & Evidence report is available as supplementary file. All other documents, such as the IFPA patient guide, are available alongside the guideline document on the EDF website: <https://www.guidelines.edf.one/guideline-methods>

III. Funding

The development of this EuroGuiDerm guideline was funded through the EuroGuiDerm Centre for Guideline Development. The European Dermatology Forum (EDF) is responsible for fundraising and holds all raised funds in one account. The EuroGuiDerm Team is not involved in fundraising or in the decision making on which GL/CS development is funded. The decisions on which GL/CS is funded are made by the EuroGuiDerm Board of Directors independently. The EDF or any other body supporting guideline work is never involved in the development of this guideline and had no say on its content or focus.

IV. Scope and purpose of this guideline

The overall aim of this guideline is to provide guidance for optimal treatment selection and management in the treatment of adults with moderate to severe plaque type psoriasis. Optimal treatment selection and management are meant to reduce morbidity caused by psoriasis and to improve the health related quality of life of affected individuals.

The objectives of the guideline are to:

- Include new treatments and the evidence that has become available
- Update the recommendations regarding biologic systemic treatment options
- Develop a treatment algorithm including biologic and nonbiologic systemic treatment options
- Provide clear recommendations on how to best monitor and manage patients considering the available treatment options
- Develop several short guidance documents with visual tools for ease of implementation
- Provide guidance on the treatment of special populations and difficult clinical situations (mostly expert consensus)



V. Population and health questions covered by the guideline

The target population are patients with plaque type psoriasis of moderate to severe severity, and patients with psoriatic arthritis, who have also been diagnosed with moderate to severe psoriasis vulgaris.

Leading health questions - all referring to adult individuals (regardless of sex or gender) with moderate or severe plaque type psoriasis – are:

- Which treatment option should be chosen with regard to patients' needs, taking efficacy, safety/tolerability of the different treatment options and comorbidities into consideration?
- How should the selected treatment option best be managed and monitored?
- How should frequent comorbid situations (e.g. concomitant arthritis) best be managed?

Necessary inclusion criteria for treatments was a European license for the treatment of psoriasis of the skin. Whenever possible and feasible, the recommendations are evidence-based, taking the results of systematic evidence synthesis based on rigorous methods ¹ as well as on the practical experience obtained by the expert group, into account.

This guideline covers the use of 'conventional' treatments (acitretin, ciclosporin, fumarates, methotrexate), biologic therapies targeting TNF (adalimumab, etanercept, certolizumab pegol, infliximab), IL-12/23p40 (ustekinumab), IL-17A (ixekizumab, secukinumab), IL-17A/IL-17F (bimekizumab), IL-17RA (brodalumab), IL-23p19 (guselkumab, risankizumab, tildrakizumab), the group of 'small molecules' (apremilast) and tyrosinekinase inhibitors (deucravacitinib).

Relevant comparison are head-to-head studies of the above mention interventions or versus placebo. The outcomes chosen are: 90% improvement in the Psoriasis Area Severity Index (PASI 90) and severe adverse events (SAEs), and PASI 75 and adverse events (AEs).

Additionally, the below listed comorbidities and special situations are addressed by the guideline.



Table 3: Overview of topics& key question in relation to comorbidities and special patient populations/issues

TOPIC	QUESTION(S)
Psoriatic arthritis	– How should psoriasis patients with concomitant psoriatic arthritis be managed?
Inflammatory bowel disease	– How should psoriasis patients with inflammatory bowel disease be managed?
Cancer	– How should psoriasis patients with a history of malignancies be managed?
Depression	– How should psoriasis patients with a history of depression and/or suicidal ideation be managed?
Diabetes mellitus	– How should psoriasis patients with diabetes mellitus be managed?
Heart disease	– How should psoriasis patients with ischaemic heart disease and/or congestive heart failure be managed?
Kidney disease	– How should psoriasis patients with kidney failure / renal impairment be managed?
Neurology	– Which treatments are appropriate for psoriasis patients with neurological diseases?
Hepatitis	– When and how should psoriasis patients be screened for viral hepatitis and how should patients who test positive be managed?
Tuberculosis screening	– How to screen for tuberculosis before and during biologic treatment?
Tuberculosis and treatment	– How to manage psoriasis in patients with positive tuberculosis test results?
Pregnancy	– How should psoriasis patients with a wish for pregnancy in the near future or who are pregnant be managed?
Vaccinations	– How should vaccinations in psoriasis patients on systemic treatment be managed?
Immunogenicity	– What is the role of anti-drug antibodies in biologic treatments?

VI. Targeted users of this guideline

This guideline applies to Europe and both, hospital and practice (private and public) based dermatologists are the target users. In addition, national medical societies are invited to adopt this guideline or adapt them to their local contexts. It is also meant to guide payers and health care authorities.



A Patient Guide to using The EuroGuiDerm Guideline for the Systemic Treatment of Psoriasis Vulgaris

by the IFPA

This guideline applies to:

- People living with moderate to severe psoriasis vulgaris
- The caregivers, family and friends who support them
- Psoriasis patient experts and advocates
- Healthcare providers

To best use the guideline, it is also recommended that health care practitioners be given sufficient time to discuss their proposed treatment approach with patients during consultations.² More Information can be found in the IFPA patient guide under: [EuroGuiDerm Guideline IFPA](#).

This [joint Q&A](#) section provides an overview of topics and key questions you may have. Remember that these responses may not be exhaustive! We strongly recommend working closely with your care provider to select the best treatment for you.

1. [What information is contained in this guideline?](#)

The guide contains information about different kinds of treatment including conventional systemic treatment, biologic therapies, biosimilars [and other new treatment options often grouped under the name of “small molecules”](#). It also offers guidance for specific comorbidities and clinical situations such as pregnancy and vaccinations.

2. [Can I talk to my healthcare provider about information in the guideline?](#)

We hope that you will! Whether you are visiting a dermatologist, primary care provider, or other specialist, we encourage you to build an informed patient-provider relationship using the [EuroGuiDerm guidelines website](#) as a reference. Propose an in-depth conversation during consultation and care visits. Your doctor is interested in your concerns and overall health improvement.

PD Dr. med. Julia-Tatjana Maul, and consultant in the Department of Dermatology at the University Hospital Zurich *recommends that patients inform themselves using the European Psoriasis Guideline or other resources such as [patient leaflets](#) about Biologics and Psoriasis Treatment from the EADV³. These are written more from a patient’s perspective and are less*



scientific.

3. [What about newer treatment options? When can I start on those therapies?](#)

Biologics are protein-based drugs which target specific immune mediators and are approved for the treatment of Pso/PsA (psoriatic disease). [Other newer treatment options block enzymes inside cells, e.g. phosphodiesterase 4 or tyrosine kinase 2.](#) With the introduction of biologic medications [and other recently approved treatments](#), we now have more options, and there has been proven improvement in quality of life of patients ⁴.

The best care may vary among individual patients. Discuss your treatment options with your dermatologist and find out what the best-recommended care looks like for you.

4. [What about biosimilars and newer treatments?](#)

Biosimilars are mimic products that can be generated after licensed biologic also called an ‘originator’ loses its patent protection. As the generation of biosimilars lacks the enormous development costs, they are often more affordable than their originator. To obtain the approval for all indications of the originator, biosimilars have to perform clinical phase 3 trials in the first licensed indication of the originator only.

In its [position paper on biosimilars](#), the International Federation of Psoriasis Associations (IFPA) welcomes the introduction of safe and effective biosimilars that can improve access to treatment options ⁵. However, as always, IFPA emphasizes the importance of the patient-provider relationship in making individual decisions to switch from an originator to a biosimilar.

5. [Which Health Care Provider should I talk to about comorbidities?](#)

All healthcare professionals involved in your care, including your dermatologist, should be aware of psoriasis and its comorbidities ⁶. The guideline has information on the management of psoriasis-associated conditions such as: psoriatic arthritis, mental health conditions, inflammatory bowel disease, diabetes and heart diseases.

Inform your treatment team about any other health conditions you experience. They will assist in timely screening, diagnosis and referrals to the appropriate specialists.

6. [If I am pregnant, breastfeeding, or I desire to become pregnant: what are my treatment options?](#)



Like many other chronic illnesses, special consideration is taken [in your treatment plan](#) when you plan to get pregnant, during pregnancy, and while breastfeeding ⁷. Besides talking to your dermatologist, it may help to talk to your gynecologist as well.

7. [What does the guideline recommend about vaccinations while on treatment for Psoriasis?](#)

Before you get your annual or seasonal vaccinations always talk to your dermatologist.

Here is what Julia-Tatjana Maul, MD, *recommends the following based on evidence on vaccines and treatment of patients with psoriasis vulgaris.*

'Psoriasis on its own should not be considered a reason to deviate from standard vaccination recommendations. In psoriasis patients, vaccination using dead vaccines and live vaccines can be performed at any time, unless a systemic treatment is given that necessitates a different strategy. However, before initiating a systemic treatment, vaccination status should be checked and completed. The seasonal flu vaccination is particularly recommended and national recommendations for vaccination should be followed. The use of live vaccines when being treated with a systemic anti-psoriatic treatment needs to be discussed with your doctor at the time point of vaccination and duration of treatment'.

8. [What should I know about use of psoriasis medication if I have another bacterial/viral infection or during pandemic outbreaks?](#)

PD Dr. Maul suggests contacting your doctor when having a bacterial or viral infection and discuss with your doctor on an individual basis if your anti- psoriatic treatments need to be stopped or paused.

9. [Are my perspectives on treatment relevant? What about patient experience?](#)

Yes! It is important that your experience as a patient and your perspectives on treatment be taken into consideration. In fact, your perspective is so important that two measures have been developed to record your perspective during clinical consultations: Patient Reported Outcome Measure (PROMs) and Patient Reported Experience Measures (PREMs).

PROMs offer a valid and reliable description of your health status from your own perspective and PREMs report your satisfaction with treatment while complementing guidelines beyond clinical care ⁸.



VII. Disease severity and treatment goals

i. Measuring disease severity

Although it has its drawbacks, the most established parameter to measure the severity of skin symptoms in psoriasis is the Psoriasis Area and Severity Index (PASI), which was first introduced in 1978 as an outcome measure in a retinoid trial ⁹.

Health related quality of life (HRQoL) is an important aspect of psoriasis, not only in defining disease severity but also as an outcome measure in clinical trials. The Dermatology Life Quality Index (DLQI) is the most commonly used score for assessing the impact of psoriasis on HRQoL. It consists of a questionnaire with ten questions related to symptoms, mental health, impact on daily life, leisure, work and school, personal relationships and burden of psoriasis treatment ¹⁰.

ii. Defining disease severity

The first European consensus effort to define treatment goals for moderate-to-severe psoriasis was conducted in 2011. ¹¹ According to the consensus, the definition of moderate-to-severe disease was '(PASI > 10 or body surface area [BSA] > 10) AND DLQI > 10', and for mild psoriasis 'PASI ≤ 10 AND BSA ≤ 10 AND DLQI ≤ 10'. Criteria to further "upgrade" mild disease to moderate-to-severe were defined as: major involvement of visible areas, major involvement of the scalp, involvement of genitals, onycholysis or onychodystrophy of at least two fingernails, presence of itch leading to scratching and the presence of recalcitrant plaques.

The DLQI describes the overall impact of skin disease on a person's HRQoL as follows: 0-1 = "no effect"; 2-5 = "small effect"; 6-10 = "moderate effect"; 11-20 = "very large effect"; 21-30 = "extremely large effect". A change of five points in the DLQI has been shown to correlate with the minimum clinically meaningful change in a person's HRQoL ¹². Although there is no correlation or only weak correlation between absolute PASI and absolute DLQI scores ¹³, there seems to be a correlation between an improvement in PASI and an improvement in the DLQI ¹⁴.

Since the European consensus, the discussion about defining disease severity has evolved further.

The International Psoriasis Council (IPC) ran a modified Delphi consensus process among its counsellors to categorize psoriasis severity and to redefine access criteria to systemic therapy. The most preferred statement from the IPC survey "rejects the mild, moderate, and severe



categories in favour of a dichotomous definition: Psoriasis patients should be classified as either candidates for topical therapy or candidates for systemic therapy; the latter are patients who meet at least one of the following criteria: (1) body surface area >10%, (2) disease involving special areas, and (3) failure of topical therapy”.¹⁵

The severity definition that reached the second highest approval rate did provide a dichotomous distinction: “a) mild or mild to moderate: that which can be adequately controlled with topical therapy alone; b) moderate to severe or severe: that which requires phototherapy or systemic therapy (including biologics¹⁵).”

A definition using precise numbers got only moderate support from the IPC counsellors, defining mild as BSA 0%-5% with special areas not affected and with DLQI <5, defining moderate as BSA 5%-10% or special areas affected; or BSA 1%-5% and DLQI 5-10, and defining severe as >10% BSA or special areas affected; or BSA 5%-10% and DLQI >10¹⁵.

A physician global assessment (PGA) score to evaluate disease severity can be beneficial for the everyday clinician in order to rapidly assess the severity of psoriasis. It is important to note that different PGAs exist and may differ in the way they are defined. A PGA score of 3 or more is commonly used in clinical trials in order to define a moderate-to-severe form of psoriasis and an indication for systemic treatment. PGA 0/1 is also used both in clinical trials as well as in the everyday clinical practice as a definition of treatment success.¹⁶⁻¹⁸

National societies are invited to define and use their own national disease severity grading in line with their local conditions. .

iii. Treatment goals

The 2011 European Consensus on Treatment Goals

The European Consensus Programme defined treatment goals for the first time for psoriasis¹¹:

In accordance with concepts of uncontrolled disease and the commonly used definition of treatment failure, an algorithm had been generated that can be used in daily practice to secure effective treatment (Figure 2). Treatment success was defined as an improvement of 75% or more in PASI. Treatment failure was defined as not achieving a PASI of 50. Reaching an improvement of more than 50% but less than 75% but achieving a DLQI score of equal to or lower than 5 was considered treatment success whereas a DLQI score above 5 was considered treatment failure.




Figure 2: Treatment goal algorithm from the 2011 “European Consensus Programme” (modified from Mrowietz et al. 2011) ¹¹

A first point in time to assess treatment success for fast acting drugs (e. g., CsA, infliximab) should start at the end of induction therapy up until 16 weeks after the initiation of treatment. For drugs with a slower onset of activity (e. g., MTX, fumarates [FUM], etanercept), treatment assessment should begin at the end of induction therapy up until 24 weeks after starting therapy. During maintenance treatment, an assessment of treatment success should be made in intervals in accordance with the safety monitoring recommendations (typically every eight to twelve weeks).

An important consideration when utilizing treatment goals is the demand for action in case the goal is not met. In psoriasis there are a number of measures that can be applied to increase efficacy such as increasing the dose, reducing the time between applications, or adding another drug (combination therapy); however, with certain drugs this may represent off-label therapy as such variations are not backed-up by the summary of product characteristics (SmPC). When dose adjustments are either ineffective or not appropriate, changing the drug is an important step. As there is little evidence on how to shift from one drug to another, a global consensus programme provided guidance based on a combination of evidence from the literature and on expert opinion ¹⁹.



Advancements after the European Consensus on Treatment Goals

Since the European consensus group process, more treatment options for psoriasis have become available and considerable progress has been made. Because of these advancements, higher treatment goals (e.g. PASI 90 or PASI 100) are aimed for ²⁰.

In addition, the focus has shifted away from percentage reduction and towards a targeted final outcome (e.g. PASI \leq 2, DLQI $<$ 2 or PGA clear or almost clear) ^{18,21}.

National societies are invited to define and use their own national disease severity grading in line with their local condition.

Time till onset of action

Psoriasis can have a severe impact on an individual's health related quality of life. The time until the onset of action of different treatments for psoriasis has been found to vary between the different treatment options ²². Although psoriasis is a chronic skin disease, rapid clearance has been identified as a crucial outcome for patients ²². Taking the time necessary for 25% or 50% of patients to achieve a given PASI or ACR (modified American Rheumatology criteria) response, available systematic reviews summarize the evidence on the speed of onset of action of the different drugs ²³⁻²⁵. Estimates of what is acceptable for a patient as 'waiting time' until a treatment becomes effective, vary largely from patient to patient. Looking at the proportion of patients dropping out of clinical trials due to a lack of efficacy as a proxy, a strong increase in the rate of dropouts was seen after 10-12 weeks ²⁶. Sequential combination of slow acting drugs with low response rates carries a risk of long patient 'waiting times', until a noticeable, clinically meaningful improvement in their health related quality of life ²⁷.



VIII. Methods Section

For the detailed description of the guideline development process, please see guideline report.

This report is available alongside the guideline document on the EDF website: <https://www.guidelines.edf.one/>. Details on the Update 2023 can be found below.

In short, the guideline development group is comprised of 24 dermatology experts from 14 countries, two patient representatives nominated by IFPA and the EuroGuiDerm methodologists. One patient representative participated actively in the 2023 update. The guideline draft texts and recommendations were developed by the experts in working groups, reviewed, discussed and amended where appropriate by the entire group. All votings were done with a minimal agreement of >50%. A structured consensus technique was used during the consensus conference.

Wording as suggested by the GRADE Working Group to standardize the wording of all recommendations was used²⁸, see below.

Wording of recommendations²⁹⁻³²

Strength	Wording	Symbols	Implications
Strong recommendation <u>for</u> the use of an intervention	'We recommend . . .'	↑↑	We believe that all or almost all informed people would make that choice. Clinicians will have to spend less time on the process of decision-making, and may devote that time to overcome barriers to implementation and adherence. In most clinical situations, the recommendation may be adopted as a policy.
Weak recommendation <u>for</u> the use of an intervention	'We suggest . . .'	↑	We believe that most informed people would make that choice, but a substantial number would not. Clinicians and health care providers will need to devote more time on the process of shared decision-making. Policy makers will have to involve many stakeholders and policy making requires substantial debate.
No <u>recommendation</u> with respect to an intervention	'We cannot make a recommendation with respect to . . .'	0	At the moment, a recommendation in favour or against an intervention cannot be made due to certain reasons (e.g. no reliable evidence data available, conflicting outcomes, etc.)
Weak recommendation	'We suggest against . . .'	↓	We believe that most informed people would make a choice against that intervention, but a substantial number would not.



against the use of an intervention			
Strong recommendation against the use of an intervention	‘We recommend against . . .’	↓↓↓	We believe that all or almost all informed people would make a choice against that intervention. This recommendation can be adopted as a policy in most clinical situations.

The recommendations are presented throughout this guideline as displayed below: first the content, then the arrows and colours indicating the direction and the strength of the recommendations, respectively and lastly the rate of expert agreement (consensus strength). Evidence-based recommendations are indicated as such.

We recommend to do tuberculosis screening according to local regulations.	↑↑	Strong consensus ¹ 100% Agreement Expert consensus
--	----	---

¹ due to personal-financial conflict of interest x abstentions

The tables ‘instruction for use’ and ‘lab controls’ have also been voted on – these are consensus-based. The rate of expert agreement is displayed too.

An internal & external review was conducted. Dissemination, implementation and monitoring plans were developed as well as a joint Q&A section for patients. For more details, see Methods & Evidence report.

Update 2023

In May 2022, an update of the Cochrane review has been published ³³.

The EuroGuiDerm Team updated the three systematic reviews supporting the chapters on psoriatic arthritis, heart disease and diabetes. Author groups were provided with a summary of the results (details on the methods and results can be found online).

In March 2023, deucravacitinib has been licensed for the treatment of psoriasis vulgaris, consequently all authors reviewed their chapters. The following sections changed and were voted on:

- New chapter on deucravacitinib
- Psoriatic arthritis
- Diabetes mellitus



- Viral hepatitis
- Depression
- Tuberculosis screening
- The algorithm as well as the decision grid.

The above mentioned changes were presented to the GDG in an online survey. All experts were asked to vote (agree / disagree/ comment). Alternative suggestions could be entered as a reply option. Voting was not anonymous but experts could not see how others had voted. Only the EuroGuiDerm Team had access to the results. All authors could participate but the votes of those with personal financial conflicts of interest did not count.

Six of 25 experts (24%) declared personal-financial conflicts of interest (see below), meaning that they did not vote or their vote was not counted. One external expert declared personal-financial conflicts of interest and was not entitled to vote. Alexander Nast is the guideline coordinator and did not vote. He does not have any personal-financial conflicts of interests.

Title	First name	Last name	Personal- financial conflicts of interest
Prof.	Zsuzsanna	Bata-Csörgő	none
Prof.	Ivan	Bogdanov	none
Dr.	Hugo	Boonen	I have been asked for presentations concerning different products to treat psoriasis. But I don't get money for prescription of certain medication. I am also member of the Belgian Psoriasis working group who gives advice to all kinds of treatment options.
Prof.	Elke MGJ	de Jong	none
Dr.	Ignacio	Garcia-Doval	Reports payment from Novartis and UCB for presentations unrelated to psoriasis (on meta-analysis and critical reading); personal payment
Prof.	Paolo	Gisondi	I have received compensation (payments) for acting as a speaker for Abbvie, Novartis, UCB
Dr.	Diljit	Kaur-Knudsen	none
Prof.	Pietro	Lampertico	Advisory Board/Speaker Bureau for: - ROCHE PHARMA/DIAGNOSTICS, GILEAD SCIENCES, GSK, ABBVIE, JANSSEN, MYR, EIGER, ANTIOS, ALIGOS, VIR, GRIFOLS, ALTONA, ROBOSCREEN (external expert, not entitled to vote)
Dr.	Satveer	Mahil	none
Dr.	Tarja	Mälkönen	Consultancy fees (Abbvie, Janssen, Lilly, Novartis)
Prof.	Vincent	Mallet	none
Dr.	Julia-Tatjana	Maul	none
	Sicily	Mburu	none
Dr.	Liam	Mercieca	none
Prof.	Ulrich	Mrowietz	Honoraria as advisor and/or speaker: AbbVie, Aditxt, Almirall, Amgen, Aristeia, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Immunic, Janssen-Cilag, LEO Pharma, Merck, Sharp & Dohme, Novartis, UCB Pharma, UNION therapeutics.
Prof.	Alexander	Nast	none



Title	First name	Last name	Personal- financial conflicts of interest
Prof.	Eva	Remenyik	none
Prof.	Dimitris	Rigopolous	none
Dr.	Kirsten Marthine	Rønholt Stausholm	<i>Has left the group</i>
Dr.	Paul- Gunther	Sator	none
Prof.	Marcus	Schmitt- Egenolf	none
Dr.	Mariusz	Sikora	none
Prof.	Catherine	Smith	none
Prof.	Phyllis I.	Spuls	none
Dr.	Olav	Sundnes	none
Dr.	Klaus	Strömer	none
	David	Trigos	<i>Has left the group</i>
	Gayle	van der Kraaij	none
Prof.	Nikhil	Yawalkar	Personal fees from Abbvie, Allmiral, Amgen, Celgene, Boehringer Ingelheim, Bristol Myers Squibb, Essex/MSD, Janssen, Leo, Lilly, Novartis, Pfizer, UCB
	Martin	Dittmann	none
Dr.	Maria	Kinberger	none
	Antonia	Pennitz	none
	Isabell	Vader	none
	Christoph	Zeyen	none

The EuroGuiDerm Living Psoriasis Guideline was updated and we disseminated this through various channels including social media and newsletters.

We would like to thank the following experts for their input on a specific chapter:

Viral hepatitis	<p>The update of this chapter was developed together with Professor Pietro Lampertico, Milan, Italy and Professor Vincent Mallet, Paris, France.</p> <p>Both were nominated by the European Association for the Study of the Liver (EASL)</p>
------------------------	---



Excerpt from the abstract of the Cochrane Review ‘Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (Review) ‘ by Emilie Sbidian and colleagues, May 2022.

“[...] Network meta-analysis at class level showed that all interventions (non-biological systemic agents, small molecules, and biological treatments) showed a higher proportion of patients reaching PASI 90 than placebo. Anti-IL17 treatment showed a higher proportion of patients reaching PASI 90 compared to all the interventions, except anti-IL23. Biologic treatments anti-IL17, anti-IL12/23, anti-IL23 and anti-TNF alpha showed a higher proportion of patients reaching PASI 90 than the non-biological systemic agents.

For reaching PASI 90, the most effective drugs when compared to placebo were (SUCRA rank order, all high-certainty evidence): infliximab (risk ratio (RR) 50.19, 95% CI 20.92 to 120.45), bimekizumab (RR 30.27, 95% CI 25.45 to 36.01), ixekizumab (RR 30.19, 95% CI 25.38 to 35.93), risankizumab (RR 28.75, 95% CI 24.03 to 34.39). Clinical effectiveness of these drugs was similar when compared against each other. Bimekizumab, ixekizumab and risankizumab showed a higher proportion of patients reaching PASI 90 than other anti-IL17 drugs (secukinumab and brodalumab) and guselkumab. Infliximab, anti-IL17 drugs (bimekizumab, ixekizumab, secukinumab and brodalumab) and anti-IL23 drugs (risankizumab and guselkumab) except tildrakizumab showed a higher proportion of patients reaching PASI 90 than ustekinumab and three anti-TNF alpha agents (adalimumab, certolizumab and etanercept). Ustekinumab was superior to certolizumab; adalimumab and ustekinumab were superior to etanercept. No significant difference was shown between apremilast and two non-biological drugs: ciclosporin and methotrexate.

We found no significant difference between any of the interventions and the placebo for the risk of SAEs. The risk of SAEs was significantly lower for participants on methotrexate compared with most of the interventions. Nevertheless, the SAE analyses were based on a very low number of events with low- to moderate-certainty for all the comparisons (except methotrexate versus placebo, which was high-certainty). The findings therefore have to be viewed with caution.

For other efficacy outcomes (PASI 75 and Physician Global Assessment (PGA) 0/1), the results were similar to the results for PASI 90. Information on quality of life was often poorly reported and was absent for several of the interventions. [...] ”. page 6, Sbidian et al. 2022³³



Plaque type psoriasis: Evidence to decision framework, Update 2023

For patients with plaque type psoriasis, what are the clinical effectiveness/efficacy, safety and tolerability of conventionals (acitretin, ciclosporin, fumaric acid esters, methotrexate), biologics (adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab or ustekinumab), small molecules (apremilast) or tyrosinekinase inhibitor (deuravacitinib) compared with each other or with placebo?

POPULATION:	Patients with moderate to severe psoriasis vulgaris																																			
INTERVENTION:	<p>Systemic treatments</p> <table border="1"> <thead> <tr> <th>Systemic conventional treatments</th> <th>Small molecules</th> <th>TNF inhibitors</th> <th>Anti-IL12/23</th> <th>Anti-IL17</th> <th>Anti-IL23</th> <th>TYK-2 inhibitors</th> </tr> </thead> <tbody> <tr> <td>Acitretin</td> <td>Apremilast</td> <td>Adalimumab</td> <td>Ustekinumab</td> <td>Brodalumab</td> <td>Guselkumab</td> <td>Deucravacitinib</td> </tr> <tr> <td>Ciclosporin</td> <td></td> <td>Certolizumab</td> <td></td> <td>Bimekizumab</td> <td>Rizankizumab</td> <td></td> </tr> <tr> <td>FAEs</td> <td></td> <td>Etanercept</td> <td></td> <td>Ixekizumab</td> <td>Tildrakizumab</td> <td></td> </tr> <tr> <td>Methotrexate</td> <td></td> <td>Infliximab</td> <td></td> <td>Secukinumab</td> <td></td> <td></td> </tr> </tbody> </table>	Systemic conventional treatments	Small molecules	TNF inhibitors	Anti-IL12/23	Anti-IL17	Anti-IL23	TYK-2 inhibitors	Acitretin	Apremilast	Adalimumab	Ustekinumab	Brodalumab	Guselkumab	Deucravacitinib	Ciclosporin		Certolizumab		Bimekizumab	Rizankizumab		FAEs		Etanercept		Ixekizumab	Tildrakizumab		Methotrexate		Infliximab		Secukinumab		
Systemic conventional treatments	Small molecules	TNF inhibitors	Anti-IL12/23	Anti-IL17	Anti-IL23	TYK-2 inhibitors																														
Acitretin	Apremilast	Adalimumab	Ustekinumab	Brodalumab	Guselkumab	Deucravacitinib																														
Ciclosporin		Certolizumab		Bimekizumab	Rizankizumab																															
FAEs		Etanercept		Ixekizumab	Tildrakizumab																															
Methotrexate		Infliximab		Secukinumab																																
COMPARISON:	All systemic treatments and placebo																																			
MAIN OUTCOMES:	<ul style="list-style-type: none"> - Psoriasis Area and Severity Index (PASI) 90% improvement - Proportion of patients that experienced a severe adverse event (SAE) 																																			
SETTING:	<ul style="list-style-type: none"> - Region: Europe (study inclusion not limited to studies done in Europe) - Setting: clinical and practice (private and public) dermatologists 																																			
PERSPECTIVE:	<ul style="list-style-type: none"> - Population perspective 																																			
BACKGROUND:	<ul style="list-style-type: none"> - Several new treatments have been developed and approved - New statistical methods have become available to allow for comparisons where no head-to-head RCTs exists - Knowledge on monitoring and management of new treatment options is limited and physicians need guidance on how to use these - Many psoriasis patients have significant comorbidity and specific advice is necessary to treat these patients - Hence, the objectives of the guideline are to: <ul style="list-style-type: none"> - Include new treatments and the evidence that has become available - Update the recommendations regarding biologic systemic treatment options (Part 1) - Develop a treatment algorithms including biologic and nonbiologic systemic treatment options - Provide clear recommendations on how to best monitor and manage patients considering the available treatment options - Develop several, short guidance documents with visual tools for ease of implementation - Provide guidance on the treatment of special populations and difficult clinical situations (mostly expert consensus; Part 2) 																																			



For patients with plaque type psoriasis, what are the clinical effectiveness/efficacy, safety and tolerability of conventionals (acitretin, ciclosporin, fumaric acid esters, methotrexate), biologics (adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab or ustekinumab), small molecules (apremilast) or tyrosinekinase inhibitor (deuravacitinib) compared with each other or with placebo?

Evidence synthesis in cooperation with: Cochrane Review ‘Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (Review) ‘ by Emilie Sbidian and colleagues, May 2022 ³³

CONFLICT OF INTERESTS:

Less than 50% of the guideline development committee declared to have personal-financial conflicts of interests (see Methods Report of this guideline).

Linking evidence to recommendations

Recommendation 2023

We **recommend** to take efficacy and safety (see Cochrane Review and drug chapters), time until onset of treatment response, comorbidities (see decision grids, section Guidance for specific clinical and comorbid situations), and individual patient factors into account when choosing a systemic treatment for moderate or severe psoriasis.

In addition, national regulations and reimbursement circumstances need to be taken into consideration and treatment algorithms should be developed on a national level.

We **recommend** the initiation of systemic treatment in patients with moderate to severe psoriasis* (as defined in each country, see also section “Defining disease severity”).

**UV therapy is not part of this guideline but it is recommended as an alternative induction therapy if suitable.*

For most patients who require systemic treatment, we **recommend** choosing a treatment from the group of the ‘conventional systemic agents’.

For cases of severe disease, we **suggest** following [Figure 1](#).

In cases of inadequate response, contra-indication or intolerability we **recommend** following [Figure 1](#).

League table below: Short term (8-24 weeks), RR and 95% CI; RRs larger than 1 for the lower triangle and smaller than 1 for the upper triangle favour the treatment on the left. Certainty of evidence high (highlighted in green), moderate (in blue), low (in yellow) and very low (in red). Source: Sbidian et al. 2022

Copyright © 2022 The Cochrane Collaboration.

Cochrane Review ‘Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis (Review) ‘ by Emilie Sbidian and colleagues, May 2022, Figure 7³³



Serious adverse events

Number of participants (studies)	1693 (6)	1730 (4)	5775 (7)	2930 (8)	8459 (20)	313 (1)	4579 (5)	4467 (7)	11342 (16)	2217 (3)	267 (1)	5440 (11)	1323 (5)	8464 (14)	127 (1)	120 (1)	2676 (7)	213 (1)	1130 (2)	-	
1693 (6)	IFX 2.26 (0.81,6.33)	1.30 (0.57,2.97)	1.62 (0.69,3.76)	1.11 (0.50,2.45)	0.95 (0.16,5.50)	1.14 (0.47,2.78)	1.31 (0.58,2.95)	1.22 (0.55,2.71)	1.49 (0.52,4.28)	1.94 (0.18,20.45)	1.17 (0.51,2.67)	1.69 (0.57,5.01)	1.48 (0.66,3.33)	0.21 (0.01,4.01)	14.82 (1.5,143.4)	1.38 (0.56,3.44)	1.49 (0.06,38.93)	1.35 (0.45,4.07)	1.18 (0.57,2.43)	19 per 1000	
2473 (5)	1.66 (0.68,4.03)	BIME 0.58 (0.25,1.31)	0.72 (0.31,1.63)	0.49 (0.23,1.07)	0.42 (0.07,2.44)	0.51 (0.21,1.22)	0.58 (0.26,1.29)	0.54 (0.25,1.15)	0.66 (0.23,1.91)	0.86 (0.08,9.07)	0.52 (0.24,1.11)	0.75 (0.25,2.23)	0.66 (0.29,1.49)	0.09 (0.00,1.78)	6.56 (0.68,63.61)	0.61 (0.24,1.53)	0.66 (0.03,17.25)	0.60 (0.20,1.81)	0.52 (0.25,1.09)	3 per 1000	
5775 (7)	1.66 (0.68,4.03)	1.00 (0.91,1.11)	IXE 1.24 (0.70,2.20)	0.85 (0.53,1.36)	0.73 (0.14,3.79)	0.88 (0.46,1.68)	1.00 (0.64,1.58)	0.94 (0.58,1.53)	1.14 (0.49,2.67)	1.49 (0.15,14.54)	0.90 (0.53,1.54)	1.30 (0.52,3.21)	1.14 (0.71,1.82)	0.16 (0.01,2.90)	11.39 (1.3,101.6)	1.06 (0.54,2.10)	1.14 (0.05,28.29)	1.04 (0.41,2.62)	0.91 (0.61,1.36)	16 per 1000	
2930 (8)	1.75 (0.72,4.24)	1.05 (0.95,1.17)	1.05 (0.94,1.18)	RISAN 0.69 (0.42,1.11)	0.59 (0.11,3.07)	0.71 (0.37,1.37)	0.81 (0.47,1.38)	0.76 (0.48,1.20)	0.92 (0.38,2.24)	1.20 (0.12,11.78)	0.72 (0.43,1.21)	1.04 (0.41,2.63)	0.92 (0.52,1.62)	0.13 (0.01,2.34)	9.17 (1.02,82.36)	0.86 (0.42,1.73)	0.92 (0.04,22.88)	0.84 (0.33,2.14)	0.73 (0.47,1.13)	10 per 1000	
9202 (21)	1.91 (0.79,4.63)	1.15 (1.08,1.23)	1.15 (1.06,1.25)	1.09 (1.00,1.20)	SECU 0.86 (0.17,4.31)	1.03 (0.57,1.86)	1.18 (0.82,1.69)	1.10 (0.75,1.61)	1.34 (0.58,3.09)	1.75 (0.18,16.83)	1.06 (0.66,1.69)	1.52 (0.63,3.65)	1.34 (0.83,2.15)	0.19 (0.01,3.36)	13.35 (1.5,117.6)	1.25 (0.66,2.36)	1.34 (0.05,32.88)	1.22 (0.50,2.98)	1.06 (0.77,1.47)	19 per 1000	
313 (1)	1.96 (0.79,4.89)	1.18 (0.93,1.50)	1.18 (0.93,1.50)	1.12 (0.88,1.43)	1.03 (0.82,1.29)	SONELO 1.20 (0.22,6.46)	1.37 (0.27,7.06)	1.29 (0.25,6.56)	1.56 (0.26,9.27)	2.04 (0.13,32.09)	1.23 (0.24,6.40)	1.78 (0.30,10.71)	1.56 (0.88,8.09)	0.22 (0.01,5.85)	15.61 (1.1,227.9)	1.46 (0.27,7.93)	1.57 (0.04,55.24)	1.42 (0.23,8.64)	1.24 (0.25,6.16)	26 per 1000	
4579 (5)	2.08 (0.86,5.07)	1.26 (1.12,1.41)	1.25 (1.11,1.42)	1.19 (1.05,1.36)	1.09 (0.98,1.21)	1.06 (0.83,1.36)	BRODA 1.14 (0.61,2.14)	1.07 (0.61,1.87)	1.30 (0.51,3.30)	1.70 (0.17,16.90)	1.02 (0.54,1.95)	1.48 (0.56,3.87)	1.30 (0.68,2.46)	0.18 (0.01,3.35)	12.95 (1.4,118.3)	1.21 (0.57,2.58)	1.30 (0.05,32.69)	1.18 (0.44,3.14)	1.03 (0.62,1.73)	18 per 1000	
4467 (7)	2.08 (0.86,5.05)	1.26 (1.16,1.36)	1.25 (1.16,1.35)	1.19 (1.08,1.32)	1.09 (1.02,1.16)	1.06 (0.84,1.34)	1.00 (0.89,1.12)	GUSEL 0.94 (0.59,1.48)	1.14 (0.48,2.68)	1.49 (0.15,14.44)	0.90 (0.56,1.44)	1.29 (0.53,3.18)	1.14 (0.68,1.89)	0.16 (0.01,2.88)	11.36 (1.3,101.0)	1.06 (0.54,2.07)	1.14 (0.05,28.14)	1.03 (0.41,2.59)	0.90 (0.62,1.33)	17 per 1000	
11063 (16)	2.66 (1.09,6.44)	1.60 (1.48,1.73)	1.60 (1.46,1.74)	1.52 (1.38,1.67)	1.39 (1.31,1.47)	1.35 (1.07,1.71)	1.28 (1.17,1.39)	1.28 (1.18,1.38)	USK 1.22 (0.53,2.82)	1.59 (0.16,15.33)	0.96 (0.59,1.56)	1.38 (0.57,3.33)	1.21 (0.75,1.96)	0.17 (0.01,3.06)	12.14 (1.4,107.1)	1.13 (0.59,2.16)	1.22 (0.05,29.92)	1.11 (0.45,2.72)	0.97 (0.69,1.36)	15 per 1000	
2217 (3)	2.70 (1.09,6.73)	1.63 (1.26,2.10)	1.63 (1.27,2.08)	1.55 (1.19,2.01)	1.41 (1.10,1.81)	1.38 (0.98,1.93)	1.30 (1.00,1.69)	1.30 (1.01,1.67)	1.02 (0.79,1.31)	TILDRA 1.31 (0.12,14.02)	0.79 (0.33,1.89)	1.14 (0.37,3.50)	1.00 (0.46,2.18)	0.14 (0.01,2.74)	9.98 (1.01,98.41)	0.93 (0.36,2.41)	1.00 (0.04,26.56)	0.91 (0.29,2.85)	0.80 (0.36,1.74)	14 per 1000	
267 (1)	3.59 (0.42,30.37)	2.16 (0.31,15.30)	2.16 (0.31,15.26)	2.06 (0.29,14.54)	1.88 (0.27,13.26)	1.83 (0.26,13.10)	1.72 (0.24,12.19)	1.72 (0.24,12.18)	1.35 (0.19,9.55)	1.33 (0.19,9.50)	DEUCRAVA 0.60 (0.06,5.87)	0.87 (0.08,9.43)	0.76 (0.68,7.42)	0.11 (0.00,4.08)	7.63 (0.3,170.4)	0.71 (0.07,7.17)	0.77 (0.02,37.57)	0.70 (0.06,7.59)	0.61 (0.06,5.71)	10 per 1000	
5376 (10)	2.89 (1.19,7.03)	1.75 (1.59,1.91)	1.74 (1.57,1.93)	1.66 (1.50,1.83)	1.51 (1.39,1.65)	1.48 (1.16,1.88)	1.39 (1.22,1.58)	1.39 (1.29,1.50)	1.09 (0.99,1.20)	1.07 (0.83,1.38)	0.81 (0.11,5.70)	ADA 1.44 (0.58,3.56)	1.26 (0.73,2.18)	0.18 (0.01,3.21)	12.65 (1.4,112.7)	1.18 (0.60,2.33)	1.27 (0.05,31.39)	1.15 (0.46,2.90)	1.01 (0.68,1.50)	17 per 1000	
1323 (5)	3.77 (1.50,9.53)	2.28 (1.69,3.07)	2.27 (1.69,3.05)	2.16 (1.59,2.93)	1.98 (1.47,2.65)	1.93 (1.33,2.79)	1.81 (1.33,2.47)	1.81 (1.35,2.44)	1.42 (1.06,1.91)	1.40 (0.98,1.99)	1.05 (0.15,7.57)	1.30 (0.96,1.77)	CERTO 0.88 (0.36,2.14)	0.12 (0.01,2.43)	8.78 (0.88,87.57)	0.82 (0.31,2.19)	0.88 (0.03,23.55)	0.80 (0.25,2.56)	0.70 (0.31,1.58)	13 per 1000	
9759 (16)	4.71 (1.94,11.44)	2.84 (2.50,3.22)	2.83 (2.54,3.16)	2.70 (2.35,3.10)	2.47 (2.20,2.76)	2.40 (1.87,3.10)	2.26 (1.96,2.61)	2.26 (2.01,2.54)	1.77 (1.58,1.99)	1.74 (1.39,2.18)	1.31 (0.19,9.29)	1.63 (1.43,1.86)	1.25 (0.95,1.65)	ETA 0.14 (0.01,2.54)	10.00 (1.12,89.10)	0.93 (0.49,1.80)	1.00 (0.04,24.82)	0.91 (0.36,2.29)	0.80 (0.54,1.18)	15 per 1000	
172 (2)	7.13 (1.08,47.09)	4.30 (0.80,23.11)	4.29 (0.80,23.05)	4.08 (0.76,21.96)	3.73 (0.69,20.03)	3.64 (0.67,19.82)	3.42 (0.64,18.42)	3.42 (0.64,18.39)	2.68 (0.50,14.42)	2.64 (0.48,14.37)	1.99 (0.15,25.89)	2.46 (0.46,13.24)	1.89 (0.34,10.37)	1.51 (0.28,8.14)	CICLO 71.47 (2.0,2585.3)	6.68 (0.4,124.4)	7.17 (0.1,522.0)	6.51 (0.3,129.5)	5.69 (0.3,100.6)	25 per 1000	
388 (5)	7.20 (1.17,44.37)	4.34 (0.87,21.58)	4.33 (0.87,21.53)	4.12 (0.83,20.51)	3.77 (0.76,18.71)	3.67 (0.73,18.53)	3.46 (0.69,17.21)	3.46 (0.70,17.18)	2.71 (0.55,13.47)	2.66 (0.53,13.43)	2.01 (0.16,24.86)	2.49 (0.50,12.37)	1.91 (0.38,9.70)	1.53 (0.31,7.60)	1.01 (0.61,1.68)	MTX 0.09 (0.01,0.86)	0.10 (0.00,4.68)	0.09 (0.01,0.91)	0.08 (0.01,0.68)	7 per 1000	
2113 (5)	6.53 (2.34,18.19)	3.94 (2.29,6.77)	3.93 (2.29,6.74)	3.74 (2.17,6.45)	3.42 (1.99,5.86)	3.33 (1.86,5.98)	3.14 (1.82,5.41)	3.14 (1.83,5.38)	2.46 (1.43,4.22)	2.42 (1.35,4.31)	1.82 (0.24,13.73)	2.26 (1.31,3.88)	1.73 (0.95,3.15)	1.39 (0.81,2.37)	0.92 (0.16,5.31)	0.91 (0.17,4.88)	APRE 1.07 (0.04,27.19)	0.98 (0.36,2.65)	0.85 (0.49,1.48)	15 per 1000	
333 (2)	11.18 (3.47,35.99)	6.74 (3.04,14.92)	6.72 (3.04,14.89)	6.40 (2.89,14.19)	5.85 (2.65,12.93)	5.70 (2.50,13.00)	5.37 (2.42,11.91)	5.37 (2.43,11.87)	4.21 (1.90,9.31)	4.13 (1.81,9.43)	3.11 (0.38,25.35)	3.86 (1.74,8.55)	2.96 (1.28,6.85)	2.37 (1.07,5.26)	1.57 (0.25,9.91)	1.55 (0.26,9.14)	1.71 (0.67,4.40)	NETA 0.91 (0.03,24.40)	0.79 (0.03,19.17)	26 per 1000	
764 (2)	11.52 (3.58,37.11)	6.95 (3.14,15.39)	6.93 (3.13,15.35)	6.60 (2.98,14.63)	6.03 (2.73,13.33)	5.88 (2.58,13.40)	5.53 (2.49,12.28)	5.53 (2.50,12.24)	4.34 (1.96,9.59)	4.26 (1.87,9.72)	3.21 (0.39,26.13)	3.98 (1.80,8.82)	3.05 (1.32,7.07)	2.45 (1.10,5.42)	1.62 (0.30,8.80)	1.60 (0.32,8.06)	1.76 (0.69,4.54)	1.03 (0.34,3.09)	FUM 0.87 (0.38,2.01)	17 per 1000	
-	50.19 (20.9,120.5)	30.27 (25.5,36.0)	30.19 (25.4,35.9)	28.75 (24.0,34.4)	26.26 (22.3,31.0)	25.60 (19.4,33.9)	24.10 (20.1,29.0)	24.11 (20.4,28.5)	18.90 (16.0,22.3)	18.57 (14.0,24.6)	13.99 (1.99,98.10)	17.35 (14.6,20.6)	13.30 (9.65,18.32)	10.65 (8.89,12.77)	7.04 (1.32,37.50)	6.97 (1.42,34.34)	7.69 (4.48,13.18)	4.49 (2.07,9.76)	4.36 (2.01,9.46)	PBO 26 per 1000	
	443 per 1000	880 per 1000	422 per 1000	415 per 1000	360 per 1000	210 per 1000	329 per 1000	388 per 1000	258 per 1000	256 per 1000	210 per 1000	267 per 1000	182 per 1000	146 per 1000	148 per 1000	147 per 1000	110 per 1000	123 per 1000	55 per 1000	25 per 1000	Anticipated absolute effects



Justification

All treatment options were found to be efficacious when compared to placebo.

Recommendations were drafted along the line of drug licensing, taking practical aspect of reimbursement into account. National societies may develop different recommendations reflecting the national reimbursement situation.


Following the label, for most patients a 'conventional' is considered as the first treatment option. Taking into consideration the higher efficacy of approved European Medical Agency (EMA) first label biologics, a "first line use" of biologics is considered in patients with severe psoriasis.

For the selection of a treatment among the 'conventionals', first line biologics and biologics / small molecules in general, many different factors need to be taken into account (see also "specific treatment circumstances") and no clear hierarchy has been decided upon by the guideline group.

"Relative effects of the intervention as estimated from the network meta-analysis model for Psoriasis Area and Severity Index (PASI) 90 and serious adverse events (SAEs) Outcomes were all measured at the induction phase (assessment from 8 to 24 weeks after randomisation). Drugs are reported in order of primary benefit ranking. Each cell contains the risk ratio (RR) and 95% confidence interval for the two primary outcomes (PASI 90 and SAEs) of the intervention in the respective column versus the comparator in the respective row. RRs larger than 1 for the lower triangle and smaller than 1 for the upper triangle favour the treatment on the left. Certainty of evidence was assessed for each comparison using CINeMA and classified in high (highlighted in green), moderate (in blue), low (in yellow) and very-low (in red). Significant results are highlighted in bold. ACI: acitretin; ADA: adalimumab; APRE: apremilast; BIME: bimekizumab; BRODA: brodalumab; CERTO: certolizumab; CICLO: ciclosporin; DEUCRAVA: deucravacitinib; ETA: etanercept; FUM: fumaric acid; IFX: infliximab; IXE: ixekizumab; GUSEL: guselkumab; MTX: methotrexate; NETA: netakimab; PBO: placebo; RISAN: risankizumab; SECU: secukinumab; SONELO: sonelokimab; TILDRA: tildrakizumab; USK: ustekinumab"³³



Sensitivity analysis for approved dosages versus other dosages



Copyright © 2022 The Cochrane Collaboration.

“Sensitivity analyses - Interval plot. Network meta-analysis results for primary outcomes (PASI 90 and serious adverse events, left and right forest plot respectively) for all the interventions depending on the doses: approved dosages versus other dosages. Outcomes were measured at the induction phase (assessment from 8 to 24 weeks after randomisation). MTX_AMM/Other: methotrexate ≥ 15 mg per week/ < 15 mg per week; CICLO_AMM/ Other: ciclosporin ≥ 3 mg/kg/day/<3 mg/kg/day; ACI_AMM/Other: acitretin ≥ 35 mg per day/<35 mg per day; FUM: fumaric acid esters all dosages; APRE_AMM/Other: apremilast 30 mg twice daily/other dosages; ETA_AMM/Other: etanercept 50 mg twice a week/Other dosage; IFX_AMM/Other: infliximab 5 mg/kg week 0, 2, 4 every 6 weeks/Other dosages; ADA_AMM/Other: adalimumab 80 mg Week 0, 40 mg Week 1 then 40 mg every other week/Other dosages; CERTO_AMM/Other: certolizumab 400



mg at week 0,2,4 then 400 mg every other week or other dosages/Other dosages; USK 45/90: ustekinumab 45/90 mg; SECU_AMM/Other: secukinumab 300 mg at week 0, 1, 2, 3, and 4 then every 4 weeks or other dosages/other dosages; IXE_AMM/Other: ixekizumab 160 mg at Week then 80 mg every other weeks until week 12 then 80 mg monthly or other dosages; TILDRA_AMM/Other: tildrakizumab 100 mg at week 0 and 4 then every 12 weeks/Other dosages; GUSEL 100: guselkumab 100 mg per injection; BRODA_AMM/Other: brodalumab 210 mg at week 0, 1, 2 then every other weeks/other dosages; RISAN_AMM/Other: risankizumab, S/C, 150 mg (two 75 mg injections) at Week 0, Week 4 and every 12 weeks thereafter/other dosages; BIME_AMM/Other: bimekizumab, S/C, 320 mg (2 x 160 mg injections) at week 0, 4, 8, 12, 16 and every 8 weeks thereafter/other dosages. DEUCRACA (deucravacitinib), SONELO (sonelokimab) and NETA (netakimab) were grouped in one dosage whatever the dosages. CI: confidence interval; PASI: Psoriasis Area and Severity Index; RR: risk ratio; AMM: 'approved dosage'" ³³



Relative effects of the class-level intervention as estimated from the network meta-analysis model

SAE							Adverse events						
AIL17	1.19 (0.91,1.54)	0.96 (0.70,1.33)	1.04 (0.78,1.38)	1.12 (0.63,2.01)	1.28 (0.58,2.81)	0.95 (0.76,1.20)	AIL17	1.12 (1.05,1.19)	1.06 (1.00,1.12)	1.06 (1.01,1.12)	0.91 (0.82,1.01)	0.99 (0.86,1.15)	1.14 (1.09,1.19)
1.14 (0.95,1.36)	AIL23	0.81 (0.57,1.16)	0.87 (0.64,1.19)	0.94 (0.52,1.72)	1.08 (0.48,2.40)	0.80 (0.61,1.06)	1.08 (0.97,1.20)	AIL23	0.94 (0.88,1.02)	0.95 (0.89,1.01)	0.81 (0.72,0.90)	0.89 (0.76,1.03)	1.02 (0.96,1.08)
1.45 (1.23,1.71)	1.27 (1.04,1.56)	AIL1223	1.07 (0.74,1.57)	1.16 (0.62,2.18)	1.33 (0.59,3.02)	0.99 (0.71,1.38)	1.18 (1.08,1.29)	1.09 (0.98,1.22)	AIL1223	1.00 (0.94,1.07)	0.86 (0.77,0.96)	0.94 (0.80,1.09)	1.08 (1.02,1.14)
1.95 (1.64,2.33)	1.72 (1.44,2.05)	1.35 (1.10,1.66)	ATA	1.08 (0.61,1.94)	1.24 (0.56,2.73)	0.92 (0.71,1.19)	1.47 (1.33,1.62)	1.36 (1.23,1.51)	1.24 (1.11,1.39)	ATA	0.85 (0.77,0.95)	0.94 (0.80,1.09)	1.07 (1.03,1.12)
2.96 (1.63,5.38)	2.60 (1.42,4.74)	2.04 (1.11,3.74)	1.51 (0.84,2.72)	SM	1.14 (0.45,2.88)	0.85 (0.50,1.45)	2.67 (2.04,3.51)	2.48 (1.89,3.27)	2.27 (1.72,2.99)	1.82 (1.40,2.38)	SM	1.10 (0.92,1.30)	1.26 (1.15,1.39)
5.74 (2.40,13.73)	5.04 (2.10,12.13)	3.95 (1.64,9.53)	2.93 (1.22,7.03)	1.94 (0.69,5.45)	CSA	0.74 (0.35,1.57)	5.22 (3.72,7.32)	4.85 (3.44,6.83)	4.43 (3.15,6.23)	3.56 (2.54,4.99)	1.95 (1.29,2.94)	CSA	1.15 (1.00,1.33)
26.78 (22.07,32.49)	23.53 (19.00,29.15)	18.47 (14.82,23.02)	13.70 (11.22,16.73)	9.06 (5.06,16.23)	4.67 (1.99,10.94)	PBO	13.43 (12.00,15.03)	12.48 (11.03,14.11)	11.39 (10.08,12.88)	9.15 (8.20,10.21)	5.02 (3.89,6.48)	2.57 (1.87,3.54)	PBO

Quality of life						
AIL17	0.04 (-0.28,0.35)	-0.04 (-0.39,0.31)	-0.29 (-0.54,-0.03)	-0.94 (-1.32,-0.56)	-0.32 (-1.17,0.53)	-1.37 (-1.60,-1.14)
1.19 (1.01,1.41)	AIL23	-0.07 (-0.39,0.24)	-0.32 (-0.57,-0.07)	-0.97 (-1.35,-0.60)	-0.35 (-1.20,0.49)	-1.41 (-1.63,-1.18)
1.36 (1.17,1.60)	1.14 (0.95,1.37)	AIL1223	-0.25 (-0.54,0.05)	-0.90 (-1.29,-0.50)	-0.28 (-1.13,0.58)	-1.33 (-1.59,-1.07)
1.69 (1.44,1.99)	1.42 (1.21,1.67)	1.24 (1.03,1.49)	ATA	-0.65 (-0.98,-0.32)	-0.03 (-0.86,0.80)	-1.08 (-1.23,-0.94)
3.58 (2.54,5.03)	3.00 (2.12,4.23)	2.62 (1.85,3.72)	2.11 (1.51,2.94)	SM	0.62 (-0.25,1.49)	-0.43 (-0.73,-0.14)
5.56 (3.56,8.68)	4.66 (2.97,7.32)	4.08 (2.59,6.41)	3.28 (2.10,5.12)	1.55 (0.92,2.62)	CSA	-1.05 (-1.87,-0.24)
14.41 (12.32,16.85)	12.07 (10.22,14.25)	10.56 (8.90,12.54)	8.50 (7.31,9.88)	4.03 (2.95,5.49)	2.59 (1.70,3.95)	PBO

Copyright © 2022 The Cochrane Collaboration.

“Outcomes were all measured at the induction phase (assessment from 8 to 24 weeks after randomisation). Drugs are reported in order of primary benefit ranking. Each cell contains the risk ratio (RR) (for dichotomous outcomes: PASI 90, serious adverse events, PASI 75, PGA 0/1, adverse events) or the standardised mean difference (SMD) (for the quality-of-life outcome), plus the 95% confidence interval, of the class level in the respective column versus the class level in the respective row. RRs larger than 1 for the lower triangle and smaller than 1 (or SMDs smaller than zero) for the upper triangle favour the treatment on the left. Significant results are highlighted in grey. AE: adverse events; PASI: Psoriasis Area and Severity Index; PGA: Physician's Global Assessment; QoL: quality of life; SAE: serious adverse events; SAE without worsening of psoriasis correspond to SAE after exclusion of flares of psoriasis; AIL12/23: anti-IL12/23; AIL17: anti-IL17; AIL23: anti-IL23, ATA: anti-TNF alpha; CSA: non-biological conventional systemic agents; PBO: placebo; SM: small molecules”³³




Certainty of evidence

What is the overall certainty of the evidence of effects?

Note that CINeMA not GRADE was used. ^{34,35}

PASI 90

“Certainty of evidence per drug for PASI 90 using CINeMA Each drug is presented as a bar, which indicates the composition of the 4-level confidence of evidence from all comparisons including that drug. Green: high confidence; blue: moderate confidence; yellow: low confidence; red: very low confidence. ACI: acitretin; ADA: adalimumab; APRE: apremilast; BIME: bimekizumab; BRODA: brodalumab; CERTO: certolizumab; CICLO: ciclosporin; CINeMA: Confidence in Network Meta-Analysis; DEUCRAVA: deucravacitinib; ETA: etanercept; FUM: fumaric acid; IFX: infliximab; IXE: ixekizumab; GUSEL: guselkumab; MTX: methotrexate; NETA: netakimab; PASI: Psoriasis Area and Severity Index; PBO: placebo; RISAN: risankizumab; SECU: secukinumab; SONELO: sonelokimab; TILDRA: tildrakizumab; USK: ustekinumab” ³³




Serious adverse events

“Certainty of evidence per drug for Serious Adverse Events using CINeMA Each drug is presented as a bar, which indicates the composition of the 4-level confidence of evidence from all comparisons including that drug. Green: high confidence; blue: moderate confidence; yellow: low confidence; red: very low confidence. ACI: acitretin; ADA: adalimumab; APRE: apremilast; BIME: bimekizumab; BRODA: brodalumab; CERTO: certolizumab; CICLO: ciclosporin; CINeMA: Confidence in Network Meta-Analysis; DEUCRAVA: deucravacitinib; ETA: etanercept; FUM: fumaric acid; IFX: infliximab; IXE: ixekizumab; GUSEL:



guselkumab; MTX: methotrexate; NETA: netakimab; PBO: placebo; RISAN: risankizumab; SECU: secukinumab; SONELO: sonelokimab; TILDRA: tildrakizumab; USK: ustekinumab”³³








IX. Recommendations

Initiation and selection of a systemic treatment

National societies are invited to define and use their own national treatment recommendations in line with local regulations and availability. The EuroGuiDerm psoriasis guideline group suggests the following recommendations as a base for national adoption/adaptation:

<p>We recommend to take efficacy and safety (see Figure 1 /Cochrane Review ³³ and drug chapters), time until onset of treatment response, comorbidities (see decision grids, section Guidance for specific clinical and comorbid situations), and individual patient factors into account when choosing a systemic treatment for moderate or severe psoriasis.</p> <p>In addition, national regulations and reimbursement circumstances need to be taken into consideration and treatment algorithms should be developed on a national level.</p>	↑↑	<p style="text-align: center;">STRONG CONSENSUS¹</p> <div style="text-align: center;">  </div> <p style="text-align: center;">EVIDENCE AND CONSENSUS BASED</p> <p style="text-align: center;">(SEE METHODS AND EVIDENCE SECTION)</p>
<p>We recommend the initiation of systemic treatment in patients with moderate to severe (as defined in each country, see also section “Defining disease severity”) psoriasis.*</p> <p><i>*UV therapy is not part of this guideline but it is recommended as an alternative induction therapy if suitable.</i></p>	↑↑	<p style="text-align: center;">CONSENSUS¹ 91%</p> <div style="text-align: center;">  </div> <p style="text-align: center;">EVIDENCE AND CONSENSUS BASED</p> <p style="text-align: center;">(SEE METHODS AND EVIDENCE SECTION)</p>
<p>For most patients who require systemic treatment, we recommend choosing a treatment from the group of the ‘conventional systemic agents’.</p>	↑↑	<p style="text-align: center;">CONSENSUS¹ 91%</p> <div style="text-align: center;">  </div> <p style="text-align: center;">EVIDENCE AND CONSENSUS BASED</p> <p style="text-align: center;">(SEE METHODS AND EVIDENCE SECTION)</p>

<p>For cases of severe disease, we suggest following Figure 1.</p>	<p>↑</p>	<p>STRONG CONSENSUS¹</p> <p>100% Agreement</p>
<p>In cases of inadequate response, contra-indication or intolerance we recommend following Figure 1.</p>	<p>↑↑</p>	<p>EVIDENCE AND CONSENSUS BASED</p> <p>(SEE METHODS AND EVIDENCE SECTION)</p>

¹ due to personal-financial conflict of interest 3 abstentions




Figure 1: Overview of treatment options for plaque type psoriasis arranged by the label as approved by European Medical Agency.



Table 1: Overview of ‘conventional’ treatment options and the expert assessment of their suitability in specific treatment circumstances (decision grid I)

Therapy Specific circumstances	Conventional systemic agents			
	Acitretin	Ciclosporin	Fumarates	Methotrexate
Concomitant psoriatic arthritis				↑ first line peripheral active joint involvement
Chronic inflammatory bowel disease: Crohn's Disease	↑ especially cases with mild paradoxical psoriasis			↑ 2nd choice oral treatment
Chronic inflammatory bowel disease: Ulcerative colitis	↑ especially cases with mild paradoxical psoriasis	↑ 2nd choice oral treatment		
Diabetes mel./ metabolic syndrome		consider alternatives		consider alternatives
Dyslipidaemia	↓			
Advanced heart failure	↑	↓		↑
Heart Disease: Ischemic heart disease	↓			↑
Concomitant latent / treated TB	↑		↑	
Pregnancy	↓↓	↑ preferred conventional	↓	↓↓



Symbols	Implications ¹
↑↑	We believe that all or almost all informed people would make that choice.
↑	We believe that most informed people would make that choice, but a substantial number would not.
	See background text and specific recommendations
↓	We believe that most informed people would make a choice against that intervention, but a substantial number would not.
↓↓	We believe that all or almost all informed people would make a choice against that choice.

¹ Adapted from GRADE



Table 2: Overview of treatment options with ‘biologics’ and ‘small molecules’ and the expert assessment of their suitability in specific treatment circumstances (decision grid II)

Therapy / Specific circumstances	Apremilast / Deucravacitinib		TNF inhibitors				anti-IL12/23	anti-IL17				anti-IL23		
	Apremilast	Deucravacitinib	Etanercept	Infliximab	Adalimumab	Certolizumab	Ustekinumab	Secukinumab	Ixekizumab	Brodalumab	Bimekizumab	Guselkumab	Tildrakizumab	Risankizumab
Concomitant psoriatic arthritis	↑		↑↑					↑↑				↑↑		↑↑
Chronic inflammatory bowel disease: Crohn's Disease				↑↑ 1st choice				↓				↑ 2nd choice if TNFi not suitable		
Chronic inflammatory bowel disease: Ulcerative colitis	↑ 2nd choice oral treatment			↑↑ 1st choice			↑↑ 1st choice	↓				↑ 2nd choice if TNFi not suitable		



Therapy / Specific circumstances	Apremilast / Deucravacitinib		TNF inhibitors				anti-IL12/23	anti-IL17				anti-IL23		
	Apremilast	Deucravacitinib	Etanercept	Infliximab	Adalimumab	Certolizumab	Ustekinumab	Secukinumab	Ixekizumab	Brodalumab	Bimekizumab	Guselkumab	Tildrakizumab	Risankizumab
Diabetes mel./ metabolic syndrome														
Dyslipidaemia														
Advanced heart failure	↑		↓↓					↑				↑		
Heart Disease: Ischemic heart disease							↑							
Concomitant latent / treated TB	↑		↓↓					↑				↑		
Pregnancy	↓	↓				↑ preferred choice biologic								



Symbols	Implications ¹
↑↑	We believe that all or almost all informed people would make that choice.
↑	We believe that most informed people would make that choice, but a substantial number would not.
	See background text and specific recommendations
↓	We believe that most informed people would make a choice against that intervention, but a substantial number would not.
↓↓	We believe that all or almost all informed people would make a choice against that choice.

¹ Adapted from GRADE



The EuroGuiDerm guideline development group considers the time a treatment has been available a relevant factor when considering different treatment options. Information on rare side effects and long-term safety data generally become more robust over time. Table 4 provides a general overview and summarizes how long the respective treatments have been in clinical use for psoriasis in Europe. The time for medications licenced before the joint EMA approval process may differ between the different countries. It is important to keep in mind that not only the date of availability is important for this but also the number of patients treated with the drug over time ('patient years').



Table 4: Overview on how long each treatment option has been in clinical use for psoriasis in Europe

Treatment	In clinical use for psoriasis since
<i>“conventional systemic agent”</i>	
Acitretin	>25 years
Ciclosporin	>25 years
Fumaric acid esters Dimethylfumarate	>25 years (in Germany) 2017 in Europe
Methotrexate	>25 years
<i>“TNF inhibitors ”</i>	
Etanercept	2004
Infliximab	2005
Adalimumab	2007 Plaque Psoriasis
Certolizumab-pegol	Since 2018 (use in other indications notably earlier: 2009)
<i>“anti-IL12/23p40”</i>	
Ustekinumab	2009
<i>“anti-IL 17”</i>	
Secukinumab	2015
Ixekizumab	2016
Brodalumab	2018
Bimekizumab	2021
<i>“anti-IL 23p19”</i>	
Guselkumab	2017
Tildrakizumab	2018
Risankizumab	2019
<i>„Phosphodiesterase 4 inhibitors“</i>	
Apremilast	2015
<i>“Tyrosinekinase 2 inhibitors”</i>	
Deucravacitinib	2023



X. Guideline text and recommendations

1. Conventional systemic therapy

1.1. Acitretin

1.1.1. Instructions for use

Table 5: Instructions for use (Acitretin) ^{18,36}

Pre-treatment



- Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI/Skindex-29 or -17)
- History and clinical examination should focus on musculoskeletal problems. If patient reports complaints, further imaging investigation may be performed
- Exclude pregnancy/breastfeeding: patient must be informed explicitly and extensively about the teratogenic risk of the medication, the necessity of effective long-term contraception (three years after cessation of treatment), and the possible consequences of becoming pregnant while taking retinoids; written documentation of this informational interview should be obtained
- Note that during and up to three years after treatment, blood donation is not permitted
- Laboratory parameters (see **Table 6**)

During treatment

- Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI/Skindex-29 or -17)
- Take capsules with a meal containing some fat or with whole milk to improve absorption
- In order to prevent elevation of serum lipids and liver enzymes, alcohol abstinence and a low-fat and low-carbohydrate diet are advised.
- Preventing pregnancy is mandatory. After satisfactory contraception for at least one month prior to treatment, start treatment on second or third day of the



menstrual cycle. . Double contraception is recommended (e. g., condom + pill; IUD/Nuva Ring + pill; cave: no low-dosed progesterone preparations/mini-pills) during and up to three years after end of therapy; effectiveness of oral contraceptives is reduced by acitretin

- Ask patient about spine and joint complaints at follow-up visits. If patient reports complaints, further imaging investigation may be performed
- Laboratory parameters (see **Table 6**)

Post-treatment

- Reliable contraception in women of child-bearing age for up to three years after therapy, double contraception, as described above, is recommended
- Patients may not donate blood for up to three years after the discontinuation of therapy

¹ due to personal-financial conflict of interest 3 abstentions

1.1.2. Recommendations for lab controls ^{18,36,37}

Table 6: Recommended laboratory controls (Acitretin)

Parameter	Period in weeks			
	Pre-treatment	4	8	every 12 weeks thereafter
Blood count*	x		x	x
Liver enzymes**	x	x	x	
Serum creatinine	x			
Pregnancy test (urine or blood)	x	Monthly, during treatment and up to 3 years after discontinuation (see national regulations)		
Fasting blood glucose	x			
Fasting triglycerides, cholesterol, HDL	x	x		x

Not all tests may be necessary for all patients. Patient history, risk exposure and patient characteristics have to be taken into account. Further specific testing may be required according to clinical signs, risk, and exposure.

* Hb, Hct, leucocytes, platelets

** Transaminases (AST, ALT), AP, γGT

The recommendations are based on clinical experience. No evidence is available.



1.1.3. Adverse drug reactions ^{38,39}

Please see SmPC for complete listing. The guideline subcommittee decided to comment on the following aspects:

In children treated with acitretin, it is advisable to monitor growth at regular intervals.

Hypertriglyceridaemia, as defined by a fasting triglyceride level of ≥ 1.7 mmol/L, is a common adverse effect of acitretin use. Dietary and lifestyle interventions including alcohol limitation and a low-fat and low-carbohydrate diet, are effective first-line management in reducing triglyceride levels.

Dryness of skin and mucosa can be improved by moisturizing the skin and using lubricating eye drops.

It is important that patients be informed about the possibility of hair loss, as well as the reversibility of any retinoid-induced hair loss.

1.1.4. Special consideration during treatment ⁴⁰

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Surgery

There is no need to discontinue or pause acitretin use in case of elective surgery.

1.1.5. Important contraindications ⁴¹

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects.

Absolute contraindications:

- Severe renal or hepatic dysfunction or hypertriglyceridemia
- As there are many other treatment options available, women of child-bearing age should generally not be treated with acitretin. Breastfeeding is also an absolute contraindication.
- Alcoholism
- Blood donation

Relative contraindications:

- Diabetes mellitus



- Hypertriglyceridemia
- History of pancreatitis

1.1.6. Drug interactions ⁴²

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects.

The concomitant administration of methotrexate and antifungal imidazoles could induce liver toxicity; tetracycline could induce idiopathic intracranial hypertension; lipid-lowering drugs could increase risk of myotoxicity; low-dose progesterone pills could have insufficient contraceptive effect.



1.2. Ciclosporin

1.2.1. Instructions for use ^{18,36}

Table 7: Instructions for use (Ciclosporin)

Pre-treatment

100% Agreement ¹

- Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI/ Skindex-29 or -17)
- History and clinical examination should focus on previous and concomitant diseases (e. g., arterial hypertension; severe infections; malignancies, including cutaneous malignancies; renal and liver diseases) and concomitant medication (see drug interactions)
- Measurement of the blood pressure on two separate occasions
- Laboratory parameters (see **Table 8**)
- Reliable contraception (caution: reduced efficacy of progesterone-containing contraceptives)
- Regular gynaecologic screening according to national guidelines
- Consultation on vaccination; susceptibility to infections (take infections seriously, seek medical attention promptly); drug interactions (inform other treating physicians about therapy); avoidance of excessive sun exposure; use of sunscreens

During treatment

During therapy with low dose ciclosporin (CsA; 2.5 to 3 mg/kg daily), follow-up intervals may be extended to two months or more. Shorter intervals may be needed in patients with risk factors, after dose increases, or those who must take concomitant medications that are likely to contribute to adverse drug reactions. Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)

- HRQoL (such as DLQI/Skindex-29 or -17)



- Clinical examination should focus on status of skin and mucous membranes (hypertrichosis, gingival changes), signs of infections, gastrointestinal or neurological symptoms (tremor, dysaesthesia), musculoskeletal/joint pain
- Repeat recommendation for sun avoidance and sun protection
- Check of concomitant medication
- Measurement of blood pressure
- Laboratory parameters (see **Table 8**)
- Reliable contraception
- Regular gynaecologic screening according to national guidelines
- If creatinine is significantly elevated and/or patient on therapy for > one year, perform creatinine clearance (or creatinine-EDTA clearance where available).
- Determination of the CsA level is recommended in selected cases

Post-treatment

- After discontinuation of CsA, patients should be followed up for skin cancer, especially in case of extensive prior therapeutic or natural UV exposure.

¹ due to personal-financial conflict of interest 3 abstentions

1.2.2. Recommendations for lab controls ^{18,36,37,43}

Table 8: Recommended laboratory controls (Ciclosporin)

Diagnostics	Period in weeks				
	Pre-treatment	4	8	12	16, thereafter every 4-8 weeks
Full blood count*	x	x	x	x	x
Liver enzymes**	x	x	x	x	x
Sodium, potassium	x	x	x	x	x
Serum creatinine	x	x	x	x	x
Urine status	x	x			x
Uric acid	x	x	x	x	x



Diagnostics	Period in weeks				
	Pre-treatment	4	8	12	16, thereafter every 4-8 weeks
Pregnancy test (urine or blood)***	X				
Cholesterol, triglycerides	X****		X		X
Magnesium*****	X		X		X
HBV	X				
HIV	X				

Not all tests may be necessary for all patients. Patient history, risk exposure and patient characteristics have to be taken into account. Further specific testing may be required according to clinical signs, risk, and exposure.

* Erythrocytes, leucocytes, platelets

** Transaminases (AST, ALT), AP, γGT, bilirubin

*** Pregnancy test is recommended as it is important to know if a patient is pregnant when starting a systemic treatment. Cyclosporine is the suggested conventional treatment option, for women who are wanting to conceive or who are pregnant.

**** Recommended two weeks before and on the day of treatment initiation (fasting)

***** Only with indication (muscle cramps)

The recommendations are based on clinical experience. No evidence is available.

1.2.3. Adverse drug reactions ³⁹

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects.

The rate of adverse effects generally demonstrated a clear dose and duration dependency. In case of short-term treatment, the adverse effects are generally reversible after drug withdrawal. In case of long-term treatment (i. e. up to two years), kidney abnormalities may be irreversible.

Kidney abnormalities

The most frequent and clinically relevant reported adverse effects include increment of serum creatinine, urea nitrogen and uric acid due to a reduced glomerular filtration rate and consequently creatinine clearance. Arterial hypertension could be also reported because of vasoconstriction of renal arteries. In case of long term ciclosporin treatment the most clinically relevant adverse effect is the impairment of renal function. In particular, kidney abnormalities follow a pattern of increasing severity from elevation of serum creatinine, reduction of the glomerular filtration rate to structural damage such as interstitial fibrosis, tubular atrophy and glomerular sclerosis.



Malignancies

As with other immunosuppressive therapies, CsA carries an increased risk of developing lymphoproliferative disorders and other malignant tumours, especially of the skin. The incidence of malignancies appears to be dependent primarily on the degree and duration of immunosuppression and on other preceding or concomitant therapies, such as photochemotherapy or MTX. Patients must be monitored carefully following long-term therapy with CsA. An increased risk of skin cancer, especially squamous cell carcinomas, has been observed in patients with psoriasis who have received long-term photochemotherapy (high cumulative doses of PUVA, > 1000 J/cm²). Moreover, nodal or cutaneous B- and T-cell lymphomas and HPV-associated carcinoma have been reported in psoriasis patients treated with CsA.

Infections

As with other immunosuppressive therapies, CsA may increase the risk of various bacterial, parasitic, viral and fungal infections, as well as the risk of infections with opportunistic pathogens. Although CsA has some inhibitory effects on HCV replication, it should be considered with caution in patients with HCV, HBV as well as HPV infection. Infections deserve special attention as possible trigger factors for psoriasis relapse. Patients in whom an infection-triggered exacerbation of psoriasis is probable should first be treated with appropriate therapy for the infection, followed by a re-examination of the indication for CsA.

Others

Gingival hyperplasia and hypertrichosis are described in less than 15% of patients. Paresthesias, more commonly as burning sensations in the hands and/or feet, tremors and muscle cramps likely related to decreased serum Mg. CsA should be used with more caution in obese elderly persons because the risk of developing renal failure increases with age and obesity.

1.2.4. Special consideration during treatment ⁴⁰

Surgery

Consider discontinuing CsA for one week prior to elective surgery.

Measuring CsA blood levels

When treating patients with psoriasis, it is generally not necessary to measure CsA blood levels. An assay may be performed to obtain information about drug intake (in case of a discrepancy



between [higher] doses and clinical response or discrepancy between [lower] doses and occurrence of ADR) or with the simultaneous intake of drugs that might influence CsA levels. In case drug levels are measured, C2 (post two hours) monitoring is the best predictor of exposure to CsA.

Measuring glomerular filtration rate

A periodic measurement of GFR is the most accurate method to assess renal tolerance under long-term or repeated treatments.

Duration of treatment

Most physicians consider CsA suitable as a short term induction therapy only. Due to its possible adverse drug reactions during long term use and in light of many other treatment options, long term treatment for psoriasis of more than two years is usually avoided.

1.2.5. Important contraindications ⁴⁴

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects. The absolute contraindications include the following:

- Impaired renal function
- Insufficiently controlled arterial hypertension
- Severe infectious disease
- History of malignancy (possible exceptions: treated basal cell carcinoma, history of squamous carcinoma in situ)
- Current malignancy
- Simultaneous PUVA therapy or extensive previous UV exposure with high risk of cutaneous malignancy
- Severe hepatic diseases (e.g. liver failure)
- Breastfeeding



1.2.6. Drug interactions ^{41,42}

Please see SmPC and other sources for complete listing. There is the potential for multiple drug reactions, compared to other anti-psoriatic systemic agents. The guideline subcommittee decided to comment on the following aspects.

The availability of CsA depends primarily on the activity of two molecules – the hepatic enzyme cytochrome P450-3A4 (CYP3A4), which is involved in its metabolism, and the intestinal P-glycoprotein, an ATP-dependent transporter protein that transports various drugs, among them CsA, from the enterocytes back into the intestinal lumen. The activities of these molecules may both vary for genetic reasons and be influenced by drugs and herbal substances. Above all, modulators and substrates of CYP3A4 are relevant for therapeutic practice.

Ciclosporin levels are increased by (CYP3A inhibition)

Calcium antagonists, amiodarone, macrolide antibiotics, aminoglycoside antibiotics, tetracyclines, quinolones, imidazoles antimycotics, oral contraceptives, androgenic steroids, danazol, allopurinol, bromocriptine, methylprednisolone (high doses), ranitidine, cimetidine, metoclopramide, propafenone, protease inhibitors (e. g., saquinavir), acetazolamide, amikacin, statins (above all atorvastatin and simvastatin because of increased risk of myopathies), cholic acids and derivatives (ursodeoxycholic acids), grapefruit juice.

Ciclosporin levels are decreased by (CYP3A induction)

Carbamazepine, phenytoin, barbiturates, metamizole, rifampicin, octreotide, ticlopidine, nafcillin, probucol, troglitazone, intravenously administered sulfadimidine and trimethoprim, St John's wort.

Other interactions

- Aminoglycosides, amphotericin B, trimethoprim and sulfamethoxazole, vancomycin, ciprofloxacin, aciclovir, melphalan, NSAIDs possibly reinforce nephrotoxic effects.
- Increased risk of a gingival hyperplasia with the simultaneous intake of nifedipine.
- Increased immunosuppression risk with simultaneous treatment with other immunosuppressive agents.
- CsA may reduce the effect of progesterone-containing contraceptives.



- During CsA therapy, an increased plasma level of some drugs including digoxin, colchicine, corticosteroids, statins and NSAIDs could occur as a result of reduced clearance.

Overdose/measures in case of overdose

Determine CsA blood level, interrupt CsA, determine vital parameters, liver, renal values, electrolytes and if needed, introduce additional measures (including consultation with other specialists).



1.3. Fumarates

1.3.1. Instructions for use

Dimethyl fumarate (DMF) is a pro-drug for oral administration; the active in vivo moiety is monomethylfumarate⁴⁵. For the treatment of psoriasis a drug containing DMF is registered in Europe (Skilarence[®]) and a mixture of DMF and three salts of ethylhydrogenfumarates (Fumaderm[®]) is registered in Germany only.

Further reference is for the DMF drug with European label.

Table 9: Instructions for use (dimethyl fumarate)

Pre-treatment

100% Agreement ¹

- Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI/Skindex-29 or -17)
- History and clinical examination
- Reliable contraception
- Laboratory parameters (see **Table 10**)

During treatment

- Objective assessment of the disease (such as PASI/BSA/PGA)
- HRQoL (such as DLQI/Skindex-29 or -17)
- Clinical examination
- Reliable contraception
- Laboratory parameters (see **Table 10**)

Post-treatment

- None

¹ due to personal-financial conflict of interest 2 abstentions



1.3.2. Recommendations for lab controls

Table 10: Recommended laboratory controls (dimethyl fumarate)

Parameter	Pre-treatment	Every 3 months
Blood count*	x	x
Liver enzymes	x	x
Serum creatinine	x	x
Urine status	x	x
Pregnancy test (urine or blood)	x	

Not all tests may be necessary for all patients. Patient history, risk exposure and patient characteristics have to be taken into account. Further specific testing may be required according to clinical signs, risk, and exposure.

* If leukocytes are < 3000/μl DMF therapy must be stopped. If lymphocytes are < 1000/μl and >700/μl monthly monitoring is required. If lymphocytes remain below 700/μl at two consecutive visits DMF treatment must be stopped. Analysis should include platelets and eosinophils.

The recommendations are based on clinical experience. No evidence is available.

1.3.3. Adverse drug reactions

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Gastrointestinal complaints, mainly diarrhoea and increased stool frequency (which occur in up to 60 % of patients) and flush symptoms are the most frequent ADR during treatment with DMF.

Leucocytopenia, lymphocytopenia, and eosinophilia can be observed during therapy with DMF. An increase in eosinophils is temporary and is usually observed between weeks four and ten of treatment. Occasionally, proteinuria occurs during DMF therapy, but disappears after dose reduction or cessation of treatment.

Overview of important side effects

Very frequent	Diarrhoea, flush, mild leukopenia and lymphopenia (approx. 50% of patients)
Frequent	Abdominal cramps, flatulence, severe lymphocytopenia (approx. 3% of patients), transient eosinophilia
Occasional	Nausea, dizziness, headache, fatigue, proteinuria, increase in serum creatinine, increase in liver enzymes
Rare	Allergic skin reaction
Very rare	None



1.3.4. Special consideration during treatment

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Gastrointestinal tolerance may be improved by taking the tablets after a meal. The administration of acetylsalicylic acid can help to decrease flush symptoms.

The dose of DMF can be adjusted to the individual effective dose ranging from the minimum available dose 30 mg/day to the maximum dose as per label 720 mg/day. In general it is recommended to follow the dose titration schedule until clinical response and subsequently adjust the dose individually.

1.3.5. Important contraindications

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Absolute contraindications

- Severe disease of the gastrointestinal tract including liver and/or the kidneys
- Pregnancy or breastfeeding (lack of clinical experience)

Relative contraindications

- Haematological disease

1.3.6. Drug interactions

There are no known drug interactions with DMF.

Because fumarates may impair renal function, drugs with known nephrotoxic potential should not be used concomitantly.

Overdose/measures in case of overdose

None



1.4. Methotrexate (MTX)

1.4.1. Instructions for use

MTX should be preferentially given subcutaneously once weekly for increased safety (oral intake has higher risk for overdosing as patients are more likely to take tablets daily instead of once weekly) and improved bioavailability (MTX is a prodrug that is polyglutaminated into its active in vivo moiety; [polyglutamination is linked to efficacy](#)) ⁴⁶. The recommended initial and maintenance dose is usually 15 mg MTX once weekly. In case of insufficient response, the dose can be increased up to 20 mg MTX once weekly. A further increase up to 25 mg MTX is only beneficial for a small subgroup of patients, [no further dose-increase is recommended](#) ⁴⁷. S.c. dosing is recommended in patients with suboptimal response to oral treatment and may be considered as the starting route of administration in high need patients.

Table 11: Instructions for use (MTX)

Pre-treatment

100% Agreement ¹

- History and clinical examination
- Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI/Skindex-29 or -17)
- Laboratory controls (see **Table 12**)
- Chest X-ray
- Reliable contraception in women of child-bearing age (starting after menstruation), and also in men
- If abnormalities in liver screening are found, refer patient to specialist for further evaluation

During treatment

- Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI/Skindex-29 or -17)
- Check concomitant medication
- Clinical examination



- Laboratory controls (see **Table 12**)
- Reliable contraception in women of child-bearing age, and also in men
- 5 mg folic acid once weekly 24 hours after MTX
- Advise alcohol abstinence

Post-treatment

- Women should be advised not to become pregnant for at least six months and men must not conceive for at least three months thereafter*

**EMA recommends 6 months as a means of precaution, the practice of the guideline group differs from this.*

¹ due to personal-financial conflict of interest 2 abstentions

1.4.2. Recommendations for lab controls

Table 12: Recommended laboratory controls (MTX)

Parameter*	Period in weeks/months			
	Pre-treatment	Within two weeks	During first two months, 1x every 4 weeks	Thereafter, every 3 months
Blood count	x	x	x	x
Liver enzymes **	x		x	x
Serum creatinine	x		x	x
Urine status	x			
Pregnancy test (urine or blood)	x			
HBV/HCV	x			
HIV	x			
Serum albumin***	x		x	x
PIIINP where available	x		Every 3 months****	

Not all tests may be necessary for all patients. Patient history, risk exposure and patient characteristics have to be taken into account. Further specific testing may be required according to clinical signs, risk, and exposure.

* If blood leucocytes < 3.0, neutrophils < 1.0, thrombocytes < 100, decrease the dose or discontinue the medication



- ** liver enzymes > 2-3x baseline values, initiate further diagnostics (including repeated testing/involve hepatologist) and consider decreasing the dose or discontinuing the medication
- *** In selected cases (e. g., in cases with suspected hypoalbuminaemia or in patients using other drugs with high binding affinity for serum albumin)
- **** In case of abnormal PIIINP during MTX treatment a hepatologist should be consulted.

The recommendations are based on clinical experience. No evidence is available.

1.4.3. Adverse drug reactions

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

The two most important ADR associated with MTX therapy are myelosuppression and hepatotoxicity. Alcohol consumption, obesity, hepatitis, and diabetes mellitus increase the risk of hepatotoxicity.

In fact, however, most causes of death due to MTX are the result of bone marrow suppression. Informing patients about the early symptoms of pancytopenia (dry cough, nausea, fever, dyspnoea, cyanosis, stomatitis/oral symptoms, and bleeding) may aid early detection.

Hypoalbuminaemia and reduced renal function increase the risk of ADR. Special care should be taken when treating geriatric patients, in whom doses should usually be lower and kidney function monitored regularly.

Overview of important side effects

Very frequent	Nausea, malaise, hair loss
Frequent	Elevated transaminases, bone marrow suppression, gastrointestinal ulcers
Occasional	Fever, chills, depression, infections
Rare	Nephrotoxicity, liver fibrosis, and cirrhosis
Very rare	Interstitial pneumonia, alveolitis

1.4.4. Special consideration during treatment

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

In case of gastrointestinal complaints during MTX therapy consuming coffee and/or dark chocolate may be helpful in up to 30% of patients ⁴⁸.



Elderly patients

Special care should be taken when treating geriatric patients, in whom doses should usually be lower and kidney function monitored regularly.

1.4.5. Important contraindications

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Absolute contraindications

- Severe infections
- Severe liver disease
- Renal failure
- Pregnancy) / breastfeeding
- Alcohol abuse
- Bone marrow dysfunction/haematologic changes
- Immunodeficiency
- Acute peptic ulcer
- Significantly reduced lung function

Relative contraindications

- Kidney or liver disorders
- Old age
- Ulcerative colitis
- History of hepatitis
- Lack of compliance
- Active desire to become pregnant (see pregnancy chapter)
- Gastritis
- Obesity (BMI>30)



- Diabetes mellitus
- Previous malignancies (see also malignancy chapter)

1.4.6. Drug interactions

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

A number of drugs, including salicylates, sulphonamides, diphenylhydantoin, and some antibiotics (i. e. penicillin, tetracyclines, chloramphenicol, trimethoprim), may decrease binding of MTX to serum albumin, thus raising the risk of MTX toxicity. Tubular secretion is inhibited by probenecid. Special care should be paid to patients who use azathioprine or retinoids simultaneously. Some NSAID may increase MTX levels and, consequently, MTX toxicity, especially when MTX is administered at high doses. As a result, it is recommended that NSAID be administered at different times of day than MTX. The question of whether folic acid reduces the efficacy of MTX remains controversial. There is some evidence that the combination of MTX and folic acid may reduce adverse reactions without affecting efficacy⁴⁹⁻⁵¹.

Table 13: List of most important drugs with potential interactions

Drug	Type of interaction
Colchicines, CsA, NSAID, penicillin, probenecid, salicylates, sulfonamides	Decreased renal elimination of MTX
Chloramphenicol, co-trimoxazole, cytostatic agents, ethanol, NSAID, pyrimethamine, sulfonamides	Increased risk of bone marrow and gastrointestinal toxicity
Barbiturates, co-trimoxazole, phenytoin, probenecid, NSAID, sulfonamides	Interaction with plasma protein binding
Ethanol, leflunomide, retinoids, tetracyclines	Increased hepatotoxicity

Overdose/measures in case of overdose

In MTX overdose, clinical manifestations of acute toxicity include myelosuppression, mucosal ulceration (particularly of the oral mucosa), and, rarely, cutaneous necrosis. Relative overdose is usually precipitated by factors that interfere with MTX renal excretion or by drug interactions. Folinic acid is a fully reduced folate coenzyme that, after intracellular metabolism,



can function in nucleic acid synthesis, thus bypassing the action of MTX. As the interval between MTX administration and the initiation of folinic acid increases, the efficacy of folinic acid as an antidote to haematological toxicity decreases.

Administer folinic acid (Calcium Leucovorin) immediately at 20 mg (or 10 mg/m²) intravenously or intramuscularly. Subsequent doses should be given at six-hour intervals either parenterally or orally.



2. Biological therapy and small molecules

2.1. Adalimumab

2.1.1. Instructions for use

Table 14: Instructions for use (Adalimumab)

Pre-treatment

100% Agreement¹

- Physicians are encouraged to enrol their patients in a registry (if available)
- Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI/Skinindex-29 or -17)
- History and clinical examination should focus on prior exposure to treatments, malignancies, infections, congestive heart failure (CHF) and neurological disease or symptoms
- Recommended measures include:
 - Check for skin cancer
 - Check for lymphadenopathy
 - Laboratory parameters (see **Table 15**)
 - Exclusion of tuberculosis (see tuberculosis chapter)
 - Check for evidence of active infection
 - Check need for vaccinations
- Reliable contraception

During treatment

- Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI/Skinindex-29 or -17)
- Clinical examination should focus on malignancies, risk factors for serious infections, congestive heart failure, and neurological symptoms
- Recommended measures include:



- Check for skin cancer
- Check for lymphadenopathy
- Laboratory parameters (see **Table 15**)
- Reliable contraception

Post-treatment

- After discontinuation of adalimumab, patients should be followed up with medical history and physical examination
- For information on continued necessity of contraception or management in case of desire to become pregnant immediately after treatment cessation, please see chapter “wish for child / pregnancy”

¹ due to personal-financial conflict of interest 4 abstentions

2.1.2. Recommendations for lab controls

Table 15: Recommended laboratory controls (Adalimumab)

Parameter	Period in weeks			
	Pre-treatment	4	12	Thereafter, every 3-6 months
Full blood count	x	x	x	x
Liver enzymes	x	x	x	x
Serum creatinine	x			
Urine status	x			
Pregnancy test (urine or blood)	x			
CRP	x			
HBV/HCV	x			
HIV	x			
Interferon gamma release assay (TB exclusion)	x			
<i>Not all tests may be necessary for all patients. Patient history, risk exposure and patient characteristics have to be taken into account. Further specific testing may be required according to clinical signs, risk, and exposure.</i>				
The recommendations are based on clinical experience. No evidence is available.				



2.1.3. Adverse drug reactions

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

In placebo-controlled trials, injection-site reactions (erythema, itching, pain, swelling, haemorrhage) were the most frequently reported ADR, occurring in 14 % of patients treated with adalimumab compared to 8 % of patients receiving placebo. The use of adalimumab can be associated with infectious adverse effects. These consisted primarily of upper respiratory tract infections, bronchitis, and urinary tract infections. More serious infections observed included infective endocarditis⁵², pneumonia, septic arthritis, prosthetic and post-surgical infections, erysipelas, cellulitis, diverticulitis, and pyelonephritis. Adverse reactions of the haematologic system, including thrombocytopenia and leukopenia, have been infrequently reported with adalimumab. Other rare side effects of adalimumab are severe allergic reactions (rash; hives; itching; difficulty in breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue). Long-term data from global clinical trials are available and reported no new safety signals and a safety profile consistent with known information about the TNFi class⁵³.

Treatment with adalimumab may result in the formation of autoantibodies and rarely in the development of lupus-like syndrome.

Malignancies, especially lymphoma, associated with the use of adalimumab occur very rarely (see special considerations during treatment)⁵⁴⁻⁵⁷. Side effects may be especially likely to occur in elderly patients, who are usually more sensitive than younger adults to the effects of adalimumab.

TNFi induced paradoxical psoriasis

TNFi are effectively used in the field of inflammatory musculoskeletal, skin and bowel diseases. However, TNFi-induced cutaneous side effects are possible. Paradoxical reactions include the development of psoriasis, pustular psoriasis and psoriasiform lesions, reflecting an immunological paradox, as TNFi are used in the treatment of psoriasis. Psoriasis can be triggered in 1.5 – 5 % under the use of TNFi. In 52% of the cases the appearance is a palmoplantar pustulosis, in 49% a plaque type and in 15% a guttata-type. A potential mechanism could be the increase of the interferon alpha production. These psoriasiform lesions can be managed by topical or systemic anti-psoriatic-therapies and/or switching to another biological, preferably from a different class⁵⁸⁻⁶⁰.



Table 16: Overview of important side effects ⁵³

Very frequent	Injection-site reaction
Frequent	Infections
Occasional	Tuberculosis, reactivation of latent tuberculosis, heart failure
Rare	Allergic reactions, adverse reactions of the haematologic system, demyelinating diseases
Very rare	Autoantibodies, drug-induced lupus, malignancies

2.1.4. Special consideration during treatment

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Surgery

There is little evidence on the effects of adalimumab in patients with psoriasis undergoing surgery. Studies in patients with rheumatoid arthritis (RA) suggest a small increase in postoperative wound infections to even a reduction in case of continued treatment ^{61,62}. For elective surgery it is conceivable to interrupt treatment prior to the procedure three to five half-lives, especially in patients with diabetes or other increased risk of infections.

Infections

Monitoring measures during treatment should take into account that symptoms such as fever can be suppressed during TNFi therapy.

Combination of TNFi and MTX

Treatment with TNFi and methotrexate can be combined. This may reduce the risk of anti-drug antibodies formation ⁶³. This combination is particularly common for infliximab as the risk for the formation of antidrug antibodies formation is highest. The combination may lead to an increased risk of infection, especially when compared to MTX monotherapy, but data are still scarce ⁶⁴ (see chapter: “Immunogenicity”).

2.1.5. Important contraindications

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Absolute contraindications

- Active tuberculosis or other severe infections such as sepsis, and/or opportunistic infections



- Congestive heart failure (NYHA class III/IV)

Relative contraindications

- Pregnancy/breastfeeding
- Latent tuberculosis
- History of recurrent or severe infections, localized infections, conditions predisposing to infections
- Patients living in geographical areas where tuberculosis and histoplasmosis are widespread
- Psoriasis patients with concomitant systemic lupus erythematosus or multiple sclerosis (MS)
- PUVA > 200 treatments (especially if followed by CsA use) – see chapter: “Cancer”
- Malignancies and lymphoproliferative disorders (see chapter malignancies)

2.1.6. Drug interactions

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

There are no known interactions of adalimumab with the metabolism of other drugs. The combination of adalimumab with immunosuppressive drugs may enhance the risk of infection.

There is insufficient information regarding the concomitant use of adalimumab with other biological therapeutics used to treat the same conditions as adalimumab. The concomitant use of adalimumab with these biologics is not recommended because of the possibility of an increased risk of infection.

Overdose/measures in case of overdose

Dose-limited toxicity has not been studied in clinical trials. The highest examined dose was multiple intravenous infusions at 10 mg/kg⁶⁵.



2.2. Apremilast

2.2.1. Instructions for use

Table 17: Instructions for use (Apremilast)

Pre-treatment

100% Agreement¹

- Physicians are encouraged to enrol their patients in a registry (if available)
- Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI/Skindex-29 or -17)
- Medical history and physical examination including:
 - Check for skin cancer
 - Check for evidence of active and chronic infection
 - Check for contraception and breastfeeding
 - Check for need for vaccines (see “vaccination”)
 - Check for hypersensitivity, metabolic, gastrointestinal and renal disorders/dysfunction and underweight
 - Check for depression, anxiety
 - Check for co-medication: CYP3A4 enzyme inducers
 - Laboratory parameters including pregnancy test (see **Table 18**)

During treatment

- Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI/ Skindex-29 or -17)
- Medical history and physical examination focusing on malignancies, infections, contraception, depression and anxiety
- Laboratory parameters only when indicated on medical history or physical examination
- Reliable Contraception



Post-treatment

- For information regarding the ongoing need for contraception immediately following treatment cessation, please see chapter “wish for child / pregnancy”

¹ due to personal-financial conflict of interest 4 abstentions

2.2.2. Recommendations for lab controls

Table 18: Recommended laboratory controls (Apremilast)

Parameter	Pre-treatment	Only when indicated on medical history or physical examination
Blood count	x	(x)
ALT, AST	x	(x)
Serum creatinine/eGFR	x	(x)
Pregnancy test (urine or blood)	x	(x)
Hepatitis B and C	Optional	(x)
HIV	Optional	(x)

Not all tests may be necessary for all patients. Medical history, risk exposure and patient characteristics have to be taken into account. Further specific testing may be required according to clinical signs, risks and exposure.

The recommendations are based on clinical experience. No evidence is available.

2.2.3. Adverse drug reactions ^{66,67}

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Diarrhoea and nausea

“The most commonly reported adverse reactions in Phase III clinical studies have been gastrointestinal (GI) disorders including diarrhoea (15.7%) and nausea (13.9%). These GI adverse reactions were mostly mild to moderate in severity, with 0.3% of diarrhoea and 0.3% of nausea reported as being severe. These adverse reactions generally occurred within the first 2 weeks of treatment and usually resolved within 4 weeks.” ⁶⁸ [A slower titration may be a useful strategy for minimizing nausea when starting new treatment with apremilast.](#) ⁶⁹



Body weight loss

“Patient weight was measured routinely in clinical studies. The mean observed weight loss in patients treated for up to 52 weeks with apremilast was 1.99 kg. A total of 14.3% of patients receiving apremilast had observed weight loss between 5-10% while 5.7% of the patients receiving apremilast had observed weight loss greater than 10%. None of these patients had overt clinical consequences resulting from weight loss. A total of 0.1% of patients treated with apremilast discontinued due to adverse reaction of weight decreased.”⁶⁸ The weight of underweight patients should be monitored from start of treatment. In case of inexplicable and significant weight loss discontinuation of treatment should be considered.

Risk of infection

Phase II/III studies reported more upper respiratory infections with apremilast compared to placebo⁷⁰⁻⁷². There are no reactivations of tuberculosis or opportunistic infections reported⁷⁰⁻⁷³. Screening for latent tuberculosis was not required before enrolment in the randomized clinical trials; however, a history of incompletely treated tuberculosis was an exclusion criterion⁷⁰⁻⁷³.

Depression and suicidal behaviour

Some patients may experience psychiatric symptoms with apremilast, including depression and suicidal thoughts. Stop treatment if patients have new psychiatric symptoms or if existing symptoms worsen. (see chapter: “Depression” for further details.)

2.2.4. Special consideration during treatment

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Surgery:

There is no evidence to date that continuous treatment with apremilast will lead to perioperative complications. Patients who need minor surgical treatments including dental treatments and skin surgery, may continue apremilast treatment. In the case of major surgery, the decision of apremilast withdrawal should be taken case-by-case considering patient characteristics, the risk of infection, the risk of psoriasis worsening after counselling with the surgeon.



2.2.5. Important contraindications

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Absolute contraindications

- Pregnancy or breast-feeding
- Severe acute infections

Relative contraindications

- Galactose intolerance, lactase deficiency or glucose-galactose malabsorption
- Malignancies or lymphoproliferative disorders
- Severe impairment of renal function (eGFR less than < 30 mL/min)
- Major depression and suicidal ideation
- Anorexia

2.2.6. Drug interactions

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Co-administration of strong cytochrome P450 3A4 (CYP3A4) enzyme inducer including rifampicin, resulted in a reduction of systemic exposure of apremilast, which may result in a loss of efficacy of apremilast.⁷⁴ Therefore, the use of strong CYP3A4 enzyme inducers including rifampicin, phenobarbital, carbamazepine, phenytoin with apremilast is not recommended. There was no clinically meaningful drug-drug interaction with ketoconazole, methotrexate and oral contraceptives⁷⁴.

Overdose/ measures in case of overdose

“In case of an overdose, it is recommended that the patient is monitored for any signs or symptoms of adverse effects and appropriate symptomatic treatment is instituted.”⁶⁸



2.3. Bimekizumab

2.3.1. Instructions for use

Table 19: Instructions for use (Bimekizumab)

Pre-treatment

100% Agreement¹

- Physicians are encouraged to enrol their patients in a registry (if available)
- Objective assessment of disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI/Skinindex-29 or -17)
- Medical history and physical examination including prior exposure to treatments, malignancies, infections, inflammatory bowel disease
- Recommended measures include:
 - Check for skin cancer
 - Check for lymphadenopathy
 - Laboratory parameters (see **Table 20**)
 - Exclusion of tuberculosis (see chapter: “tuberculosis”)
 - Check for evidence of active infection
 - Check need for vaccines
- Reliable contraception

During treatment

- Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI, Skindex-29 or 17)
- Laboratory controls (see **Table 20**)
- Medical history and physical examination focusing on infections (in particular upper respiratory tract infections, candida, tuberculosis), contraception and signs or symptoms of inflammatory bowel disease

Post-treatment



- After discontinuation of bimekizumab, patients should be followed up with medical history and physical examination
- For information regarding the ongoing need for contraception immediately following biologic treatment cessation, please see chapter: “Wish for child / pregnancy”

2.3.2. Recommendations for lab controls

Table 20: Recommended laboratory controls (Bimekizumab)

Parameter	Pre-treatment	After 3-6 months
Full blood count	X	X
Liver enzymes	X	X
Serum creatinine	X	
Urine status	X	
Pregnancy test (urine or blood)	X	
CRP	X	
HBV/HCV	X	
HIV	X	
Interferon gamma release assay (TB exclusion)	x	
<i>Not all tests may be necessary for all patients. Patient history, risk exposure and patient characteristics have to be taken into account. Further specific testing may be required according to clinical signs, risk, and exposure.</i>		
The recommendations are based on clinical experience. No evidence is available.		

2.3.3. Adverse drug reactions

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Current evidence suggests a similar safety profile for bimekizumab compared to other IL-17 antagonists ixekizumab and secukinumab and IL-17R antagonist brodalumab. (In all phase III trials (BE READY, BE VIVID, BE SURE and BE RADIANT), bimekizumab was well tolerated. [Recently, safety data were pooled from a cohort of patients from 4 phase II randomized clinical trials \(BE ABLE 1, BE ABLE 2, PS0016, and PS0018\) and 4 phase III randomized clinical trials \(BE](#)



VIVID, BE READY, BE SURE, and BE BRIGHT). In this analysis a total of 1789 patients (1252 [70.0%] men; mean [SD] age, 45.2 [13.5] years) were treated with 1 or more doses of bimekizumab. Total bimekizumab exposure was 3109.7 person-years. Treatment emergent adverse events (TEAEs) occurred at an exposure adjusted incidence rate (EAIR) of 202.4 per 100 person-years and did not increase with longer bimekizumab exposure. The 3 most frequently reported TEAEs were nasopharyngitis (19.1 per 100 person-years; 95% CI, 17.4-20.9 per 100 person-years), oral candidiasis (12.6 per 100 person-years; 95% CI, 11.3-14.0 per 100 person-years), and upper respiratory tract infection (8.9 per 100 person-years; 95% CI, 7.8-10.1 per 100 person-years). Most oral candidiasis events were mild or moderate; 3 events led to discontinuation. The EAIRs of inflammatory bowel disease (0.1 per 100 person-years; 95% CI, 0.0-0.3 per 100 person-years), adjudicated suicidal ideation and behaviour (0.0 per 100 person-years; 95% CI, 0.0-0.2 per 100 person-years), and adjudicated major adverse cardiac events (0.5 per 100 person-years; 95% CI, 0.3-0.8 per 100 person-years) were low. ⁷⁵

Inflammatory Bowel Disease

There is limited data in patients with IBD. Patients with a known history of Crohn's disease were excluded from phase III clinical trials. One case of ulcerative colitis was reported in a patient who received bimekizumab. Caution is advised in prescribing bimekizumab in patients with a history of IBD.

Candidiasis

In all phase III clinical trials ⁷⁶⁻⁷⁹, the majority of oral candidiasis cases were mild or moderate and no cases led to discontinuation. The incidence of bimekizumab oral candidiasis infections seems to be higher than observed with other IL-17 inhibitors ⁸⁰. The dual inhibition of IL-17A and IL-17F could impair more profoundly the normal mucocutaneous defense and, consequently, put at a greater risk of oral candidiasis. Early treatment of candida infections, either with topical or systemic treatment is recommended. [For further information on treatment of candidiasis, see SmPC of antifungal drugs or international guidelines.](#) ^{81,82} Cases are usually described as mild-to-moderate, respond to standard treatment and do not require bimekizumab treatment discontinuation. [In case of recurrent infections, consider changing the antipsoriatic drug.](#) Note that clinically significant, severe infections are always a contraindication for all biologics.



2.3.4. Special consideration during treatment

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Surgery

There is no data on the management of surgery in patients treated with bimekizumab. The decision to discontinue of bimekizumab prior to surgery must be based on individual factors, such as type and risk of surgical procedure, patient characteristics, severity of psoriasis in case of treatment discontinuation etc. Counselling with the surgeon is advised.

2.3.5. Important contraindications

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Absolute contraindications:

- Clinically important active infections

Relative contraindications:

- Pregnancy or breastfeeding
- Inflammatory bowel disease

2.3.6. Drug interactions

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

No drug interactions expected. Combination therapy with other immunosuppressant agents has not been studied.

Overdose/ measures in case of overdose

No cases of overdose have been reported. Doses of up to 320 mg have been administered in clinical studies. In case of overdose, the patient should be monitored and appropriate symptomatic treatment should be instituted immediately.



2.4. Brodalumab

2.4.1. Instructions for use

Table 21: Instructions for use (Brodalumab)

Pre-treatment

100% Agreement¹

- Physicians are encouraged to enrol their patients in a registry (if available)
- Objective assessment of disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI/Skinindex-29 or -17)
- Medical history and physical examination including prior exposure to treatments, malignancies, infections, inflammatory bowel disease, depression and/or suicidal ideation or behaviour
- Recommended measures include:
 - Check for skin cancer
 - Check for lymphadenopathy
 - Laboratory parameters (see **Table 22**)
 - Exclusion of tuberculosis (see chapter: “tuberculosis”)
 - Check for evidence of active infection
 - Check need for vaccines
- Reliable contraception

During treatment

- Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI, Skindex-29 or 17)
- Laboratory controls (see **Table 22**)
- Medical history and physical examination focusing on infections (in particular upper respiratory tract infections, candida, tuberculosis), contraception, symptoms of



depression and/or suicidal behaviour and signs or symptoms of inflammatory bowel disease

Post-treatment

- After discontinuation of brodalumab, patients should be followed up with medical history and physical examination
- For information regarding the ongoing need for contraception immediately following biologic treatment cessation, please see chapter: “Wish for child / pregnancy”

¹ due to personal-financial conflict of interest 4 abstentions

2.4.2. Recommendations for lab controls

Table 22: Recommended laboratory controls (Brodalumab)

Parameter	Pre-treatment	After 3-6 months
Full blood count	X	X
Liver enzymes	X	X
Serum creatinine	X	
Urine status	X	
Pregnancy test (urine or blood)	X	
CRP	X	
HBV/HCV	X	
HIV	X	
Interferon gamma release assay (TB exclusion)	x	
<i>Not all tests may be necessary for all patients. Patient history, risk exposure and patient characteristics have to be taken into account. Further specific testing may be required according to clinical signs, risk, and exposure.</i>		
The recommendations are based on clinical experience. No evidence is available.		

2.4.3. Adverse drug reactions

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Current evidence suggests a similar safety profile for brodalumab compared to other IL-17 antagonists ixekizumab and secukinumab. Serious infections, candidiasis, and neutropenia are considered adverse events of interest.

Common adverse events (occurring in $\geq 1/100$ to $< 1/10$ of patients) include influenza, tinea infections (including tinea pedis, tinea versicolor, tinea cruris), neutropenia, headache,



oropharyngeal pain, diarrhoea, nausea, arthralgia, myalgia, fatigue and injection site reactions. A 120 week follow-up of a phase III trial (AMAGINE 2) with 1790 patients receiving brodalumab or ustekinumab or placebo with subsequently brodalumab, showed a comparable safety profile as the first year of the study. Among the most frequent treatment emergent adverse events in all brodalumab treatment groups throughout the duration of the study were arthralgia, headache, diarrhoea, oropharyngeal pain, and *Candida* species infections. In this study 168 patients received brodalumab 210 Q2W during the entire 120 week period and in whom showed 319.7 AEs per 100 PY, and 8.8 SAEs per 100 PY⁸³. Five year safety data are available from an open label extension of a Phase II trial with 181 patients and showed one or more SAEs in 29 (16%) patients. The only SAE reported by more than one patient was myocardial infarction (3 patients; 1,7%)⁸⁴.

Neutropenia

The exposure adjusted event rates of neutropenia per 100 patient-years of exposure to brodalumab 210mg Q2W through week 52 were 0.3 in the AMAGINE-2 study and 0.3 in the AMAGINE-3 study. The cases of neutropenia were not associated with serious infections, and most cases were mild (absolute neutrophil count, >1000 per cubic millimeter), transient and reversible. No cases of thrombocytopenia were reported.^{83,85}

Suicidal ideation and behaviour

During the clinical development program for psoriasis, four events of suicide (one of which was later adjudicated as indeterminate) and ten attempts of suicide/suicidal behaviour were reported in phase II and III trials amongst 4464 patients with a total treatment duration of 9161.8 patient years of brodalumab exposure.⁸⁶ The follow-up time-adjusted incidence rates of SIB events were comparable between the brodalumab and ustekinumab groups throughout the 52-week controlled phases (0.20 vs 0.60 per 100 patient-years).⁸⁵

The majority of patients with suicidal behaviour had a history of depression and/or suicidal ideation or behaviour and a causal association between treatment with brodalumab and increased risk of suicidal ideation and behaviour has not been established.⁸⁶⁻⁸⁸

On the other hand, of patients treated 12 weeks with brodalumab 210 mg 67% showed improvement of symptoms of depression and anxiety while approximately 20% showed a worsening of these symptoms.⁸⁶ [Three year pharmacovigilance data from the U.S. from 1854 patients \(estimated brodalumab exposure 2736 patient-years\) reported one episode of suicide attempt in a patient with a history of depression. No completed suicides were reported.⁸⁹ \[Worldwide postmarketing data extracted from Food and Drug Administration Adverse Event\]\(#\)](#)



Reporting System (FAERS) showed a comparable number of suicides per patient prescribed for brodalumab in regards to other biologics.⁹⁰ The risk and benefit of treatment with brodalumab should be carefully weighed for patients with a history of depression and/or suicidal ideation or behaviour, or for patients who develop such symptoms. During treatment, patients should be monitored for the emergence or worsening of depression, suicidal ideation, anxiety, or other mood changes. If a patient suffers from new or worsening symptoms of depression and/or suicidal ideation or behaviour is identified, it is recommended to discontinue treatment with brodalumab.

Inflammatory Bowel Disease

Patients with a known history of Crohn's disease were excluded from phase III clinical trials for psoriasis. One case of new onset Crohn's disease was reported in a patient who received various doses of brodalumab throughout the study.^{65,85} A phase II trial of 130 patients with Crohn's disease randomized to brodalumab (210 mg, 350mg or 700 mg) or placebo was terminated early due to a disproportionate number of cases of worsening disease activity and no evidence of meaningful efficacy.⁹¹

Candidiasis

Related to the mechanism of action of brodalumab higher rates of fungal infections, primarily non-serious skin and mucosal candida infections are observed.⁸⁰ Early treatment of candida infections, either with topical or systemic treatment is recommended. [For further information on treatment of candidiasis, see SmPC of antifungal drugs or international guidelines.](#)^{81,82} Cases are usually described as mild-to-moderate, respond to standard treatment and do not require brodalumab treatment discontinuation. [In case of recurrent infections, consider changing the antipsoriatic drug.](#) Note that clinically significant, severe infections are always a contraindication for all biologics.

2.4.4. Special consideration during treatment

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Surgery

There is no data on the management of surgery in patients treated with brodalumab. The decision to discontinue of brodalumab prior to surgery must be based on individual factors,



such as type and risk of surgical procedure, patient characteristics, severity of psoriasis in case of treatment discontinuation etc. Counselling with the surgeon is advised.

Inflammatory Bowel Disease

There is limited data in patients with IBD. Patients with a known history of Crohn's disease were excluded from phase III clinical trials. One case of Crohn's disease was reported in a patient who received various doses of brodalumab throughout the study. Caution is advised in prescribing brodalumab in patients with a history of IBD. ^{65,85}

2.4.5. Important contraindications

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Absolute contraindications:

- Clinically important active infections

Relative contraindications:

- Depression and history of suicidal behaviour
- Pregnancy or breastfeeding
- Inflammatory bowel disease

2.4.6. Drug interactions

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

No drug interactions expected. Combination therapy with other immunosuppressant agents has not been studied.

Overdose/ measures in case of overdose

No cases of overdose have been reported. Doses of up to 700 mg have been administered in clinical studies. In case of overdose, the patient should be monitored and appropriate symptomatic treatment should be instituted immediately.



2.5. Certolizumab – pegol

2.5.1. Instructions for use

Table 23: Instructions for use (Certolizumab – pegol)

Pre-treatment

100% Agreement¹

- Physicians are encouraged to enrol their patients in a registry (if available)
- Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI/Skindex-29 or -17)
- History and clinical examination should focus on prior exposure to treatments, malignancies, infection, congestive heart failure, and neurological symptoms
- Recommended measures include:
 - Check for malignancy, mainly skin cancer, and premalignant lesions
 - Check for lymphadenopathy
 - Laboratory parameters (see **Table 24**)
 - Exclusion of tuberculosis (see chapter: “tuberculosis”)
 - Check for evidence of active infections
 - Check need for vaccinations
- Discuss contraception (see pregnancy : “wish for child/pregnancy “)

During treatment

- Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
- HRQoL such as (DLQI/Skindex-29 or -17)
- Clinical examination should focus on lymphadenopathy, malignancies, especially skin cancer, premalignant lesions, risk factors for serious infections, congestive heart failure, and neurological symptoms
- Recommended measures include:
 - Laboratory parameters (see **Table 24**)



- Discuss contraception (see chapter 3.12 : “wish for child/ pregnancy”)

Post-treatment

- After discontinuation of certolizumab – pegol, patients should be followed up with medical history and physical examination.
- For information regarding the ongoing need for contraception immediately following biologic treatment cessation, please see chapter: “wish for child / pregnancy”

¹ due to personal-financial conflict of interest 3 abstentions

2.5.2. Recommendations for lab controls

Table 24: Recommended laboratory controls (Certolizumab – pegol)

Parameter	Period in weeks			
	Pre-treatment	4	12	Thereafter, every 3-6 months
Full blood count	x	x	x	x
Liver enzymes	x	x	x	x
Serum creatinine	x			
Urine status	x			
Pregnancy test (urine or blood)	x*			
CRP	x			
HBV/HCV	x			
HIV	x			
Interferon gamma release assay (TB exclusion)	x			

Not all tests may be necessary for all patients. Patient history, risk exposure and patient characteristics have to be taken into account. Further specific testing may be required according to clinical signs, risk, and exposure.

** Pregnancy test is recommended as it is important to know if a patient is pregnant when starting a systemic treatment. Certolizumab is the suggested biologic treatment option, for women who are planning conception or are pregnant and require a systemic therapy.*

The recommendations are based on clinical experience. No evidence is available.



2.5.3. Adverse drug reactions

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Most evidence for adverse drug reactions to certolizumab-pegol are derived from studies on rheumatoid arthritis. Specific studies on psoriasis^{92,93} show a safety profile comparable to etanercept (12 weeks) and a safety profile that was consistent with the therapeutic class of TNFi for psoriasis up to 48 weeks. These data are derived from 234 (CIMPASI-1⁹²), 227 (CIMPASI-2⁹²) and 559 patients (CIMPACT⁹³). Most common adverse drug reactions consisted of nasopharyngitis, upper respiratory tract infections, and headache. No opportunistic infections were reported. Serious infections were rare.

In line with the other TNFi and the SmPC the following adverse events can be expected:

Common are viral infections, bacterial infections. Uncommon infections are serious bacterial infections (sepsis), tuberculosis or fungal infections.

Special attention is needed for non-melanoma skin cancer (NMSC) as psoriasis patients are more at risk for NMSC⁹⁴. However, in this SR adjustment for highly relevant confounding factors such as prior phototherapy were lacking⁹⁴. For more detailed information see chapter malignancies. Other malignancies, especially lymphoma, associated with the use of certolizumab-pegol are uncommon. Other rare side effects of certolizumab-pegol are severe allergic reactions and lupus-like syndrome.

Other

As a class, TNFi may be associated with the development or worsening of demyelinating diseases and MS (see respective chapters).

Worsening of pre-existing heart failure, and accordingly TNFi are contraindicated in patients with severe heart failure (NYHA class III or IV), and patients with less severe disease should be monitored carefully and undergo regular monitoring by a cardiologist (see respective chapters).

TNFi induced paradoxical psoriasis

TNFi are effectively used in the field of inflammatory musculoskeletal, skin and bowel diseases. However, TNFi induced cutaneous side effects are possible. Paradoxical reactions include the development of psoriasis, pustular psoriasis and psoriasiform lesions, reflecting an immunological paradox, as TNFi are used in the treatment of psoriasis. Psoriasis can be triggered in 1,5 – 5 % under the use of TNFi. In 52% of the cases the appearance is a palmoplantar



pustulosis, in 49% a plaque type and in 15% a guttata-type. A potential mechanism could be the increase of the interferon alpha production. These psoriasiform lesions can be managed by topical or systemic anti-psoriatic-therapies and/or switch to another biological, preferably from a different class.⁵⁸⁻⁶⁰

Table 25: Overview of important side effects

Very frequent	Injection-site reaction
Frequent	Infections
Occasional	Tuberculosis, reactivation of latent tuberculosis, heart failure
Rare	Allergic reactions, adverse reactions of the haematologic system, demyelinating diseases
Very rare	Autoantibodies, drug-induced lupus, malignancies

2.5.4. Special consideration during treatment

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Surgery

There is little evidence on the effects of certolizumab in patients with psoriasis undergoing surgery. For the group of TNFi in general, studies in rheumatoid arthritis patients suggest a small increase in postoperative wound infections to even a reduction in case of continued treatment^{61,62}. For elective surgery it is conceivable to interrupt treatment prior to the procedure three to five half-lives, especially in patients with diabetes or other increased risk of infections.

Infections

Corresponding monitoring measures during treatment should take into account that symptoms such as fever can be suppressed during TNFi therapy.

Combination of TNFi and MTX

A treatment with TNFi and methotrexate can be combined. This may reduce the risk of formation of anti-drug antibodies⁶³. This combination is particularly common for infliximab as the risk for the formation of antidrug antibodies formation is highest. The combination may lead to an increased risk of infection, especially when compared to MTX monotherapy, but data is still scarce⁶⁴.



2.5.5. Important contraindications

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Absolute contraindications

- Active tuberculosis or other severe infections such as sepsis, and opportunistic infections
- Congestive heart failure (NYHA class III/IV)

Relative contraindications

- Latent tuberculosis
- History of recurrent or severe infections, localized infections, conditions predisposing to infections
- Patients living in geographical areas where tuberculosis and histoplasmosis are widespread
- Psoriasis patients with concomitant systemic lupus erythematosus or multiple sclerosis (MS)
- PUVA > 200 treatments (especially if followed by CsA use) – see chapter: “cancer”
- Malignancies and lymphoproliferative disorders (see chapter: “malignancies”)

2.5.6. Drug interactions

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

The combination of certolizumab-pegol with immunosuppressive drugs may enhance the risk of infection. There is insufficient information regarding the concomitant use of certolizumab-pegol with other biological therapeutics used to treat the same conditions. The concomitant use of certolizumab-pegol with these biologics is not recommended because of the possibility of an increased risk of infection.

Overdose/measures in case of overdose

No dose-limited toxicity was observed in clinical trials. Repeated subcutaneous study injections of 800 mg have been given.



2.6. Deucravacitinib

2.6.1. Instructions for use

Table 26: Instructions for use (Deucravacitinib)

Pre-treatment

100% Agreement ¹

- Physicians are encouraged to enroll their patients in a registry (if available)
- Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI/Skindex-29 or -17)
- Medical history and physical examination including prior exposure to treatments, risk factors, signs and symptoms of infection, malignancies.
- Recommended measures include:
 - Check for skin cancer
 - Check for lymphadenopathy
 - Exclusion of tuberculosis (see chapter: “tuberculosis”)
 - Check for evidence of active and chronic infection
 - Check need for vaccinations according to current immunization guidelines including prophylactic herpes zoster vaccination.
- Laboratory parameters (see **Table 27**)
- Exclude pregnancy/breastfeeding
- Reliable contraception

Advise the patient to discontinue the treatment and seek further diagnostic evaluation if they experience muscle pain, tenderness, or weakness, especially if accompanied by malaise or fever.



During treatment

- Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI/Skindex-29 or -17)
- Clinical examination including risk factors, signs and symptoms of infection, malignancies.
- Laboratory parameters (see **Table 27**)
- Reliable contraception

Post-treatment

- After discontinuation of deucravacitinib, patients should be followed up with medical history and physical examination
- For information regarding the ongoing need for contraception immediately following treatment cessation, please see chapter “wish for child / pregnancy”

¹ due to personal-financial conflict of interest 5 abstentions



2.6.2. Recommendations for lab controls

Table 27: Recommended laboratory controls (Deucravacitinib)

Parameter	Period in weeks		
	Pre-treatment	4	12, thereafter every 12 weeks
Full blood count	x	x	x
Liver enzymes	x	x	x
Serum creatinine	x	x	x
Lipid profile	x	x	x
Urine status	x	x	x
Pregnancy test (urine or blood)	x		
HBV/HCV	x		
HIV	x		
Creatine phosphokinase (CPK)	x	in case of muscle pain during treatment	
Interferon gamma release assay (TB exclusion)	x		

Not all tests may be necessary for all patients. Patient history, risk exposure and patient characteristics must be considered. Further specific testing may be required according to clinical signs, risk, and exposure.

The recommendations are based on opinion taking into account that the experience with this drug is still limited. The currently suggested monitoring goes beyond the laboratory controls currently suggested by SmPC. Due to personal-financial conflict of interest 3 abstentions

2.6.3. Adverse drug reactions ⁹⁵⁻⁹⁸

Please see SmPC for complete listing. The guideline subcommittee decided to comment on the following aspects:

The most common adverse drug reactions (occurring in $\geq 1\%$ and with a higher rate than in the placebo group) in pooled data from POETYK PSO-1 and POETYK PSO-2 trials through week 16 were upper respiratory infections, increased blood creatinine phosphokinase (CPK) levels, herpes simplex, mouth ulcers, folliculitis, and acne (**Table 28**). Headache, diarrhea, and nausea were also reported, with a similar frequency in the deucravacitinib and placebo groups. Through Week 52, no new adverse drug reactions were identified, and their incidence rates did not increase compared to those observed during the first 16 weeks of treatment.



Table 28: Overview of important side effects (Deucravacitinib)

Very common	Upper respiratory infections*
Common	Herpes simplex infections**, oral ulcers***, acneiform rash****, folliculitis
Uncommon	Herpes zoster

* nasopharyngitis, upper respiratory tract infection, viral upper respiratory tract infection, pharyngitis, sinusitis, acute sinusitis, rhinitis, tonsillitis, peritonsillar abscess, laryngitis, tracheitis, and rhinotracheitis

** oral herpes, herpes simplex, genital herpes, and herpes viral infection

*** aphthous ulcer, mouth ulceration, tongue ulceration, and stomatitis

**** acne, dermatitis acneiform, rash, rosacea, pustule, rash pustular, and papule

Infections

Deucravacitinib may increase the risk of infections. The majority of infections were non-serious and mild to moderate in severity upper respiratory tract infections which did not lead to treatment discontinuation. The most common serious infections reported with deucravacitinib included pneumonia and COVID-19, which is attributable to the ongoing pandemic.

Herpes virus reactivation (e.g., herpes zoster, herpes simplex), was reported in clinical studies. Most of the herpes zoster cases were mild to moderate, localized (involved a single dermatome), followed a benign clinical course, and did not lead to discontinuation. During POETYK PSO-1, PSO-2, and the open-label extension trial, 10 out of 18 patients who reported events of herpes zoster were under 50 years of age and there was a case of multidermatomal herpes zoster in an immunocompetent subject who received deucravacitinib. Physicians should educate patients about early signs and symptoms of herpes zoster, advising that treatment should be sought as early as possible.

Laboratory Abnormalities

In terms of pooled laboratory abnormality data from clinical trials, treatment with deucravacitinib was associated with increases in creatine phosphokinase (CPK) levels (from asymptomatic to rhabdomyolysis), increases in triglyceride levels and liver serum transaminase elevations ≥ 3 times the upper limit of normal. Interrupt deucravacitinib if myopathy or liver injury is suspected. Patients should be instructed to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.



Malignancies

In pooled data from the entire treatment periods during PSO-1, PSO-2, and the open-label extension trial (total deucravacitinib exposure of 2482 patient–years; PY), malignancies were reported in 22 patients (0.9 per 100 PY) including 11 cases of non-melanoma skin cancer (0.4 per 100 PY) and 3 subjects with lymphoma (0.1 per 100 PY).

2.6.4. Special consideration during treatment ⁹⁷⁻¹⁰⁰

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Potential Risks Related to JAK Inhibition

These safety concerns led the FDA and EMA to endorse the measures to minimise risk of serious heart-related events, cancer, blood clots, and death associated with Janus kinase (JAK) inhibitors.

It is not known whether deucravacitinib may be associated with the observed or potential adverse reactions of JAK inhibition. Deucravacitinib is a highly selective TYK2 inhibitor with minimal or no activity against JAK 1/2/3 at clinically relevant doses and concentrations. Allosteric mechanism of TYK2 inhibition reduces the chance of off-target effects and data from PSO-1, PSO-2, and the open-label extension trial demonstrated consistent safety profiles of deucravacitinib in patients with psoriasis. Although further observations are needed to fully characterize the long-term safety of deucravacitinib.

Surgery

There is no data on the management of surgery in patients treated with deucravacitinib. The decision to discontinue of deucravacitinib prior to surgery should be taken case-by-case considering type and risk of surgical procedure, patient characteristics, the risk of infection, the risk of psoriasis worsening. Counselling with the surgeon is advised.

American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty recommend withholding JAK inhibitors for at least 3 days prior to surgery.



2.6.5. Important contraindications⁹⁵⁻⁹⁷

[Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects.](#)

Contraindications:

- Hypersensitivity to the active substance or to any of the excipients
- Active tuberculosis or active serious infections
- Severe hepatic impairment (Child-Pugh C)
- Pregnancy

The risks and benefits of treatment with deucravacitinib should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection, who have been exposed to tuberculosis, with a history of a serious or an opportunistic infection, or with underlying conditions that may predispose them to infection.

2.6.6. Drug interactions^{97,101}

[Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects.](#)

Results from healthy volunteer studies showed that no clinically significant differences in the deucravacitinib pharmacokinetics were observed when administered with concomitant medications that inhibit or induce various drug metabolizing enzymes and transporters, including cyclosporine (dual Pgp/BCRP inhibitor), fluvoxamine (CYP1A2 inhibitor), ritonavir (CYP1A2 inducer), diflunisal (UGT1A9 inhibitor), pyrimethamine (OCT1 inhibitor), famotidine (H2 receptor antagonist), or rabeprazole (proton pump inhibitor). No clinically significant differences in the pharmacokinetics of the following drugs were observed when co-administered with deucravacitinib: rosuvastatin, methotrexate, mycophenolate mofetil and oral contraceptives (norethindrone acetate and ethinyl estradiol).

Combination therapy of deucravacitinib with other immunomodulatory agents, including biologics, or phototherapy has not been evaluated in plaque psoriasis.



Overdose/ measures in case of overdose

There is no experience regarding human overdosage with deucravacitinib. In the case of overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and appropriate symptomatic treatment be instituted immediately.



2.7. Etanercept

2.7.1. Instructions for use

Table 29: Instructions for use (Etanercept)

Pre-treatment

100% Agreement ¹

- Physicians are encouraged to enrol their patients in a registry (if available)
- Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI/Skindex-29 or -17)
- History and clinical examination should focus on prior exposure to treatments, malignancies, infection, congestive heart failure, and neurological symptoms
- Recommended measures include:
 - Check for malignancy, mainly skin cancer, and premalignant lesions
 - Check for lymphadenopathy
 - Laboratory parameters (see **Table 30**)
 - Exclusion of tuberculosis (see chapter: “tuberculosis”)
 - Check for evidence of active infection
 - Check need for vaccinations
- Reliable contraception

During treatment

- Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
- HRQoL such as (DLQI/Skindex-29 or -17)
- Clinical examination should focus on lymphadenopathy, malignancies, especially skin cancer, premalignant lesions, risk factors for serious infections, congestive heart failure, and neurological symptoms
- Recommended measures include:
 - Laboratory parameters (see **Table 30**)



- Reliable contraception

Post-treatment

- After discontinuation of etanercept, patients should be followed up with medical history and physical examination.
- For information regarding the ongoing need for contraception immediately following biologic treatment cessation, please see chapter “wish for child / pregnancy”

¹ due to personal-financial conflict of interest 4 abstentions

2.7.2. Recommendations for lab controls

Table 30: Recommended laboratory controls (Etanercept)

Parameter	Period in weeks			
	Pre-treatment	4	12	Thereafter, every 3-6 months
Full blood count	x	x	x	x
Liver enzymes	x	x	x	x
Serum creatinine	x			
Urine status	x			
Pregnancy test (urine or blood)	x			
CRP	x			
HBV/HCV	x			
HIV	x			
Interferon gamma release assay (TB exclusion)	x			

Not all tests may be necessary for all patients. Patient history, risk exposure and patient characteristics have to be taken into account. Further specific testing may be required according to clinical signs, risk, and exposure.

The recommendations are based on clinical experience. No evidence is available.

2.7.3. Adverse drug reactions

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Analysis of results from two major North-American studies that followed up 506 patients up to four years showed no increase in the incidence of malignancies or infections among psoriasis



patients treated with etanercept compared to patients receiving placebo and/or to the general population ¹⁰², and a low risk of serious infection of 0.9 per 100 patient-years ¹⁰³. Of note, no case of lymphoma or of tuberculosis was reported, and major cardiovascular events were very rare.

As a class, TNFi may be associated with the development or worsening of demyelinating diseases and MS. Infliximab and etanercept have been associated with worsening of pre-existing heart failure, and accordingly TNFi are contraindicated in patients with severe heart failure (NYHA class III or IV), and patients with less severe disease should be monitored carefully and undergo regular monitoring by a cardiologist.

Although antinuclear antibodies (ANA) and, to a lesser extent, anti-double strand (ds) DNA antibodies may develop during the use of TNFi (between 10 and 70 % for etanercept in patients with RA and 18 % in psoriasis patients ¹⁰²), they are often of IgM isotype and disappear after discontinuation of therapy, while clinical autoimmune manifestations, notably drug-induced lupus, remain very rare.

TNFi induced paradoxical psoriasis

TNFi are effectively used in the field of inflammatory musculoskeletal, skin and bowel diseases. However, TNFi induced cutaneous side effects are possible. Paradoxical reactions include the development of psoriasis, pustular psoriasis and psoriasiform lesions, reflecting an immunological paradox, as TNFi are used in the treatment of psoriasis. Psoriasis can be triggered in 1,5 – 5 % under the use of TNFi. In 52% of the cases the appearance is a palmoplantar pustulosis, in 49% a plaque type and in 15% a guttata-type. A potential mechanism could be the increase of the interferon alpha production. These psoriasiform lesions can be managed by topical or systemic anti-psoriatic-therapies and/or switch to another biological, preferably from a different class. ⁵⁸⁻⁶⁰

Table 31: Overview of important side effects

Very frequent	Injection-site reaction
Frequent	Infections
Occasional	Tuberculosis, reactivation of latent tuberculosis, heart failure
Rare	Allergic reactions, adverse reactions of the haematologic system, demyelinating diseases
Very rare	Autoantibodies, drug-induced lupus, malignancies



2.7.4. Special consideration during treatment

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Surgery

There is little evidence on the effects of etanercept in patients with psoriasis undergoing surgery. Studies in patients with rheumatoid arthritis (RA) suggest a small increase in postoperative wound infections to even a reduction in case of continued treatment. For elective surgery it is conceivable to interrupt treatment prior to the procedure three to five half-lives, especially in patients with diabetes or other increased risk of infections.

Infections

Corresponding monitoring measures during treatment should take into account that symptoms such as fever can be suppressed during anti-TNF therapy.

2.7.5. Important contraindications

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Absolute contraindications

- Active tuberculosis or other severe infections such as sepsis, and opportunistic infections
- Congestive heart failure (NYHA class III/IV)

Relative contraindications

- Pregnancy/breastfeeding
- Latent tuberculosis
- History of recurrent or severe infections, localized infections, conditions predisposing to infections
- PUVA > 200 treatments (especially if followed by CsA use) – see also chapter: “Cancer”
- Demyelinating disease
- Malignancies or lymphoproliferative disorders (see chapter malignancies)



2.7.6. Drug interactions

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

There are no known interactions of etanercept with the metabolism of other drugs. The combination of etanercept with immunosuppressive drugs may enhance the risk of infection. The combination of etanercept and anakinra has been associated with an increased risk of serious infections and neutropenia, and has not demonstrated increased clinical benefit. The concurrent administration of etanercept and abatacept did not demonstrate an increased clinical benefit. On the contrary, there was an increased incidence of SAE. The concomitant use of etanercept with these biologics is not recommended because of the possibility of an increased risk of infection.

Overdose/measures in case of overdose

No dose-limited toxicity was observed in clinical trials with patients suffering from RA. Intravenous administration of 32 mg/m² was the highest examined dose, followed by subcutaneous injections of 16 mg/m² twice weekly (BIW). There is no known antidote for etanercept ¹⁰⁴.



2.8. Guselkumab

2.8.1. Instructions for use

Table 32: Instructions for use (Guselkumab)

Pre-treatment

100% Agreement¹

- Physicians are encouraged to enroll their patients in a registry (if available)
- Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI, Skindex-29 or 17)
- Medical history and physical examination including prior exposure to treatments, malignancies, infections
- Recommended measures include:
 - Check for skin cancer
 - Check for lymphadenopathy
 - Laboratory parameters (see **Table 33**)
 - Exclusion of tuberculosis (see chapter: “tuberculosis”)
 - Check for evidence of active infection
 - Check need for vaccines
- Reliable contraception

During treatment

- Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI, Skindex-29 or 17)
- Laboratory controls (see **Table 33**)
- Medical history and physical examination including infections, including monitoring signs and symptoms of tuberculosis
- Reliable contraception

Post-treatment



- After discontinuation of guselkumab, patients should be followed up with medical history and physical examination
- For information regarding the ongoing need for contraception immediately following biologic treatment cessation, please see chapter “wish for child / pregnancy”

¹ due to personal-financial conflict of interest 3 abstentions

2.8.2. Recommendations for lab controls

Table 33: Recommended laboratory controls (Guselkumab)

Parameter	Pre-treatment	Thereafter, every 3-6 months
Full Blood count	x	x
Liver enzymes	x	x
Serum creatinine	x	
Urine status	x	
Pregnancy test (urine or blood)	x	
CRP	x	
HBV/HCV	x	
HIV	x	
Interferon gamma release assay (TB exclusion)	x	

Not all tests may be necessary for all patients. Patient history, risk exposure and patient characteristics must be considered. Further specific testing may be required according to clinical signs, risk, and exposure.

The recommendations are based on clinical experience. No evidence is available.

2.8.3. Adverse drug reactions

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Overall, guselkumab was well tolerated in clinical trials in psoriasis. The most commonly reported adverse drug reactions were upper respiratory tract infections, and, less frequently, gastroenteritis, herpes, headache, diarrhoea, urticaria and arthralgias. Less than 1% of injections led to usually mild or moderate injection site reaction such as erythema.

2.8.4. Special consideration during treatment

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Surgery



The overall risk of infections in patients treated with anti-IL-23 antibodies (for example the rate of serious infections observed per 100 patient-years of exposure in clinical trials in psoriasis) appears to be comparable to that of other classes of targeted therapies in psoriasis; however, specific infections related to the mechanism of action, such as an increased Tb risk with TNFi and an increased risk of mucocutaneous candida infections with IL-17 inhibitors have not been reported for anti-IL-23 antibodies. There is only limited data available on the management of surgery in patients receiving anti-IL-23 treatment. The decision to interrupt guselkumab treatment prior to surgery must be based on individual factors, such as type and risk of surgical procedure, patient characteristics, individual infection risk etc. In case of continuing treatment, the procedure is best placed between two doses.

2.8.5. Important contraindications

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Absolute contraindications:

- Clinically relevant active infections such as active Tb

Relative contraindications:

- Acute, recurrent or chronic infections
- Pregnant or breastfeeding woman (due to lack of experience in humans)

2.8.6. Drug interactions

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Combination therapy with immunosuppressants, including biologics, or phototherapy have not been evaluated.

Overdose/ measures in case of overdose

In clinical trials single guselkumab doses of up to 10 mg/kg bodyweight have been administered intravenously and up to 300 mg subcutaneously with no observation of toxic effects. In the event of overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and appropriate symptomatic treatment be instituted immediately.



2.9. Infliximab

2.9.1. Instructions for use

Table 34: Instructions for use (Infliximab)

Pre-treatment

100% Agreement¹

- Physicians are encouraged to enrol their patients in a registry (if available)
- Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI/Skindex-29 or -17)
- History focusing on prior exposure to treatments. History and clinical examination should focus on malignancies, infection, congestive heart failure, and neurological symptoms
- Recommended measures include:
 - Check for skin cancer
 - Check for lymphadenopathy
 - Laboratory parameters (see **Table 35**)
 - Exclusion of tuberculosis (see chapter: “tuberculosis”)
 - Check for evidence of active infection
 - Check need for vaccinations
- Reliable contraception

During treatment

- Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI/ Skindex-29 or -17)
- Clinical examination should focus on malignancies, risk factors for serious infections, congestive heart failure, and neurological symptoms
- Recommended measures include:
 - Check for skin cancer



- Check for lymphadenopathy
- Laboratory parameters (see **Table 35**)

- Reliable contraception

Post-treatment

- After discontinuation of infliximab, patients should be followed up with medical history and physical examination
- For information regarding the ongoing need for contraception immediately following biologic treatment cessation, please see chapter “wish for child / pregnancy”

¹ due to personal-financial conflict of interest 4 abstentions

2.9.2. Recommendations for lab controls

Table 35: Recommended laboratory controls (Infliximab)

Parameter	Period in weeks			
	Pre-treatment	2	6	Thereafter, prior to each infusion
Full blood count	x	x	x	x
Liver enzymes	x	x	x	x
Serum creatinine	x			
Urine status	x			
Pregnancy test (urine or blood)	x			
CRP	x	x	x	x
HBV/HCV	x			
HIV	x			
Interferon gamma release assay (TB exclusion)	x			

Not all tests may be necessary for all patients. Patient history, risk exposure and patient characteristics have to be taken into account. Further specific testing may be required according to clinical signs, risk, and exposure.

The recommendations are based on clinical experience. No evidence is available.



2.9.3. Adverse drug reactions

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Key safety considerations for infliximab include common side effects (mainly infections and infusion reactions), as well as rare but important side effects, such as opportunistic infections, particularly tuberculosis. The relationship between infliximab and some other significant events that have been observed infrequently during treatment, including cases of severe liver toxicity, lymphoma or other malignancy, or congestive heart failure is less clear and therefore increased caution is recommended.

Infusion reactions

In clinical trials, infusion reactions (defined as any adverse event occurring during or within one hour after completion of the infusion) were the most common reasons for discontinuation of therapy. Infusion reactions were seen in approximately 18 % of infliximab-treated patients in phase III clinical trials vs approximately 5 % of patients receiving placebo. Most infusion reactions were mild to moderate, and included symptoms such as flushing, pruritus, fever or chills, headache, and urticaria. Severe infusion reactions, such as anaphylactic reactions, convulsions, erythematous rash and serum-sickness-like delayed-type hypersensitivity reactions (myalgia, arthralgia and/or exanthema occurring between one and 14 days after infusion) occurred in ~1 % of patients. One percent of infusions were accompanied by cardiopulmonary reactions, primarily chest pain, hypotension, hypertension or dyspnoea. Approximately 3 % of patients discontinued infliximab because of infusion reactions, and all patients recovered with treatment and/or discontinuation of the infusion.

If mild to moderate infusion reactions occur, treatment can usually be continued after decreasing the infusion rate or temporarily stopping the infusion. In these cases, pre-treatment with oral antihistamines, paracetamol/acetaminophen, and/or glucocorticosteroids should be considered for future infusions.

Infections

Infections are the most common serious adverse event described in spontaneous post-launch reports. Tuberculosis, bacterial infections (including sepsis and pneumonia), invasive fungal, viral, and other opportunistic infections have been observed in patients receiving infliximab. Some infections have been fatal; the most frequently reported opportunistic infections with a mortality rate of > 5% include pneumocystis, candidiasis, listeriosis and aspergillosis. In all



completed clinical trials with infliximab, 36.4 % of patients in the placebo groups ($n = 1600$; average weeks of follow-up: 29.0) and 52.0 % of patients in the infliximab groups ($n = 5706$; average weeks of follow-up: 45.5) experienced more than one infection (Centocor, Inc. Data on file, Module 2.7.4 summary of clinical safety) (Psoriasis BLA, 2006; Pages 207, 209, 219). Serious infections were seen in 2 % of placebo-treated and in 4 % of infliximab-treated patients, the difference being due mainly to a higher rate of pneumonia and abscesses among patients receiving infliximab.

Antinuclear antibodies and skin symptoms reminiscent of cutaneous lupus erythematosus

Approximately half of patients treated with infliximab may develop ANA that are frequently of transient nature. Anti-dsDNA antibodies were newly detected in approximately one-fifth of infliximab-treated patients compared with 0 % of placebo-treated patients. These autoantibodies are usually of low titre and mostly not associated with clinical symptoms. Treatment can be continued in patients with newly developed ANA without associated symptoms. The formation of autoantibodies has been associated in less than 1 % of cases with the onset of symptoms reminiscent of lupus erythematosus, which are almost always confined to the skin. In such patients it is recommended to discontinue infliximab treatment.

TNFi paradoxical psoriasis

TNFi are effectively used in the field of inflammatory musculoskeletal, skin and bowel diseases. However, TNFi cutaneous side effects are possible. Paradoxical reactions include the development of psoriasis, pustular psoriasis and psoriasiform lesions, reflecting an immunological paradox, as TNFi agents are used in the treatment of psoriasis. Psoriasis can be triggered in 1, 5 – 5 % under the use of TNFi agents. In 52% of the cases the appearance is a palmoplantar pustulosis, in 49% a plaque type and in 15% a guttata-type. A potential mechanism could be the increase of the Interferon alpha production. These psoriasiform lesions can be managed by topical or systemic anti-psoriatic-therapies and/or switch to another biological, preferably from a different class.⁵⁸⁻⁶⁰

Table 36: Overview of important side effects

Very frequent	Injection-site reaction
Frequent	Infections
Occasional	Tuberculosis, reactivation of latent tuberculosis, heart failure
Rare	Allergic reactions, adverse reactions of the haematologic system, demyelinating diseases



Very rare

Autoantibodies, drug-induced lupus, malignancies

2.9.4. Special consideration during treatment

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Surgery

In the absence of controlled studies, the decision on how to manage TNFi therapy during surgery will be primarily based on individual factors such as activity of underlying disease, individual infection risk, reason for, type and risk of surgical procedure etc. While in many patients, minor surgical procedures may be carried out without interrupting TNFi therapy but with intensified prophylaxis and monitoring for pre- and peri-operative infections, treatment may be halted for some weeks in others. Elective surgery may best be placed between two infliximab infusions given at eight week intervals. In addition, an increased risk for infusion reaction may have to be considered when infusions are paused and restarted.

Infections

Monitoring measures during treatment should take into account that symptoms such as fever can be suppressed during TNFi therapy.

Combination of TNFi and MTX

A treatment with TNFi and methotrexate can be combined. This may reduce the risk of formation of anti-drug antibodies⁶³. This combination is particularly common for infliximab as the risk for the formation of antidrug antibodies formation is highest. The combination may lead to an increased risk of infection, especially when compared to MTX monotherapy, but data is still scarce⁶⁴, see chapter: “Immunogenicity”.

2.9.5. Important contraindications

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Absolute contraindications

- Active tuberculosis or other severe infections such as sepsis, and opportunistic infections
- Active chronic hepatitis B
- Congestive heart failure (NYHA class III/IV)



- Hypersensitivity to infliximab, murine proteins or any component of the formulation

Relative contraindications

- Pregnancy or breastfeeding
- Demyelinating diseases
- Latent tuberculosis
- History of recurrent or severe infections, localized infections, conditions predisposing to infections
- Patients living in geographical areas where tuberculosis and histoplasmosis are widespread
- Psoriasis patients with concomitant systemic lupus erythematosus or multiple sclerosis (MS)
- PUVA > 200 treatments (especially if followed by CsA use) – see chapter: “Cancer”
- Malignancies or lymphoproliferative disorders (see chapter malignancies)
- Hepatobiliary disorders

2.9.6. Drug interactions

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

There are no known interactions of infliximab with the metabolism of other drugs. The combination of infliximab with immunosuppressive drugs may enhance the risk of infection.⁶⁴

The combination with PUVA therapy might enhance the risk for skin cancer development.

There is insufficient information regarding the concomitant use of infliximab with other biological therapeutics used to treat the same conditions as infliximab. The concomitant use of infliximab with these biologics is not recommended because of the possibility of an increased risk of infection.



2.10. Ixekizumab

2.10.1. Instructions for use

Table 37: Instructions for use (Ixekizumab)

Pre-treatment

100% Agreement ¹

- Physicians are encouraged to enrol their patients in a registry (if available)
- Objective assessment of disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI/Skindex-29 or -17)
- Medical history and physical examination including prior exposure to treatments, malignancies, infection, inflammatory bowel disease
- Recommended measures include:
 - Check for skin cancer
 - Check for lymphadenopathy
 - Laboratory parameters (see **Table 38**)
 - Exclusion of tuberculosis (see chapter tuberculosis)
 - Check for evidence of active infection
 - Check need for vaccines
- Reliable contraception

During treatment

- Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI, Skindex-29 or 17)
- Laboratory parameters (see **Table 38**)
- Medical history and physical examination focusing on infections (in particular upper respiratory tract infections, candida, tuberculosis), contraception, signs or symptoms of inflammatory bowel disease

Post-treatment



- After discontinuation of ixekizumab, patients should be followed up with medical history and physical examination
- For information regarding the ongoing need for contraception immediately following biologic treatment cessation, please see chapter “wish for child / pregnancy”

¹ due to personal-financial conflict of interest 4 abstentions

2.10.2. Recommendations for lab controls

Table 38: Recommended laboratory controls (Ixekizumab)

Parameter	Pre-treatment	After 3-6 months
Full blood count	X	X
Liver enzymes	X	X
Serum creatinine	X	
Urine status	X	
Pregnancy test (urine or blood)	X	
CRP	X	
HBV/HCV	X	
HIV	X	
Interferon gamma release assay (TB exclusion)	X	
<i>Not all tests may be necessary for all patients. Patient history, risk exposure and patient characteristics have to be taken into account. Further specific testing may be required according to clinical signs, risk, and exposure.</i>		
The recommendations are based on clinical experience. No evidence is available.		

2.10.3. Adverse drug reactions

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Common adverse events (occurring in $\geq 10\%$ of patients) include injection site reactions, upper airway infections. Adverse events (occurring in 1-10% of patients) include oropharyngeal pain, nausea, tinea infections, and mucocutaneous herpes simplex.



Injection site reactions

The most frequent injection site reactions observed were erythema and pain. These reactions were predominantly mild to moderate in severity and did not lead to discontinuation of ixekizumab. ¹⁰⁵ The SmPC also notes that a single-blind randomized cross-over study ¹⁰⁶ compared the original formulation with a citrate-free formulation in 45 healthy patients. During injection and 10 minutes after, VAS pain score was significantly lower in patients who received the citrate-free formulation (difference in LS Mean VAS score -21.69 and -4.47, respectively).

^{105,106}

Infections

In the placebo-controlled period of the phase III clinical studies in plaque psoriasis, infections were reported in 27.2 % of patients treated with ixekizumab for up to 12 weeks compared with 22.9 % of patients treated with placebo.

The majority of infections were non-serious and mild to moderate in severity, most of which did not necessitate treatment discontinuation. Serious infections occurred in 13 (0.6 %) of patients treated with ixekizumab and in three (0.4 %) of patients treated with placebo. Over the entire treatment period, infections were reported in 52.8 % of patients treated with ixekizumab (46.9 per 100 patient years). Serious infections were reported in 1.6 % of patients treated with ixekizumab (1.5 per 100 patient years).

Laboratory assessment of neutropenia and thrombocytopenia

In plaque psoriasis studies, 9% of patients receiving ixekizumab developed neutropenia. In most cases, the blood neutrophil count was $\geq 1,000$ cells/mm³. Such levels of neutropenia may persist, fluctuate or be transient. 0.1% of patients receiving ixekizumab developed a neutrophil count < 1000 cells/mm³. In general, neutropenia did not require discontinuation of ixekizumab. 3% of patients exposed to ixekizumab had a shift from a normal baseline platelet value to $< 150,000$ platelet cells/mm³ to $\geq 75,000$ cells/mm³. Thrombocytopenia may persist, fluctuate or be transient.

Inflammatory Bowel Disease

Cases of new or exacerbations of Crohn's disease and ulcerative colitis have been reported. Caution should be exercised when prescribing ixekizumab to patients with inflammatory bowel disease, including Crohn's disease and ulcerative colitis, and patients should be monitored closely.



Candidiasis

Related to the mechanism of action of ixekizumab higher rates of fungal infections, primarily non-serious skin and mucosal candida infections are observed. Early treatment of candida infections, either with topical or systemic treatment is recommended. [For further information on treatment of candidiasis, see SmPC of antifungal drugs or international guidelines.](#) ^{81,82}

Treatment with IL-17 inhibitors is associated with increased risk of infection ⁸⁰, particularly by mucocutaneous and cutaneous candidiasis. Cases are usually described as mild-to-moderate, respond to standard treatment and do not require treatment discontinuation. [In case of recurrent infections, consider changing the antipsoriatic drug.](#) Note that clinically significant, severe infections are always a contraindication for all biologics.

[Recently, two new large studies have been published regarding the safety of ixekizumab. In data from 17 clinical trials involving more than 18,000 patient-years of exposure in almost 7000 patients, the long-term safety profile was consistent with that previously reported in patients with psoriasis. No new or unexpected safety events were detected.](#) ¹⁰⁷

[Another study on the safety of ixekizumab in patients with psoriatic arthritis \(PsA\) in 1401 patients with 2247.7 patient-years showed that the overall safety profile and tolerability of ixekizumab were consistent with the known safety profile in patients with PsA. No new or unexpected safety events were detected](#) ¹⁰⁸.

2.10.4. Special consideration during treatment

Please see SmPC and other sources for complete listing ¹⁰⁹. The guideline subcommittee decided to comment on the following aspects based on references ¹⁰⁹⁻¹¹³.

Surgery

There is no data on the management of surgery in patients treated with ixekizumab. The decision to discontinue ixekizumab prior to surgery must be based on individual factors, such as type and risk of surgical procedure, patient characteristics, severity of psoriasis in case of treatment discontinuation etc. Counselling with the surgeon is advised.

2.10.5. Important contraindications

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Absolute contraindications:

- Clinically important active infections



Relative contraindications:

- Pregnancy or breastfeeding
- Inflammatory bowel disease

2.10.6. Drug interactions

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

In plaque psoriasis studies, the safety of ixekizumab in combination with other immunomodulatory agents or phototherapy has not been evaluated.

No interaction was seen when ixekizumab was administered concomitantly with methotrexate (MTX) and/or corticosteroids in patients with psoriatic arthritis.

Overdose/ measures in case of overdose

Doses up to 180 mg have been administered subcutaneously in clinical trials without dose-limiting toxicity. Overdoses up to 240 mg, subcutaneously, as a single administration in clinical trials, have been reported without any serious adverse events. In the event of overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and appropriate symptomatic treatment be instituted immediately.



2.11. Risankizumab

2.11.1. Instructions for use

Table 39: Instructions for use (Risankizumab)

Pre-treatment

100% Agreement¹

- Physicians are encouraged to enroll their patients in a registry (if available)
- Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI, Skindex-29 or 17)
- Medical history and physical examination including prior exposure to treatments, malignancies, infections
- Recommended measures include:
 - Check for skin cancer
 - Check for lymphadenopathy
 - Laboratory parameters (see **Table 40**)
 - Exclusion of tuberculosis (see chapter: “tuberculosis”)
 - Check for evidence of active infection
 - Check need for vaccines
- Reliable contraception

During treatment

- Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI, Skindex-29 or 17)
- Laboratory parameters (see **Table 40**)
- Medical history and physical examination including infections, including monitoring signs and symptoms of tuberculosis
- Reliable contraception

Post-treatment



- After discontinuation of risankizumab, patients should be followed up with medical history and physical examination
- For information regarding the ongoing need for contraception immediately following biologic treatment cessation, please see chapter “wish for child / pregnancy”

¹ due to personal-financial conflict of interest 4 abstentions

2.11.2. Recommendations for lab controls

Table 40: Recommended laboratory controls (Risankizumab) ¹¹⁴

Parameter	Period in weeks/months	
	Pre-treatment	Thereafter, every 3-6 months
Full Blood count	x	x
Liver enzymes	x	x
Serum creatinine	x	
Urine status	x	
Pregnancy test (urine or blood)	x	
CRP	x	
HBV/HCV	x	
HIV	x	
Interferon gamma release assay (TB exclusion)	x	

Not all tests may be necessary for all patients. Patient history, risk exposure and patient characteristics must be considered. Further specific testing may be required according to clinical signs, risk, and exposure.

The recommendations are based on clinical experience. No additional evidence available.

2.11.3. Adverse drug reactions

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Most commonly reported adverse drug reactions were upper respiratory tract infections, including nasopharyngitis, rhinitis, pharyngitis, sinusitis, and tonsillitis.



Injection-site reactions include erythema, pain, pruritus, reaction, swelling, hematoma and haemorrhage.

A recent study ¹¹⁵ using the FDA adverse reporting database (FAERS) suggested a potential signal between use of risankizumab and reports of cerebrovascular accident (CVA). However, this finding was not consistent across the p19 class, and whilst the authors explored the potential confounding effect of the underlying disease (psoriasis) associated risk of CVA, long-term observational data will be necessary to establish whether or not this association is real, and if so, the causal relationship between the two.

2.11.4. Special consideration during treatment

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Surgery

There is only limited data available on the management of surgery in patients receiving anti-IL-23 treatment. The decision of interrupting risankizumab treatment prior to surgery must be based on individual factors, such as type and risk of surgical procedure, patient characteristics, individual infection risk etc. In case of continuing treatment, the procedure is best placed between two doses.

2.11.5. Important contraindications

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects: ¹¹⁴

Absolute contraindications:

- Clinically important active infections

Relative contraindications:

- Acute, recurrent or chronic infections
- Pregnancy or breastfeeding

2.11.6. Drug interactions

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Combination therapy with immunosuppressants, including biologics, or phototherapy have not been evaluated. ^{114,116}



Overdose/ measures in case of overdose

In the event of overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and appropriate symptomatic treatment be instituted immediately ¹¹⁴.



2.12. Secukinumab

2.12.1. Instructions for use

Table 41: Instructions for use (Secukinumab)

Pre-treatment

100% Agreement¹

- Physicians are encouraged to enrol their patients in a registry (if available)
- Objective assessment of disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI/Skindex-29 or -17)
- Medical history and physical examination including prior exposure to treatments, malignancies, infections, inflammatory bowel disease
- Recommended measures include:
 - Check for skin cancer
 - Check for lymphadenopathy
 - Laboratory parameters (see **Table 42**)
 - Exclusion of tuberculosis (see chapter: “tuberculosis”)
 - Check for evidence of active infection
 - Check need for vaccines
- Reliable contraception

During treatment

- Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI, Skindex-29 or 17)
- Laboratory parameters (see **Table 42**)
- Medical history and physical examination focusing on infections (in particular upper respiratory tract infections, candida, tuberculosis), contraception, signs or symptoms of inflammatory bowel disease

Post-treatment



- After discontinuation of secukinumab, patients should be followed up with medical history and physical examination
- For information regarding the ongoing need for contraception immediately following biologic treatment cessation, please see chapter “wish for child / pregnancy”

¹ due to personal-financial conflict of interest 4 abstentions

2.12.2. Recommendations for lab controls

Table 42: Recommended laboratory controls (Secukinumab)

Parameter	Period in weeks/months	
	Pre-treatment	After 3-6 months
Full blood count	X	X
Liver enzymes	X	X
Serum creatinine	X	
Urine status	X	
Pregnancy test (urine or blood)	X	
CRP	X	
HBV/HCV	X	
HIV	X	
Tuberculosis	X	
<i>Not all tests may be necessary for all patients. Patient history, risk exposure and patient characteristics have to be taken into account. Further specific testing may be required according to clinical signs, risk, and exposure.</i>		
The recommendations are based on clinical experience. No evidence is available.		

2.12.3. Adverse drug reactions ^{117,118}

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Infections

In the placebo-controlled period of clinical studies in plaque psoriasis infections were reported in 28.7% of patients treated with secukinumab and 18.9% of patients with placebo. Most cases of infection were mild or moderate upper respiratory tract infections which did not require



treatment discontinuation. Mucosal or cutaneous candidiasis were more frequent with secukinumab. Cases responded to standard treatment and did not require treatment discontinuation.¹¹⁹

Neutropenia

Neutropenia is a rare adverse effect. The exposure-adjusted incidence rate per 100 patient-years for neutropenia with secukinumab treatment was 0.3% in a total of 5181 patients from plaque psoriasis clinical trials representing secukinumab exposures of 10,416.9 patient-years. Grade 3 neutropenia (defined as an absolute neutrophil count between 1.0 and $0.5 \times 10^9/L$) was reported in 0.6% patients and grade 4 neutropenia (defined as an absolute neutrophil count of less than $0.5 \times 10^9/L$) was reported in 0.04% patients with no dose dependency or temporal relationship to infection in most cases. Most cases of neutropenia were mild, transient and reversible. In contrast to ixekizumab, thrombocytopenia has not been reported.¹²⁰

Crohn's disease

The effect of secukinumab on Crohn's disease was studied in a randomized placebo-controlled proof-of-concept trial¹²¹. Secukinumab 2x10 mg/kg was administered i.v. on day one and day 22. The study was prematurely discontinued due to lack of effect. Four of 39 patients reported exacerbations of Crohn's disease. In the phase III psoriasis clinical trial program, three cases of Crohn's disease were reported as serious adverse events out of which two were exacerbations of pre-existing disease.¹²² In patients with psoriasis and Crohn's disease caution, should be exercised and alternative biologicals may be considered before using secukinumab.

Candidiasis

Related to the mechanism of action of secukinumab, higher rates of fungal infections, primarily non-serious skin and mucosal candida infections are observed.⁸⁰ Early treatment of candida infections, either with topical or systemic treatment is recommended. [For further information on treatment of candidiasis, see SmPC of antifungal drugs or international guidelines.](#)^{81,82} Cases are usually described as mild-to-moderate, respond to standard treatment and do not require treatment discontinuation. [In case of recurrent infections, consider changing the antipsoriatic drug.](#) Note that clinically significant, severe infections are always a contraindication for all biologicals.



2.12.4. Special consideration during treatment

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Surgery

Real life data on perioperative management of secukinumab has not yet become available. However, there is no evidence to date that continuous treatment with secukinumab will lead to perioperative complications. Patients who need minor surgical treatments including dental treatments and skin surgery, may continue secukinumab treatment. In the case of major surgery, the decision of secukinumab withdrawal should be taken case-by-case considering patient characteristics, the risk of infection, the risk of psoriasis worsening and after counselling with the surgeon.

2.12.5. Important contraindications

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Absolute contraindications:

- Clinically important active infections

Relative contraindications:

- Pregnancy or breastfeeding
- Inflammatory bowel disease

2.12.6. Drug interactions

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Combinations of secukinumab with other immunosuppressive agents (except for methotrexate)¹¹⁹ or phototherapy have not been studied.

IL-17 has no direct effect on CYP450 expression. The anti-inflammatory effect of secukinumab may influence CYP450 levels and therefore might interact with the doses of CYP450 dependent medication, especially those with a narrow therapeutic range such as warfarin.¹¹⁹ Therapeutic monitoring of such drugs should be considered while starting secukinumab.



Overdose/ measures in case of overdose

No cases of overdose have been reported. Doses of up to 30 mg/kg have been administered in clinical studies. In case of overdose, the patient should be monitored and appropriate symptomatic treatment be instituted immediately.



2.13. Tildrakizumab

2.13.1. Instructions for use

Table 43: Instructions for use (Tildrakizumab)

Pre-treatment

100% Agreement¹

- Physicians are encouraged to enroll their patients in a registry (if available)
- Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI, Skindex-29 or 17)
- Medical history and physical examination including prior exposure to treatments, malignancies, infections
- Recommended measures include:
 - Check for skin cancer
 - Check for lymphadenopathy
 - Laboratory parameters (see **Table 44**)
 - Exclusion of tuberculosis (see chapter: “tuberculosis”)
 - Check for evidence of active infection
 - Check need for vaccines
- Reliable contraception

During treatment

- Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI, Skindex-29 or 17)
- Laboratory parameters (see **Table 44**)
- Medical history and physical examination including infections, including monitoring signs and symptoms of tuberculosis
- Reliable contraception

Post-treatment



- After discontinuation of tildrakizumab, patients should be followed up with medical history and physical examination
- For information regarding the ongoing need for contraception immediately following biologic treatment cessation, please see chapter: “Wish for child / pregnancy”

¹ due to personal-financial conflict of interest 4 abstentions

2.13.2. Recommendations for lab controls

Table 44: Recommended laboratory controls (Tildrakizumab)

Parameter	Pre-treatment	Thereafter, every 3-6 months
Full Blood count	x	x
Liver enzymes	x	x
Serum creatinine	x	
Urine status	x	
Pregnancy test (urine or blood)	x	
CRP	x	
HBV/HCV	x	
HIV	x	
Interferon gamma release assay (TB exclusion)	x	

Not all tests may be necessary for all patients. Patient history, risk exposure and patient characteristics must be considered. Further specific testing may be required according to clinical signs, risk, and exposure.

The recommendations are based on clinical experience. No evidence is available.

2.13.3. Adverse drug reactions

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

During the placebo controlled phase of clinical studies, all types of infections were low and equal to placebo ¹²³ as well as exposure-adjusted incidence rates of severe infections, malignancies, confirmed extended MACEs, and hypersensitivity reactions over 148 weeks ¹²⁴.

2.13.4. Special consideration during treatment

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Surgery

Due to the specific mechanism of action of tildrakizumab, IL23p19 inhibition, the probability of wound healing disorders occurring is low. Patients undergoing surgery should be closely



screened for infections and it is recommended to schedule operations so that they do not fall within the period of the next tildrakizumab dose.

2.13.5. Important contraindications

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Absolute contraindications:

- Clinically important active infections

Relative contraindications:

- Acute, recurrent or chronic infections
- Pregnancy/Breastfeeding

2.13.6. Drug interactions

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Tildrakizumab is cleared by general protein catabolism processes with no contribution of cytochrome P450 enzymes, and it is not eliminated by renal or hepatic pathways. Therefore, tildrakizumab does not affect the pharmacokinetics of concomitant medications metabolised by CYP enzyme.¹²⁵

Overdose

Doses up to 10 mg/kg intravenously have been safely administered in clinical trials.¹²⁵



2.14. Ustekinumab

2.14.1. Instructions for use

Table 45: Instructions for use (Ustekinumab)

Pre-treatment

100% Agreement ¹

- Physicians are encouraged to enroll their patients in a registry (if available)
- Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI, Skindex-29 or 17)
- Medical history and physical examination including prior exposure to treatments, malignancies, infections
- Recommended measures include:
 - Check for skin cancer
 - Check for lymphadenopathy
 - Laboratory parameters (see **Table 46**)
 - Exclusion of tuberculosis (see chapter: “tuberculosis”)
 - Check for evidence of active infection
 - Check need for vaccines
- Reliable contraception

During treatment

- Objective assessment of the disease (such as PASI/BSA/PGA; arthritis)
- HRQoL (such as DLQI, Skindex-29 or 17)
- Laboratory parameters (see **Table 46**)
- Medical history and physical examination including infections, including monitoring signs and symptoms of tuberculosis
- Reliable contraception

Post-treatment



- After discontinuation of ustekinumab, patients should be followed up with medical history and physical examination
- For information regarding the ongoing need for contraception immediately following biologic treatment cessation, please see chapter “wish for child / pregnancy”

¹ due to personal-financial conflict of interest 4 abstentions

2.14.2. Recommendations for lab controls

Table 46: Recommended laboratory controls (Ustekinumab)

Parameter	Pre-treatment	Thereafter, every 3-6 months
Full Blood count	x	x
Liver enzymes	x	x
Serum creatinine	x	
Urine status	x	
Pregnancy test (urine or blood)	x	
CRP	x	
HBV/HCV	x	
HIV	x	
Interferon gamma release assay (TB exclusion)	x	
<i>Not all tests may be necessary for all patients. Patient history, risk exposure and patient characteristics must be considered. Further specific testing may be required according to clinical signs, risk, and exposure.</i>		
The recommendations are based on clinical experience. No evidence is available.		

2.14.3. Adverse drug reactions

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Infections

Placebo-controlled studies of patients with psoriasis or psoriatic arthritis demonstrate a similar incidence of infections including serious infections between ustekinumab-treated and placebo-treated patients with no relationship between incidence of infections and dose of ustekinumab received. No patient with latent tuberculosis who received antibiotic prophylaxis prior to ustekinumab treatment developed tuberculosis.

2.14.4. Special consideration during treatment

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:



Surgery

No recommendation exists in the SmPC regarding surgery in patients treated with ustekinumab. In case of major surgery with high risk of infectious complications, it seems prudent to withhold ustekinumab treatment 15 weeks before surgical intervention. Re-start treatment following surgery if wound healing is satisfactory and there is no evidence of infection.

2.14.5. Important contraindications

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

Absolute contraindications:

- Clinically important active infections

Relative contraindications:

- Acute, recurrent or chronic infections
- Pregnancy or breastfeeding
- Previous history of malignancies

2.14.6. Drug interactions

Please see SmPC and other sources for complete listing. The guideline subcommittee decided to comment on the following aspects:

As IL-12 and IL-23 do not alter CYP 450 enzymes in vitro, no relevant interactions with drugs are expected with ustekinumab ¹²⁶.

Overdose/measures in case of overdose

Single doses of up to 6 mg/kg have been administered in clinical studies with no apparent toxicity.



2.15. Biosimilars

Biosimilars are defined as “a biological medicine that is similar to another biological medicine that has already been authorised for use. Biological medicines are medicines that are made by or derived from a biological source, such as a bacterium or yeast. They can consist of relatively small molecules such as human insulin or erythropoietin, or complex molecules such as monoclonal antibodies”¹²⁷. Biosimilars are developed to be similar to an existing biologic (the ‘reference medicine’). They are not 100 % identical but “essentially the same biological substance, though there may be minor differences due to their complex nature and production methods”¹²⁷. For etanercept and its biosimilar GP2015, multiple switches have been shown to not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis¹²⁸.

Two systematic reviews^{129,130} identified through a non-systematic search evaluated the efficacy and safety of biosimilars in patients with psoriasis.

Moots et al.¹²⁹ identified two studies comparing adalimumab and etanercept with their respective biosimilars (ABP501 and GP2015), while García-Beloso et al.¹³⁰ identified six studies comparing adalimumab with biosimilars, including one study in patients with psoriasis or psoriasis arthritis.

Moots et al.¹²⁹ reported that PASI75 response rates after 12 weeks were comparable between etanercept (72%) and the biosimilar GP2015 (70%), but did not report on PASI75 response rates for adalimumab and its biosimilar ABP501. Injection site reactions were more common with adalimumab (5.2%) and etanercept (14.2%) compared to their respective biosimilars (ABP501 (1.7%) and GP2015 (4.9%)). The incidence of adverse events after 16 weeks was higher in the biosimilar ABP501 group (67.2%) than in the adalimumab group (63.3%), but the incidence of serious adverse events was similar between the two groups (5.1% vs. 4.6%).¹²⁹

García-Beloso et al. did not perform a meta-analysis due to heterogeneity but concluded that switching from adalimumab to an adalimumab biosimilar may not affect efficacy, safety, or immunogenicity based on a narrative synthesis of the results.¹³⁰

However, it should be noted that this information is based on a selective (non-systematic) search and that a comprehensive systematic review may provide more robust evidence.



At the time of preparing this guideline, biosimilars were available in Europe for adalimumab, etanercept and infliximab. The recommendations of this guideline apply equally to the originator and its biosimilar.

At the time of conducting this guideline, the Food and Drug Administration (FDA) has accepted a biologics license application for an ustekinumab biosimilar candidate (AVT04). It is expected that the FDA will announce its final decision on this ustekinumab biosimilar in the second half of 2023 ¹³¹.



2.16. Newly approved medications and treatments in the pipeline

The field of psoriasis treatments is evolving rapidly and several new treatments have been developed. For any guideline, it is a challenge to be up to date with the rapidly changing market of psoriasis treatments. New medications with very little use during regular clinical practice are difficult to assess with expert opinion knowledge. The guideline group has decided to focus on the licensed treatment options at the time point of the consensus conference. The group decided against a prospective inclusion of new drugs that are likely to be licensed in the near future, also in light of the lack of expert experience with these new drugs.

This guideline should be maintained as a “living” guideline, closely linked to the “living” Psoriasis Cochrane Review. An update including newly approved medications will be pursued in due time.



3. Guidance for specific clinical and comorbid situations

3.1. Psoriatic arthritis: How should psoriasis patients with concomitant psoriatic arthritis be managed?

This chapter is based on the corresponding chapter in the previous versions of the guideline ^{17,18}. An existing systematic review and meta-analysis was updated, details of which can be found in the individual chapter, see website.

The aim of this updated review is to continuously inform the guideline development group about new evidence on the treatment of patients with plaque type psoriasis who also have psoriatic arthritis (PsA). Therefore, only treatments approved for plaque-type psoriasis and psoriatic arthritis are discussed. Please note that there are an increasing number of treatments available that are only approved for psoriatic arthritis and that clinical trials are increasingly distinguishing between different manifestations of PsA, namely peripheral arthritis, axial disease, enthesitis and dactylitis. Please consult the relevant guidelines and treatment recommendations, which focus primarily on PsA ^{132,133}.

Results/Answer ¹³⁴⁻¹³⁷:

We **recommend** interdisciplinary cooperation with a rheumatologist for the confirmation of the diagnosis of psoriatic arthritis and the selection of a suitable treatment whenever needed.



STRONG CONSENSUS¹

100% Agreement

EXPERT CONSENSUS

¹ due to personal-financial conflict of interest 4 abstentions

Treatments are usually categorized as NSAIDs (e. g. diclofenac), conventional synthetic disease modifying anti rheumatic drugs (csDMARDs) e. g. MTX, targeted synthetic (ts)DMARDs (e.g. apremilast) and biological (b)DMARDs (e. g. TNFi).

Head to head trials allowing direct comparison between the different groups or between the individual drugs are extremely rare. Indirect comparisons, e.g. network meta-analyses, are limited by the low number of trials for psoriatic arthritis. See Table 47 for an overview of RCT data on psoriatic arthritis.

Table 47: Summary of the results for drugs approved for psoriasis of the skin and psoriatic arthritis (Dressler et al. ¹³⁸ updated, see methods section, blue – new data/studies in March 2023

	Patients achieving ARC20 after 12-24 weeks	Patients with at least one adverse event
--	--	--



	RR	95% CI	Certainty Evidence (GRADE)	RR	95% CI	Certainty Evidence (GRADE)
Head-to-head comparisons:						
ADA 40 mg Q2W+ MTX 15 mg p.o./s.c. QW vs. MTX up to 20-25 mg p.o./s.c. or highest tolerable dose QW	2.06	1.55 to 2.73	LOW	1.08	0.88 to 1.32	VERY LOW
ADA 40mg EOW (1) vs. SEC 300mg LD then Q4W	0.92	0.82 to 1.02	MODERATE	1.02	0.95 to 1.10	MODERATE
APR vs. MTX (no dosage given)	0.83	0.42 to 1.66	VERY LOW	0.53	0.16 to 1.76	VERY LOW
ETA 50mg QW + MTX up to 20mg QW vs. MTX up to 20mg QW	1.28	1.11 to 1.48	LOW	1.01	0.92 to 1.11	MODERATE
INF 5mg/kg w0, 2, 6, 14 + MTX 15mg QW vs. MTX 15mg/ QW	1.40	1.07 to 1.84	VERY LOW	1.65	1.08 to 2.52	VERY LOW
IXE 80mg Q2W (LD 160mg w0) vs. ADA 40mg EOW (1)	1.08	0.86 to 1.36	LOW	1.02*	0.83 to 1.25	MODERATE
Placebo comparisons:						
ADA 40mg EOW (2)	2.08	1.52 to 2.86	MODERATE	1.07	0.83 to 1.39	MODERATE
APR 30mg BID	2.01	1.69 to 2.40	MODERATE	1.24	1.12 to 1.36	LOW
CZP 400mg LD then 200mg Q2W	2.71	1.95 to 3.76	MODERATE	1.01*	0.86 to 1.19	MODERATE
CZP 400mg LD then 400mg Q4W (3)	2.36	1.68 to 3.31	MODERATE	1.05*	0.90 to 1.23	MODERATE
ETA 25mg BIW	5.47	3.27 to 9.16	LOW	no data		
GUS 100mg LD then Q8W (4)	2.13	1.82 to 2.50	HIGH	0.99	0.87 to 1.13	HIGH
INF 5mg/kg w0, 2, 6, 14	4.38	2.24 to 8.56	MODERATE	1.13	0.87 to 1.47	LOW
IXE 80mg Q2W (LD160mg w0)	2.21	1.71 to 2.86	MODERATE	1.39*	1.09 to 1.78	LOW
MTX 7.5mg to 10mg to 15mg	1.82	0.97 to 3.40	LOW	no data		
RZB 150mg w0, 4, 16	1.76	1.56 to 2.00	HIGH	1.03*	0.92 to 1.15	HIGH
SEC 300mg + LD vs. PBO (ACR20 w16-24)	2.55	2.09 to 3.10	MODERATE	1.01	0.91 to 1.11	MODERATE
SEC 300mg + LD vs. PBO (ACR20 w12)	2.74	1.93 to 3.89	MODERATE	0.83	0.65 to 1.06	LOW
UST 45mg	1.95	1.52 to 2.50	HIGH	no data		
UST 90mg (5)	2.26	1.80 to 2.82	MODERATE	0.96	0.75 to 1.24	VERY LOW

1 - 80mg LD only for pts. with moderate-to-severe PsO

2 - No LD of 80mg (this would be the case for PsO)

3 - For psoriasis vulgaris, 400mg Q2W can also be considered

4 - For patients at high risk of joint damage according to clinical judgement, a dose of 100 mg every 4 weeks may be considered (SMPc)

5- For Pso patient with >=100kg (dosis not licensed for PsA); one study reported induction dose of QW (weeks 0-3).

*treatment emergent adverse events

Abbreviations: ACR20 = 20% improvement in American College of Rheumatology response criteria; RR = risk ratio; 95% CI = 95% confidence interval; ETA = etanercept; MTX = methotrexate; mg = milligrams; QW= once a week; INF = infliximab; kg = kilograms IXE = ixekizumab; ADA = adalimumab; Q2W = once every 2 weeks; EOW = every other week; PBO = placebo; APR = apremilast; BID = twice a day; CZP = certolizumab pegol; Q4W = once every 4 weeks; BIW = twice a week; W = week; Sec = secukinumab; LD = loading dose; RZB: risankizumab; GUS: Guselkumab, UST = ustekinumab; Q12W = every 12 weeks.

Non-steroidal anti-inflammatory drugs (NSAIDs)



The role of NSAIDs is usually in the relief of symptoms of psoriatic arthritis for patients with mild and non-erosive articular as well as para-articular involvement. Treatment of NSAIDs should be limited to the lowest required dosage for the shortest period as needed ¹³⁹.

Treatment initiation

We **recommend** starting treatment early to prevent progression of disease and erosive destruction of joints.



STRONG CONSENSUS ¹

100% Agreement

EXPERT CONSENSUS

¹ due to personal-financial conflict of interest 4 abstentions

Peripheral active joint involvement (PsA) despite the use of NSAIDs or glucocorticoid site injections (if applicable) and/or polyarthritis increased inflammatory markers and erosive changes, and extra-articular musculoskeletal manifestations are indicators that systemic therapy is needed.

Conventional synthetic DMARDs (e.g. MTX)

We **suggest** monotherapy with a synthetic DMARD (e.g. MTX) as first-line treatment for most patients with moderate to severe psoriasis of the skin and active joint involvement (PsA).



STRONG CONSENSUS ¹

100% Agreement

EVIDENCE AND EXPERT CONSENSUS
TABLE 47

¹ due to personal-financial conflict of interest 4 abstentions

This recommendation takes account of the label/price/reimbursement situation in most European countries, the efficacy on skin and peripheral joints, the safety profile and the long-term experience.



Biological DMARDs

<p>For patients with an inadequate response after at least one synthetic DMARD, we recommend using a biological DMARD as monotherapy or in combination with a synthetic DMARD.</p> <p><i>In cases of severe active joint involvement (PsA) where a sufficient response cannot be expected with the use of a conventional treatment, we recommend using a biologic as first-line therapy.</i></p>	↑↑	<p>STRONG CONSENSUS</p> <p style="text-align: center;">100% Agreement</p> <p>EVIDENCE AND EXPERT CONSENSUS TABLE 47</p>
<p>When choosing a bDMARD for patients with moderate to severe psoriasis of the skin and active joint involvement (PsA), we recommend taking into account aspects of efficacy with regard to skin and the joints, comorbidity, practicability and safety.</p>	↑↑	<p>STRONG CONSENSUS</p> <p style="text-align: center;">100% Agreement</p> <p>EXPERT CONSENSUS</p>

¹ due to personal-financial conflict of interest 4 abstentions

The following drugs have been approved for the treatment of psoriatic arthritis by the European Medicines Agency: the TNFi adalimumab, certolizumab – pegol, etanercept, and infliximab; the IL-17 antagonists ixekizumab and secukinumab; the IL-23 antagonists guselkumab and risankizumab and the IL12/23p40 antagonist ustekinumab.

For the available evidence see Table 47.

Previous guidelines have given preference to TNFi over other bDMARDs. *The available evidence does not support this approach any longer and shows that other drugs approved by the European Medicines Agency for PsA might be equally effective.* Biological DMARDs can be used as monotherapy or in combination with a conventional synthetic DMARD.

Small molecules

Apremilast is the only small molecule currently approved for both plaque type psoriasis and psoriatic arthritis. There are no head-to-head trials comparing apremilast with biological DMARDs. A head-to-head trial with MTX showed comparable efficacy ¹⁴⁰.

<p>We suggest using apremilast for patients with moderate to severe psoriasis of the skin and active joint involvement (PsA) if an oral treatment is desired or if other systemic agents have led to an inadequate response or if they are contraindicated or not tolerated.</p>	↑	<p>STRONG CONSENSUS ¹</p> <p style="text-align: center;">100% Agreement</p> <p>EVIDENCE AND EXPERT CONSENSUS TABLE 47</p>
---	---	--

¹ due to personal-financial conflict of interest 4 abstentions

In line with the inclusion criteria of this guideline, for this chapter we included only drugs licensed for both, plaque type psoriasis and PsA. Be aware that updacitinib and tofacitinib are



licensed and approved for use in psoriatic arthritis, and can show benefit in psoriasis, although they have not been systematically assessed in the scope of this guideline.

Other treatment options

Local injection of glucocorticoids can be recommended in patients with active mono- or oligoarthritis, dactylitis and in enthesal areas (enthesitis).

Systemic use of glucocorticoids should not be standard for the treatment of psoriatic arthritis, but if needed, e. g. during flares, “systemic steroids at the lowest effective dose may be used with caution”¹⁴¹. Tapering of glucocorticoids should be done slowly and in a step-wise manner when feasible.

Axial spondyloarthritis

We **suggest** using TNFi or IL-17 antagonists for patients with moderate to severe psoriasis of the skin and concomitant PsA manifestation in the form of axial involvement or enthesitis.



STRONG CONSENSUS¹

100% Agreement

EXPERT CONSENSUS

¹ due to personal-financial conflict of interest 4 abstentions



3.2. Inflammatory bowel disease: How should psoriasis patients be managed with concomitant inflammatory bowel disease? (last update: 10/2021)

Narrative review of the existing literature and an assessment of approval status of psoriasis therapies for Crohn’s disease and ulcerative colitis were conducted. Existing guidelines were consulted ^{41,142,143}.

Results/Answer:

<p>We recommend working in collaboration with the treating gastroenterologist when prescribing a systemic therapy in psoriasis patients with concomitant chronic inflammatory bowel disease.</p>	<p>↑↑</p>	
<p>In patients with psoriasis and active IBD or a history of IBD, we recommend to preferentially use approved targeted therapies with a documented efficacy in these conditions:</p> <p><i>Crohn’s disease:</i> anti-TNF (infliximab, adalimumab, certolizumab) and anti-IL-12/23p40 (ustekinumab).</p> <p><i>Ulcerative colitis:</i> anti-TNF (infliximab, adalimumab) and anti-IL-12/23p40 (ustekinumab).</p>	<p>↑↑</p>	
<p>If these first-choice treatments cannot be used, we suggest the following treatments to be considered as second choice targeted treatment options in patients with psoriasis and IBD:</p> <p><i>Crohn’s disease:</i> Anti-IL-23p19 (preferred risankizumab, guselkumab; also possible: tildrakizumab)</p> <p><i>Ulcerative colitis:</i> Anti-IL-23p19 (preferred risankizumab, guselkumab; also possible: tildrakizumab)</p>	<p>↑</p>	<p>STRONG CONSENSUS¹</p> <p>100% Agreement</p> <p>EXPERT CONSENSUS</p>
<p>If these first-choice treatments cannot be used, we suggest the following treatments to be considered as second choice oral treatment options in patients with psoriasis and IBD</p> <p><i>Crohn’s disease:</i> Methotrexate</p> <p><i>Active ulcerative colitis:</i> Ciclosporine (preferred), apremilast (also possible)</p>	<p>↑</p>	
<p>In combination with other treatments, we suggest acitretin as an adjunct therapy for patients with IBD and psoriasis, especially in cases with mild paradoxical psoriasis</p>	<p>↑</p>	



We suggest against the use of anti-IL 17 antibodies in patients with inflammatory bowel disease.



STRONG CONSENSUS¹

100% Agreement

EXPERT CONSENSUS

¹ due to personal-financial conflict of interest 4 abstentions

Likely due to an overlap in the pathophysiology and genetic background of psoriasis and Crohn's disease, the risk of psoriasis patients developing Crohn's disease is approximately two- to threefold higher compared to the general population ^{144,145}.

The IL-17A antibody secukinumab and the IL-17RA antibody brodalumab have failed in studies in Crohn's disease, with some patients experiencing worsening of their disease during treatment ^{91,121}. Cases of newly onset Crohn's disease and ulcerative colitis have been observed during treatment of psoriasis patients with IL-17 inhibitors. The observed signal is, however, low, and it is presently unclear if the rate exceeds the rate expected in a psoriasis population ¹⁴⁶. In a recent summary of the safety observed in clinical trials of secukinumab in psoriasis, for example, the event-rate per 100 patient-years of exposure was 0.05 (95% confidence interval 0.02-0.1) for Crohn's disease (approximately one case per 2000 patients treated for one year) and 0.1 (0.07-0.2) for ulcerative colitis (approximately one case per 1000 patients treated for one year) ¹²⁰. Since anti-TNF antibodies and ustekinumab, and possibly anti-IL-23 antibodies, are effective in treating Crohn's disease ¹⁴⁷, the use of these biologics in psoriasis may decrease the occurrence of new onset Crohn's disease cases in psoriasis patients. ¹⁴⁸

The prescription information for bimekizumab, ixekizumab and secukinumab include a warning regarding the use of these drugs in patients with inflammatory bowel disease, while active Crohn's disease is a contraindication for the use of brodalumab.

In contrast, ustekinumab, adalimumab, infliximab, and certolizumab are all targeted therapies approved not only for the treatment of psoriasis, but also for the treatment of Crohn's disease and, in the case of adalimumab, infliximab and ustekinumab, ulcerative colitis. Notably, the anti-TNF fusion protein etanercept failed in clinical trials in Crohn's disease (reviewed in Whitlock SM et al. 2018 ¹⁴⁹).

There is an ongoing phase II/III clinical development program for the IL-23p19 inhibitors guselkumab and risankizumab in Crohn's disease and ulcerative colitis. In the case of risankizumab, positive clinical effects have been published for the induction and long term treatment of patients with Crohn's disease ^{147,150} and are supported by immunological findings



in the intestinal mucosa of patients with Crohn's disease receiving the drug¹⁵¹. There are several published case reports on the successful use of guselkumab in patients with Crohn's disease^{152,153}.

Due to their intestinal side effect profile with a relatively frequent induction of abdominal pain, loose stools and diarrhoea, fumarates should not be used in patients with inflammatory bowel disease. Severe gastrointestinal diseases are listed as contraindication in the prescription information of Fumaderm[®] and Skilarence[®].

Inhibition of PDE4 with apremilast has shown positive effects in a phase 2 trial with ulcerative colitis¹⁵⁴.

Methotrexate has limited efficacy in Crohn's disease^{155,156} and probably even less in ulcerative colitis^{157,158}, but there is a considerable body of experience and no signal for a worsening of these conditions.

Acitretin may be considered neutral in patients with psoriasis and inflammatory bowel disease and has been used in the treatment of patients with inflammatory bowel disease that developed psoriasiform lesions (including cases of so called paradoxical psoriasis) during treatment with TNF antagonist⁶⁰.

Cyclosporine is frequently used in the treatment of steroid-refractory ulcerative colitis and has demonstrated long term outcomes similar to those of infliximab¹⁵⁹.



3.3. Cancer: How should psoriasis patients with a history of malignancies be managed?

This chapter is based on the corresponding chapter in the previous versions of the guideline ^{17,18,160}. A search was conducted, details of which can be found in the individual chapter, see website.

Results/Answer:

Theoretically, immunomodulatory therapies used for psoriasis have the potential to affect the course of a malignant disease, and the safety of using them in this context is uncertain.

In clinical practice, different scenarios are associated with different risks and the answer might not be the same for each of them. Patients can present with pre-cancer (such as cervical dysplasia, colonic polyps or Barrett's esophagus), low risk cancer (NMSC, cancer with a long period of non-recurrence, usually defined as more than 5 years), or high-risk cancer (active cancer, recent aggressive cancer).

Available evidence to guide clinicians in these situations is scarce. Patients with malignancies are excluded from randomized clinical trials, so RCTs will not provide valid answers. Information about patients with previous cancer can only come from observational studies, which are less valid, as they are commonly affected by confounding by indication. There are techniques that can help control for this type of confounding, but these kinds of analyses require large numbers of patients that are difficult to enroll. This power issue is the reason for results usually being given for different cancers merged and also for different drugs grouped.

Most of the data available is of marginal relevance to this question:

Overall risk of cancer in psoriasis:

Psoriasis is associated with increased mortality due to many diseases, including an increased risk of cancer. It is not clear whether this is due to the disease itself, or is influenced by lifestyle factors (mainly alcohol and smoking) or therapy ¹⁶¹.

A recent systematic review and meta-analysis of 112 observational cohort studies of patients with psoriasis and psoriatic arthritis revealed a slightly increased risk of several cancer types, particularly keratinocyte cancer and lymphoma ¹⁶².



Association of therapy and incident cancer in psoriasis and other immune-mediated disease:

Some studies have studied the possible association of the use of systemic therapies for psoriasis and incident of cancer (in patients without previous history of cancer).

A systematic review of RCTs and observational studies exploring the risk of cancer in psoriasis patients treated with biologics described an increased risk of non-melanoma skin cancer in those patients being treated with TNFi. However, included studies lacked adjustment for highly relevant confounding factors such as prior phototherapy. Data on other cancers do not show a risk associated with exposure to drugs. However, the studies are likely to be underpowered to ascertain the risk of individual types of cancer. ¹⁶³ [The chapter authors also consider extensive light damage resulting from repeated and prolonged sunbathing as a significant confounding factor, as per their perspective.](#)

Vaengebjerg et al did not find increased risk of cancer in patients with psoriasis and psoriatic arthritis on biologics compared with other systemic therapies ¹⁶². Similarly, recent data has not shown an increase in the incidence of cancer in patients treated with secukinumab ¹⁶⁴ or tildrakizumab, but these studies are based on RCT patients and do not have untreated comparison populations. ¹⁶⁵

There are also some studies describing the risk of cancer associated with systemic therapy for other immune-mediated disorders, mainly rheumatoid arthritis, other rheumatic disorders and inflammatory bowel disease. Results in these disorders might not be appropriately extrapolated to psoriasis patients, as psoriatic patients receive less immunosuppressive therapy (specially corticosteroids) and the associated disorders are different ¹⁶⁶.

Most studies are reassuring and did not find a relationship between exposure to TNFi and risk of incident cancer in rheumatoid arthritis and psoriatic arthritis ¹⁶⁷. Luo et al, analyzing data from nine cohorts, described an increased risk of cancer in psoriatic arthritis patients treated with disease modifying antirheumatic drugs, which was not seen in patients receiving biologics. However, this increase was due to NMSC and included studies have not considered the likely effect of previous PUVA therapy ¹⁶⁸. SmPCs of TNFi contain information regarding the risk of lymphoma/leukemia. However, these are rare events and data supporting this association are conflicting. So far no such association have been shown for psoriasis patients ¹⁶³.



Risk of cancer recurrence in patients exposed to systemic therapy for psoriasis:

Few studies provide information that is relevant for answering this question.

Regarding patients with precancerous conditions (data available only for cervical dysplasia), a study using routine data of women with rheumatoid arthritis (RA), describe that initiation of therapy with a biological disease-modifying anti-rheumatic drug (bDMARD) was associated with an increased, but not statistically significant, risk of high-grade cervical dysplasia or cervical cancer compared to initiation of a nonbiological (nb)DMARD ¹⁶⁹. Conversely, a review analyzing 238 women with RA and a history of cervical carcinoma in situ, no genital cancer was observed in the TNFi-treated group over a median of 5.2 years of follow-up compared with two incidents of genital cancer in the nbDMARD-treated group, during a median follow-up of 3.9 years ¹⁷⁰.

A systematic review of patients with a history of cancer and exposed to TNFi therapy assessing for the risk of the occurrence of new cancer or cancer re-occurrence compared to non-biologic disease modifying antirheumatic drugs (DMARD), included nine studies with 11679 patients. None of them were studies on psoriasis. The outcome measures were heterogeneous, with many studies focused on describing NMSC. Overall, the study did not find an increased risk of recurrence in patients treated with TNFi compared to nbDMARD ¹⁷¹.

A retrospective study, based on routine data, of patients with rheumatoid arthritis and inflammatory bowel disease, and a previous NMSC, described an increased risk of a second NMSC in patients treated with methotrexate that was higher with longer exposures. TNFi use was also associated with an increased risk, mostly in a subgroup (patients with RA and concomitant use of methotrexate). ¹⁷²

Another systematic review analyzed the risk of cancer recurrence in patients with immune-mediated diseases exposed to immune-suppressive therapies. They included 16 observational studies with 11702 participants after a cancer diagnosis and with 1698 new or recurrent cases of cancer. Only one very small study, and not contributing to the final analysis, was focused on psoriasis patients. Overall, rates of cancer recurrence were similar among participants receiving TNFi therapy, immune-modulator therapy or no immunosuppression, but was higher among patients receiving combination immune suppression ¹⁷³.

French guidelines have reviewed the risk of cancer associated with systemic therapies. Ciclosporine has been clearly linked to an increased risk of cancer and a recommendation to



avoid it has been issued. Evidence from larger patient cohort over long periods of time on the risk of the newer drugs such as the anti IL 17, anti 23 antibodies and apremilast is still very scarce.⁴¹ From a theoretical point of view, acitretin has lower efficacy but might also have the lowest risk in these patients. Phototherapy is associated with skin cancer, but not with other cancers. Although evidence is not strong, there does not seem to be a difference in risk with methotrexate and TNFi, except for a possible increase in risk of NMSC for methotrexate⁴¹.



<p>We recommend taking the burden of psoriasis, and the risk of cancer worsening or recurrence (pre-cancer vs low risk vs high risk) into account for shared therapeutic decision making.</p>	<p>↑↑</p>	
<p>For patients with recent malignancy we recommend topical therapies, phototherapy (narrow band UVB) * and/or acitretin. *except patients with a recent, and/or high risk of cutaneous malignancy</p>	<p>↑↑</p>	
<p>We recommend to discuss the decision to initiate immunosuppressive therapies, in psoriasis patients with a current or recent diagnosis of cancer in the previous five years case-by-case with cancer specialists and to reach an informed decision, respecting the patient's preference.</p>	<p>↑↑</p>	
<p>In case of inadequate response to topical therapies, phototherapy, (narrow band UVB) and/or acitretin we suggest using MTX in psoriasis patients with a previous history of cancer.* <i>(*for patients with history of non-melanoma skin cancer, see background text)</i></p>	<p>↑</p>	<p>STRONG CONSENSUS¹</p> <div style="display: flex; align-items: center; justify-content: center;"> <div style="background-color: #8BC34A; border-radius: 50%; width: 30px; height: 30px; margin-right: 5px;"></div> <div style="border: 1px solid #8BC34A; padding: 2px 5px; font-size: 8px;">100% Agreement</div> </div> <p>EXPERT CONSENSUS</p>
<p>We suggest apremilast can be used in psoriasis patients with a previous history of cancer despite the lack of long term experience based on pathophysiological considerations on a case-by-case basis including discussion with cancer specialist</p>	<p>↑</p>	
<p>We suggested against using ciclosporin in psoriasis patients with a previous history of cancer.</p>	<p>↓</p>	
<p>We suggest TNFi, ustekinumab can be used based on existing safety data on a case-by-case basis including discussion with cancer specialist. We suggest anti-IL17, anti IL23 can be used in psoriasis patients with a previous history of cancer despite the lack of long term experience based on pathophysiological considerations on a case-by-case basis including discussion with a cancer specialist.</p>	<p>↑</p>	

¹ due to personal-financial conflict of interest 3 abstentions



3.4. Depression: How should psoriasis patients with a history of depression and/or suicidal ideation be managed?

This chapter is based on the corresponding chapter in the previous versions of the guideline^{17,18}. A search was conducted, details of which can be found in the individual chapter, see website.

Results/Recommendations:

Psoriasis is associated with a higher risk for psychiatric comorbidities including anxiety and depression while results on suicide ideation and suicide are more unclear^{143,174-177}. In general, interventions that are effective for psoriasis correspondingly also improve symptoms of depression. Clinical studies using adalimumab, etanercept, ustekinumab, ixekizumab, guselkumab, [risankizumab](#) or fumarates for the treatment of psoriasis have shown that all these anti-inflammatory drugs not only improve psoriatic manifestations, but also symptoms of depression^{176,178-184}. In head-to-head studies, guselkumab was associated with greater improvements in symptoms of depression compared with adalimumab¹⁸⁰, and [risankizumab greater improvements compared to ustekinumab](#)¹⁸⁴. In a prospective, longitudinal registry study, biologic therapy was found to have the greatest improvement on symptoms of depression followed by conventional systemic therapy and phototherapy^{143,185}. Taken together, these data suggest that the more effective the intervention for psoriasis, the greater the benefit to the mood. However, whether the overall beneficial effect on depressive symptoms is direct, or indirect (through improvement in psoriasis and therefore mood) is not clear. [No treatment related emergent risk of depression or suicidality has been reported in phase III trials with deucravacitinib compared to apremilast or placebo](#)^{95,96}.

Systemic treatments for psoriasis with special attention to a possible increased risk of depression, suicide ideation and completed suicide are discussed below:

Acitretin: Acitretin has been reported to be associated with depression in some case reports^{186,187}. However, more recent reviews of the literature conclude that except for very few cases of depression and suicidal ideation there are no convincing evidence-based data to support an association between acitretin and depression/suicidality^{188,189}. A formal review of retinoids (including acitretin and isotretinoin) carried out by EMA's Pharmacovigilance Risk Assessment Committee in 2018¹⁹⁰ concluded that it was not possible to identify a clear increase



in the risk of neuropsychiatric disorders in people taking oral retinoids compared to those that did not. However, the EMA decided to include a warning about the possible risk in the product information for oral retinoids, since PRAC noticed that severe skin disorders themselves increase the risk of psychiatric disorders ¹⁹¹. Based on the above, the guideline group did not consider there to be sufficient evidence to specifically counsel against use of acitretin in those patients with mood disorders but, in common with all systemic therapies, clinicians should monitor for mood changes given that people with psoriasis are at increased risk of anxiety and depression.

Brodalumab: In two out of three phase III studies of efficacy and safety of brodalumab in patients with plaque psoriasis (AMAGINE 1-3) cases of suicide were reported (two patients in each of studies 1 and 2) ^{192,193}. An expert opinion (2019) discussing these observed cases of suicide highlighted the following aspects ¹⁹⁴: Further review of the suicides by the Columbia Classification Algorithm of Suicide Assessment Review Board confirmed only three of the cases as suicides. All of them had underlying psychiatric disorders or stressors and all three suicides occurred at one center. Both symptoms of depression and anxiety decreased during treatment with brodalumab ¹⁹³.

In the European SmPC, the reported Suicidal ideation and behaviour, including completed suicide in patients treated with brodalumab was mentioned. However, it was also stated that a causal association between treatment with brodalumab and increased risk of suicidal ideation and behaviour has not been established. In the SmPC, it is recommended that risk and benefit of treatment with brodalumab should be carefully weighed for patients with a history of depression and/or suicidal ideation. Patients, caregivers, and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal ideation, anxiety, or other mood changes, and they should contact their healthcare provider if such events occur. If a patient suffers from new or worsening symptoms of depression and/or suicidal ideation or behavior is identified, it was recommended to discontinue treatment with brodalumab ¹⁹⁵.

Apremilast: Results from two phase III studies including patients with moderate-to-severe psoriasis (ESTEEM 1 and ESTEEM 2) with open-label extension for up to four years, showed that patient reported depression occurred in 1.4% of patients treated with apremilast and in 0.5% of receiving placebo. The incidence of depression did not increase over time. There was one suicide attempt, and no completed suicides with apremilast ¹⁹⁶. Similar results were achieved in an open-label extension study (for up to additional four years) of three phase III studies of patients with psoriatic arthritis (PsA); 1.2% in patients treated with apremilast and 0.8% in patients



receiving placebo. There were two suicide attempts, and no completed suicides with apremilast¹⁹⁷. Postmarketing experience, including five cases of completed suicides, was reported and a new safety information was published for apremilast provided by Celgene in agreement with the European Medicines Agency and the Health Products Regulatory Authority in 2016¹⁹⁸ and last updated in 2022¹⁹⁹. In here it was stated that evidence from clinical trials and postmarketing experience describe the risk of depression and suicidal ideation as important and identified risk (i.e. sufficient proof of link with apremilast). The SmPC and patient leaflet for apremilast was updated to add a warning about depression (common adverse reaction ($\geq 1/100$ to $< 1/10$)) and suicidal behavior and ideation (uncommon adverse reaction ($\geq 1/1,000$ to $< 1/100$))²⁰⁰.

It was recommended that risks and benefits of starting or continuing treatment with apremilast should be carefully assessed in patients with previous or existing psychiatric symptoms or if concomitant treatment with other medicinal products likely to cause psychiatric events are in use or intended. Additionally, it was recommended to discontinue treatment with apremilast in patients suffering from new or worsening psychiatric symptoms, or if suicidal ideation or suicidal attempt is identified.

<p>We recommend to be aware of signs and symptoms of anxiety and depression in patients with psoriasis and monitor for symptoms of depression and/or suicidal ideation or anxiety during systemic treatments for psoriasis especially in those with a history of any of the above.</p>	<p>↑↑</p>	<p>STRONG CONSENSUS¹</p> <p style="text-align: center;">100% Agreement</p>
<p>We suggest using alternatives to brodalumab and apremilast in patients with a history of depression and/or suicidal ideation.</p>	<p>↑</p>	<p>EXPERT CONSENSUS</p>

¹ due to personal-financial conflict of interest 4 abstentions



3.5. Diabetes: How should psoriasis patients with diabetes mellitus be managed?

A systematic review was conducted. The Method & Evidence Reports can be found in the individual chapter, see website.

Results/Answer:

Moderate-to-severe psoriasis is commonly accompanied by metabolic disorders including type 2 diabetes mellitus, obesity, dyslipidaemia, nonalcoholic fatty liver disease and metabolic syndrome.²⁰¹ In particular, several meta-analyses confirmed the association between psoriasis and diabetes as well as the new AAD guidelines^{143,201-203}. Amstron et al.²⁰¹ found that psoriasis had an odds ratio (OR) of 1.59 (95 % CI, 1.38-1.83) for diabetes. The pooled OR was 1.53 (95 % CI, 1.16-2.04) for mild psoriasis and 1.97 (95 % CI, 1.48-2.62) for severe psoriasis. A nationwide population-based cohort study involving 14,158 adults with psoriasis confirmed that the risk of diabetes in psoriatic patients correlated to the severity of psoriasis.²⁰⁴ The association between psoriasis and diabetes could be explained considering a common genetic background, insulin resistance, and the unhealthy lifestyles such as over-eating and sedentary lifestyle, which are common in patients with psoriasis.²⁰⁵ In addition, there is a strong association between psoriasis and obesity which induces itself insulin resistance.²⁰⁶ Obesity itself is a significant risk factor to develop type 2 diabetes¹⁴³.

Systemic treatments for psoriasis could also impair glucose homeostasis and/or other metabolic parameters, especially in case of continuous and prolonged use. Short-term treatment with methotrexate does not appear to have a negative effect on carbohydrate metabolism parameters in patients with psoriasis or psoriatic arthritis²⁰⁷⁻²⁰⁹. However, MTX should be administered with caution in the case of diabetes and obesity, due to the increased risk of [liver toxicity, liver enzyme increase and liver fibrosis](#)²¹⁰⁻²¹². Ciclosporin (CsA) can increase insulin resistance, interfere with fatty acid metabolism favouring the development of dyslipidaemia and the increase of serum uric acid²¹³. In a prospective cohort study on the Psocare registry, it was found that CsA was associated with a significant risk of developing diabetes at week 52, which is not surprising because the calcineurin inhibitors either tacrolimus or CsA are associated with a higher risk of new-onset diabetes in transplant recipients²¹⁴. The diabetogenic effect of CsA has been assumed to be related to inhibition of insulin secretion from pancreas islet cells²¹⁵, an effect that may be even more relevant in obese psoriatic patients.



Acitretin effects on insulin resistance are not clearly established. There is no evidence that fumarates and apremilast could affect insulin resistance. Additionally, diabetes is not a contraindication for the use of apremilast or fumarates.

The safety and efficacy of deucravacitinib in psoriatic patients with diabetes has not been investigated, yet. However, in POETYK PSO-1 clinical trial⁹⁵, there were no reports of metabolism disorders due to deucravacitinib leading to treatment discontinuation during weeks 0-52. The mechanism of action of deucravacitinib, i.e. blocking the tyrosine-kinase 2 protein and the cellular signals that run through, it is not expected to alter insulin sensitivity.

Clinically significant dyslipidaemia has been rarely reported in patients receiving TNFi, but this is not a common issue in clinical practice²¹⁶. Body weight gain could occur in patients treated with TNFi^{217,218}. In contrast, ustekinumab²¹⁹, IL-17²²⁰ and IL-23 inhibitors usually do not increase body weight in patients with chronic plaque psoriasis. Apremilast has been shown to cause weight loss in clinical trials²²⁰. Studies addressing the effects of TNF- α blockade on glucose homeostasis in patients with psoriasis and/or PsA were very limited and gave conflicting results. The Homeostasis Model Assessment (HOMA) and the Quantitative Insulin Sensitivity Check Index (QUICKI) are two widely used non-invasive surrogate markers of insulin resistance, used in the following studies. A study in 62 patients with chronic inflammatory rheumatic diseases, of whom 18 patients were affected by PsA, did not show any significant improvement in glucose homeostasis during the first six months of treatment with TNFi.²²¹ A recent prospective study in a cohort of 210 PsA patients treated with various TNFi (adalimumab n = 70, etanercept n = 70) or MTX (n = 70) found that those receiving TNFi had significant improvements in glucose levels and other features of the metabolic syndrome compared with those treated with MTX.²²² Similarly, the effects of TNFi on insulin sensitivity/resistance in patients with psoriasis gave discordant results. A small randomized, double-blind study in twelve psoriatic patients at high risk of developing type 2 diabetes failed to observe a significant effect of a two-week treatment with etanercept on insulin secretion and sensitivity.²²³ No significant changes in either insulin sensitivity or levels of fasting blood glucose were observed in a study in psoriatic patients after twelve weeks of treatment with adalimumab.²²⁴ In contrast, in two different studies respectively on nine and 89 patients with plaque psoriasis etanercept improved insulin sensitivity.^{225,226} Other TNFi also appear to improve insulin sensitivity in diabetic and non-diabetic patients with psoriasis^{227,228}.



A pooled analysis of data from the phase III randomised controlled trials for secukinumab showed a neutral effect on fasting plasma glucose, lipid parameters and liver enzymes. In patients with fasting plasma glucose >125 mg/dl at baseline (diagnostic criterion for diabetes) secukinumab treatment presented a trend towards lowering fasting glucose concentration compared to placebo treatment during the first 12 weeks ²²⁹. Finally, patients with moderate-to-severe psoriasis are candidate for interventions aimed to reduce their cardiovascular risk profile. Screening for cardiovascular risks including diabetes, hypertension and dyslipidemia should be recommended for all psoriasis patients ¹⁴³. Non-pharmacological interventions, such as weight loss, should be recommended to obese patients. Indeed, it has been reported that a low-calorie diet inducing a moderate weight loss (i. e., 5 to 10 % of body weight) increases the responsiveness of obese patients with moderate-to-severe chronic plaque psoriasis to systemic treatments ²³⁰⁻²³³. Moreover, body weight loss could also increase insulin sensitivity in obese patients with psoriasis.

Etanercept does not have an impact on the glycemic control in diabetes patients, which was shown in the PRISTINE trial ²³⁴.




Finally, it should be considered that diabetic nephropathy eventually occurring in patients with psoriasis could reduce the clearance of any systemic treatments for psoriasis including MTX and CsA. ^{235,236} CsA should be considered cautiously in patients with diabetes mellitus as significantly increased serum creatinine concentration could be observed ²³⁷.

In addition to any medical treatment, appropriate supportive care should be offered, e.g. weight loss programs for obese patients with metabolic syndrome or dyslipidaemia.

Data from the CorEvitas Psoriasis Registry indicates a weaker treatment response ²³⁸ or shorter drug survival ²³⁹ to psoriasis treatments in diabetic patients with newly initiated tumour necrosis factor inhibitors (TNFi) ²³⁹, interleukin (IL)-17i ²³⁸, IL-12/23i ²³⁹, or IL-23i ²³⁹ than in non-diabetic patients. Van Muijen et al. found lower drug survival rates due to ineffectiveness in diabetic patients with psoriasis receiving with respect to guselkumab ²⁴⁰. In contrast, Mendes-Bastos et al. indicated that patients with diabetes had a higher drug persistence than those without diabetes when treated with secukinumab ²⁴¹.

In conclusion, diabetes is not a contraindication to the use of biological drugs or small molecules in patients with psoriasis for safety issues, but it could reduce their effectiveness.



<p>We suggest considering alternatives to methotrexate in people with type 2 diabetes (if accompanied by metabolic syndrome and/or evidence of liver damage) when alternative treatments can be prescribed.</p>	<p>↑</p>	<p>STRONG CONSENSUS¹</p> <p style="text-align: center;"></p> <p>EXPERT CONSENSUS</p>
<p>We suggest considering alternatives to ciclosporine in people with type 2 diabetes (if accompanied by metabolic syndrome and/or evidence of liver damage) when alternative treatments can be prescribed.</p>	<p>↑</p>	<p>STRONG CONSENSUS¹</p> <p style="text-align: center;"></p> <p>EXPERT CONSENSUS</p>
<p>We suggest against using acitretin as a first line treatment in patients with dyslipidaemia.</p>	<p>↓</p>	<p>STRONG CONSENSUS²</p> <p style="text-align: center;"></p> <p>EXPERT CONSENSUS</p>

¹ due to personal-financial conflict of interest 3 abstentions

² due to personal-financial conflict of interest 2 abstentions



3.6. Heart disease: How should psoriasis patients with ischaemic heart disease and/or congestive heart failure be managed?

This chapter is based on the previous chapter^{17,18}. A systematic search was conducted, details of which can be found in the Methods & Evidence Report.

Results/Recommendations

a) Ischaemic heart disease/atherosclerosis


Summary/key points

- Patients with psoriasis have an approximately two- to threefold increased relative risk for developing cardiovascular events such as myocardial infarction or stroke compared to individuals without psoriasis. The cardiovascular risk seems to correlate with disease severity. The link between psoriasis and cardiovascular disease is likely to be driven by an increased prevalence of classical cardiovascular risk factors among patients with psoriasis such as the components of the metabolic syndrome. There is also evidence for an independent risk conferred by the systemic inflammatory nature of the disease.
- A careful history should be obtained from all patients to determine whether they have established cardiovascular disease. Appropriate investigations and treatment should be initiated in accordance with current European Society of Cardiology guidance²⁴².
- Patients without a history of cardiovascular disease, should have their cardiovascular risk factors assessed and be given lifestyle advice including avoiding smoking, maintaining a healthy diet, increasing physical activity and maintaining a healthy blood pressure with other treatments in accordance with current European Society of Cardiology guidance^{243,244}.
- With the exception of methotrexate, there are no studies formally evaluating the effect of any anti-psoriatic therapy as a treatment for coronary heart disease. In general, it seems that the reduction of psoriatic inflammation is beneficial in psoriatic patients with cardiovascular comorbidity (indirect effect), but direct effects of treatments for psoriasis on atherosclerotic inflammation may also play a role.
- Multiple studies with different therapies have produced evidence on parameters of cardiovascular risk and/or assessed cardiovascular events during the treatment of patients with psoriasis.



- From these studies it appears that methotrexate, the anti-TNFs, in particular adalimumab, and ustekinumab improve parameters of cardiovascular risk in patients with psoriasis.
- While in some experimental models IL-17 has been associated with stabilizing properties of unstable atherosclerotic disease, treatment with IL-17 inhibitors has not been associated with an increased rate of cardiovascular events. Moreover, inhibition of IL-17, especially with secukinumab, has shown to improve surrogate markers of endothelial dysfunction.
- The data available on inhibitors of IL-23p19 indicate that they are safe in patients with cardiovascular comorbidity, but information on their potential effects on cardiovascular factors risk is limited.
- Treatment with apremilast is associated with weight loss in some patients. Experimental studies indicate potentially beneficial effects of apremilast in models of atherosclerosis. Neither clinical trial data nor observational studies indicate that apremilast is associated with an increased risk of cardiovascular events in psoriasis patients with ischemic heart disease or cardiovascular risk factors.
- There is no evidence that fumarates are associated with increased cardiovascular events in patients with ischemic heart disease.
- Ciclosporine may induce or worsen arterial hypertension, a condition often found in patients with ischemic heart disease, and worsen dyslipidaemia. The metabolism of ciclosporine may interfere with drugs used in patients with ischemic heart disease such as beta-blockers or calcium antagonists.
- Acitretin has very limited anti-inflammatory potential and may induce or worsen hyperlipidaemia.
- [The search in MEDLINE via Ovid did not identify systematic reviews on the efficacy and safety of using deucravacitinib in patients with psoriasis and heart disease.](#)



We suggest against cyclosporine or acitretin as preferred treatments in patients with psoriasis and ischemic heart disease.	↓	
We suggest methotrexate as preferred first-line therapy in patients with psoriasis and ischemic heart disease* if other patient characteristics do not preclude its use.	↑	STRONG CONSENSUS ¹ 
We suggest TNFi, ustekinumab, and IL-17 inhibitors as preferred targeted therapies in patients with psoriasis and ischemic heart disease*.	↑	EXPERT CONSENSUS

¹ due to personal-financial conflict of interest 3 abstentions

* in case of concomitant congestive heart failure, also note the recommendations from the respective section

Moderate-to-severe psoriasis is associated with several well-established cardiovascular risk factors including obesity, hypertension, diabetes, dyslipidaemia, and metabolic syndrome ²⁴⁵. Psoriasis severity has been linked to a higher prevalence of these risk factors. However, there is conflicting evidence as to whether psoriasis is associated with increased cardiovascular events and whether psoriasis itself represents is an independent cardiovascular risk factor ²⁴⁶. Indeed, a large cohort study in Rotterdam found no difference in the risk of ischemic heart disease hospitalizations in patients with psoriasis compared with matched control subjects ²⁴⁷. Stern and Huibregtse ²⁴⁸ found that patients with very severe psoriasis have increased all-cause mortality, but that severe psoriasis is not an independent risk factor for ischaemic heart disease. The aforementioned studies are in contrast to a large and growing body of literature that suggests patients with more severe psoriasis carry a clinically relevant increased risk of mortality due to ischaemic heart disease. Samarasekera et al. ²⁴⁹ critically evaluated 14 cohort studies and meta-analysed the magnitude of cardiovascular risk for the primary outcomes of cardiovascular mortality, stroke, and myocardial infarction (MI). Increased risk was identified only in individuals with severe psoriasis (defined as requiring systemic therapy or hospital admission): the risk ratio relative to the general population was 1.37 (95 % CI, 1.17-1.60) for cardiovascular mortality, 3.04 (95 % CI 0.65-14.35) for MI, and 1.59 (95 % CI, 1.34-1.89) for stroke. The relative risks of cardiovascular disease were highest in the younger, severe psoriasis population (e. g., 3.10 [95 % CI, 1.98-4.86] for MI at 30 years), and absolute risks were greatest in older individuals with severe psoriasis (e. g., 23.2 excess MIs per 10,000 person-years at 60 years). ²⁴⁹ Geata et al. showed an approximately 25% increased relative risk of cardiovascular disease in patients with psoriasis, independently of smoking, obesity and hyperlipidemia ²⁵⁰. The pooled relative risks for cardiovascular mortality in psoriasis compared with general population were 1.15 (95% CI 1.09-



1.21) in all patients with psoriasis, 1.05 (95% CI 0.92-1.20) in those with mild psoriasis, and 1.38 (95% CI 1.09-1.74) in severe disease ¹⁶¹. A recent systematic review and meta-analysis indicates that subclinical coronary artery disease diagnosed with cardiac computed tomography angiography is more prevalent in patients with psoriasis, with an increased burden of disease and number of high-risk coronary plaques ²⁵¹.

It has been proposed that there may be overlapping immune pathways in both psoriasis and ischaemic heart diseases that may underlie this association ^{252,253}. It is also a matter of great interest whether systemic anti-psoriatic treatments affect cardiovascular risk by reducing the overall inflammatory burden. It is not known whether systemic treatments could modify cardiovascular outcomes including the rate of MI. However, studies investigating the effects of systemic treatments on cardiovascular risk factors including metabolic parameters (e. g., serum lipids), blood pressure or biomarkers of inflammation and atherosclerosis (e. g., C-reactive protein, endothelial dysfunction) have been completed. Multiple studies have failed to show any significant changes in metabolic parameters in patients receiving both PUVA and narrowband UVB therapy ^{254,255}. In contrast, systemic retinoids (i. e., acitretin) commonly increase serum triglycerides and cholesterol by shifting high-density lipoproteins to low-density lipoproteins ^{255,256}. Similarly, ciclosporin can increase serum lipids, plasma glucose and blood pressure in a dose-dependent fashion ^{213,257}. Therapy with MTX is associated with a reduced risk of cardiovascular morbidity and mortality in patients with RA as well as in patients with psoriasis and psoriatic arthritis ²⁵⁸⁻²⁶¹. In a longitudinal cohort study of 6902 patients with psoriasis, Ahlehoff et al. found that treatment with methotrexate was associated with a reduced risk of cardiovascular events compared to patients treated with other antipsoriatic therapies such as ciclosporin and retinoids ²⁶². Methotrexate therapy decreases carotid intima-media thickness (a marker of arteriosclerosis) in patients with moderate-to-severe psoriasis ²⁶³. Preclinical and pilot studies suggest possible cardioprotective effects of apremilast and fumarates but there is no clinical evidence that either affect cardiovascular risk ^{182,264}.

The effect of biological therapies on the risk of ischaemic heart disease is unclear. Treatment with TNFi and ustekinumab have been shown to reduce aortic vascular inflammation and decrease systemic inflammatory biomarkers ²⁶⁵⁻²⁶⁹. [Randomized controlled trials show that ustekinumab reduces aortic vascular inflammation and that TNFi and phototherapy reduce CRP and IL-6.](#) ²⁷⁰ Therapy with TNFi improves biomarkers of atherosclerosis by reducing intima media thickness and arterial stiffness in patients with RA, spondyloarthropathies, PsA and psoriasis ²⁷¹⁻



²⁷³. Secukinumab may have a beneficial effect on cardiovascular risk in patients with psoriasis by improving endothelial function measured by flow-mediated dilation ²⁷⁴.

There is conflicting evidence on the effects of biologic therapy on the incidence of cardiovascular incidents in patients with psoriasis.

A large cohort study of 25,554 patients with psoriasis followed for eight years using administrative and pharmacy claims data from a large U.S. insurer (i. e., United Health Group) did not show a reduced risk of MI in those receiving systemic therapy compared to those exposed to phototherapy ²⁷⁵. A comparison of patients with first time hospital-diagnosed psoriasis between 1995 and 2002 (early era cohort) and those diagnosed between 2006 and 2013 (late era cohort), did not show any change in MI risk despite increased cardiovascular disease prevention and the availability of biologic therapy ²⁷⁶. A meta-analysis of 22 randomized, placebo-controlled, double-blind studies of IL-12/23 antibodies and TNFi agents comprising 10,183 adult patients evaluated the possible association between biologic therapies and major adverse cardiovascular events (MACE). Compared with placebo, there was no significant difference in the rate of MACE observed in patients receiving anti-IL-12/IL-23 antibodies or TNFi treatments. However, the authors acknowledged that the study may have been underpowered to identify a significant difference. ²⁷⁷ However, other studies have shown different outcomes. In particular, Wu et al. ²⁷⁸ assessed whether patients with psoriasis treated with TNFi inhibitors had a decreased risk of MI compared with those treated with other systemic therapies, phototherapy or topical. This was a retrospective cohort study of 8,845 patients, 1,673 received a TNFi for at least two months, 2,097 received conventional systemic treatments or phototherapy, and 5,075 received only topical treatment. After adjusting for MI risk factors, the TNFi cohort had a significantly lower risk of MI compared with the topical cohort (adjusted hazard ratio, 0.50; 95 % CI, 0.32-0.79). The difference in incidence of MI between TNFi and conventional systemic treatments or phototherapy was not significant. ²⁷⁸ In a Danish nationwide real-world study of 2400 patients with severe psoriasis enrolled in a registry, treatment with biological agents (n=693) or MTX (n=799) was associated with lower cardiovascular disease event rates than treatment with other anti-psoriatic therapies. ²⁷⁹ This is consistent with Wu et al. who found that psoriasis patients receiving TNFi had a lower major cardiovascular event risk compared to those receiving methotrexate and cumulative exposure to TNFi was associated with an 11% cardiovascular event risk reduction ²⁸⁰. Concern was expressed over initial analyses linking IL-12/23 inhibitors with MACE in the first week of therapy.



However, additional meta-analysis of clinical trials and data from registries in psoriasis and psoriatic arthritis suggest that licensed biologic therapies, including TNFi (adalimumab, etanercept and infliximab), anti-IL-17A agents (secukinumab and ixekizumab) or ustekinumab are not associated with MACEs ²⁸¹⁻²⁸⁴. In a large prospective cohort study using the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) there was no significant differences in the risk of major cardiovascular events between etanercept, adalimumab, ustekinumab and methotrexate ²⁸⁵. Similarly, in 60028 patients with psoriasis or psoriatic arthritis from multiple US databases, no significant difference was found in the risk of MACEs after initiation of therapy with TNFi or ustekinumab ²⁸⁶

A systematic review and meta-analysis of cohort studies or RCTs ²⁸⁷ found that the use of bDMARDs might be associated with reduced risks of CV events in patients with systemic inflammatory conditions. In sensitivity analysis for patients with psoriasis, compared with non-bDMARD users (controls), the risks of myocardial infarction (bDMARD vs. control: 6324 vs. 2675, OR = 0.90, 95% CI, 0.45 to 1.80, $I^2= 0\%$), heart failure (bDMARD vs. control: 869 vs. 511, OR = 0.78, 95% CI, 0.14 to 4.33, $I^2= 0\%$), cardiovascular (CV) death (bDMARD vs. control: 2177 vs. 1052, OR = 0.71, 95% CI, 0.18 to 2.85, $I^2= 0\%$), all-cause mortality (bDMARD vs. control: 36677 vs. 1719, OR = 0.80, 95% CI, 0.26 to 2.45, $I^2= 0\%$) were not significantly reduced in bDMARD users. When data were pooled across all systemic inflammatory conditions, CV events might be less frequent in TNFi users and in bDMARD users with follow-up over one year compared to controls. ²⁸⁷

Different studies on psoriatic arthritis, which showed conflicting results, were identified through a hand search. A large cohort study from the UK using a medical record data-base found a higher incidence of MACE in patients with psoriatic arthritis without DMARD prescription (HR 1.24; 95%CI 1.03 to 1.49), while patients with psoriatic arthritis with DMARD prescription did not show a significantly higher incidence (HR 1.17; 95%CI 0.95 to 1.46) when compared with matched control patients (without the diagnosis of psoriasis, PsA or rheumatoid arthritis and without DMARD prescription) ²⁸⁸. Conversely, Eder et al. ²⁸⁹ investigated the incidence of cardiovascular events in a large psoriatic arthritis clinic and found no difference in MACE between TNFi versus MTX versus untreated patients with PsA, and further no increased incidence in patients treated with glucocorticoids or NSAIDs. Another cohort study from a UK register found a significantly higher incidence rate of MACE in patients receiving glucocorticoids (IRR 4.95; 95%CI 2.04 to 12.01) as compared with patients receiving DMARDs (including MTX and bDMARDs: IRR 1.31,



95%CI 0.99 to 1.73) and patients with psoriatic arthritis without drug prescription (reference group) ²⁹⁰.


b) Heart failure

Summary/key points

- Heart failure (HF) is a clinical syndrome characterized by typical symptoms (e.g. breathlessness, ankle swelling and fatigue) that may be accompanied by signs (e.g. elevated jugular venous pressure, pulmonary crackles and peripheral oedema) caused by a structural and/or functional cardiac abnormality, resulting in a reduced cardiac output and/or elevated intracardiac pressures at rest or during stress. ²⁴³
- Common causes include coronary artery disease (previous myocardial infarction), arterial hypertension, atrial fibrillation, valvular heart disease and cardiomyopathies. The condition may, therefore, co-exist with ischemic heart disease.
- Patients with suspected or confirmed heart failure should be referred to a cardiologist for investigation and treatment in accordance with current European Society of Cardiology guidance ²⁹¹.
- The NYHA functional classification is commonly used to describe the severity of symptoms and exercise intolerance in patients with heart failure. (<https://manual.jointcommission.org/releases/TJC2018A/DataElem0439.html>)
 - Class I - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc.
 - Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.
 - Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20—100 m). Comfortable only at rest.
 - Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.
- There is evidence that TNFi, especially adalimumab and infliximab, worsen advanced heart failure and both drugs are contraindicated in patients with congestive heart failure NYHAIII/IV and must be used with caution in patients with milder forms of congestive heart failure (NYHA I/II). Etanercept must be used with caution in patients with congestive heart failure.



- The use of other targeted therapies in patients with psoriasis and congestive heart failure seems to be neutral depending on the underlying cause (caution infection).
- The use of methotrexate, acitretin and apremilast in patients with psoriasis and heart failure seems to be neutral depending on the underlying cause.
- Ciclosporin may increase the blood pressure and reduce kidney function in patients with psoriasis and heart failure and interfere with many drugs used in the treatment of this condition.
- Fumarates may reduce kidney function in patients with psoriasis and heart failure.

We suggest against using cyclosporine in patients with psoriasis and advanced congestive heart failure.	↓	
We suggest that methotrexate, acitretin and apremilast are considered as treatment in patients with psoriasis and advanced congestive heart failure*.	↑	STRONG CONSENSUS ¹ 
We suggest that ustekinumab, inhibitors of IL-17 and of IL-23 are considered as treatment in patients with psoriasis and advanced congestive heart failure*.	↑	
We recommend against using TNFi in patients with psoriasis and advanced congestive heart failure.	↓↓	
We recommend discussing the choice of a systemic therapy in psoriasis patients with advanced congestive heart failure with a cardiologist.	↑↑	

¹ due to personal-financial conflict of interest 3 abstentions

* in case of concomitant ischaemic heart failure, also note the recommendations from the respective section

TNF- α in heart failure (HF) stems from the observations that TNF- α exerts negative inotropic effects and is capable of promoting fibrosis, hypertrophy and cardiomyopathy in animal models²⁹². Moreover, cardiac specific TNF- α levels are regulated by pressure and volume load in animals and in humans²⁹³. Therefore, a small series of clinical trials was conducted with TNFi to investigate their potential beneficial effects in patients with HF. Both RENAISSANCE and RECOVER^{294,295} were large, multicenter, randomized, double blind, placebo-controlled trials of etanercept in HF. Both studies failed to show improved mortality or decreased hospitalizations due to CHF. The key finding of the RENAISSANCE trial was a trend towards higher mortality in etanercept-treated subjects, a concern heightened by the apparent dose-response relationship. The combined analysis of these studies showed a trend towards increased mortality and/or HF



hospitalizations in the combined twice-weekly/thrice-weekly etanercept group compared with placebo. ^{294,295} Infliximab was evaluated in a phase II randomized, double-blind, placebo-controlled pilot study. ²⁹⁶ This pilot study did not show any beneficial effect of infliximab over placebo in terms of efficacy. Higher-dose infliximab (10 mg/kg) was associated with an increase in both all-cause mortality and the number of hospitalizations due to HF at weeks 28 and 54. In summary, the results of randomized, placebo-controlled trials with both etanercept and infliximab suggest a deleterious effect of higher doses of TNFi in patients with NYHA class III or IV HF. In particular, there was a trend toward higher mortality and a greater number of hospitalizations for HF. However, a recent Cochrane systematic review including 163 randomized controls trials with 50,010 participants and 46 extension studies with 11,954 participants, found that the rate of new diagnosis of HF were not statistically significantly different between those patients treated with biologics and those with control treatments. ²⁹⁷ The cardiovascular safety data extracted from 74 articles and, corresponding to 77 randomised controlled trials of TNFi, anti-IL 12/23, anti-IL 23 and anti-IL 17 agents for the treatment of psoriatic arthritis or psoriasis showed no significant difference in CHF incidence in patients receiving biological agents in comparison to placebo ²⁸⁴. In conclusion, only moderate-to-severe CHF is a concern for initiating TNFi therapy in patients with psoriasis.



3.7. Kidney disease: How should psoriasis patients with kidney failure / renal impairment be managed?

Narrative review of the existing literature was conducted.

Results/Answer:

A number of risk factors that predispose one to chronic kidney disease (CKD) are especially prevalent in people with multiple comorbidity including diabetes, hypertension, cardiovascular disease being treated with drugs that may impair kidney function. A UK population based study suggests that the risk of CKD [stage 3-5](#) was [slightly](#) increased in people with psoriasis, independent of these risk factors ²⁹⁸. Thus, the optimal choice of systemic therapy in the context of CKD is likely to be a relatively common clinical scenario. This is supported by data from the Spanish long-term pharmacovigilance registry indicating that 13 % of the total cohort were categorized as having “chronic renal failure” ²⁹⁹.

[In a recent large-scale population-based study from Israel chronic renal failure occurrence was similar between psoriasis patients and the population control. In this study there was significantly less dialysis and kidney transplantation in the psoriasis group and more other kidney disease as compared to the control cohort. In pediatric patients there was no difference between psoriasis and the population for all kidney disorders ³⁰⁰.](#)

[Kidney diseases in psoriasis need to be seen in the context of other frequently associated disorders, in particular hypertension. It was shown that interleukin-17 can induce endothelial cell dysfunction and together with hypertension this may lead to renal injury. Salt intake was found as an aggravation factor ³⁰¹.](#)

[Management of comorbidity is necessary to provide a holistic approach on psoriatic disease.](#)

In people with established CKD, the following factors were considered when evaluating the treatment options for psoriasis:

- the likely effect of the psoriasis treatment on residual kidney function
- the impact of CKD on pharmacokinetics/pharmacodynamics of the psoriasis treatment
- potential drug interactions
- associated CKD co-morbidity



Systemic therapies

Acitretin

National guidelines in the UK ³⁰², US ⁴⁴ and Spain ⁴² all recommend avoiding acitretin in moderate-to-severe renal disease, although no evidence is cited underpinning these recommendations. There were no studies identified that specifically address the use of acitretin for psoriasis in the context of CKD. Acitretin is widely used in the renal transplant population for skin cancer prophylaxis where stage 3 CKD is common; a recent systematic review in this population showed no increased in AEs when compared to placebo ³⁰³. Limited data from RCTs do not indicate that acitretin is a nephrotoxic drug. Acitretin is highly lipophilic, penetrates readily into body tissues and is highly protein (albumin) bound. Hypoalbuminemia in association with CKD may therefore potentially increase drug clearance. It is metabolized in the liver to 13-cis acitretin and etretinate, and then undergoes glucuronidation into inactive, water-soluble forms. In healthy patients, acitretin is excreted entirely in the form of these inactive metabolites, in approximately equal parts via the kidneys and the bile. In a single report ³⁰⁴, the mean areas under the plasma concentration versus time curves of acitretin and 13-cis acitretin following a single oral dose of 50 mg of acitretin in six patients on hemodialysis were, in fact, about 50 % lower than healthy controls. No retinoids were detectable in the dialysate.

In summary, acitretin is not known to be nephrotoxic, and CKD (any stage) would not be predicted to markedly impact on drug disposition.

Apremilast

Apremilast has no known nephrotoxic potential. In the pivotal clinical trials there was no evidence for treatment emergent adverse events related to renal function ^{305,306}.

In patients with mild to moderate impairment of kidney function, no dose adjustment of apremilast is necessary. When patients have severe impairment of kidney function (eGFR below 30 ml/min/1.73 m² or CLcr < 30 ml/min) the dose of apremilast should be reduced to 30 mg once daily. When starting treatment with apremilast in case of severe renal insufficiency only the morning dose should be given as total daily dose (recommendations according to SmPC).

Fumarates

Fumarates are known to be potentially nephrotoxic, and may rarely cause an irreversible, proximal renal tubular nephropathy with long-term use. Recent studies ³⁰⁷ of dimethyl fumarate (for MS) confirm proteinuria and reduction in eGFR to occur more commonly than placebo;



German guidelines and the SmPC specify careful monitoring of serum creatinine, and treatment cessation in the event of significant change. In health, fumarates are extensively metabolised by ubiquitous esterases, and so CKD would not be predicted to significantly impact on drug clearance^{308,309}.

Ciclosporin

Ciclosporin has established nephrotoxic potential. Acute nephrotoxicity can occur within weeks of treatment initiation, is reversible, and arises due to dose-dependent vascular dysfunction, involving afferent arteriolar constriction that leads to increased vascular resistance and a decrease in glomerular filtration rate. Tubular dysfunction may also occur, characterized by decreased magnesium re-absorption, decreased uric acid excretion, decreased potassium and hydrogen ion secretion, and distal tubular acidosis. Chronic nephrotoxicity^{310,311} is largely irreversible and is characterized by progressive arteriolar hyalinosis, interstitial fibrosis, tubular atrophy, and glomerular sclerosis. Chronic nephrotoxicity is more likely to occur with higher daily doses, larger cumulative doses and long-term therapy (more than 1-2 years). In one long-term psoriasis study, patients with a pre-treatment creatinine of > 100 µmol/L were more likely to discontinue therapy. In a study performed in patients with (stage 5) terminal renal failure, the systemic clearance was approximately two thirds of that in patients with normally functioning kidneys. Less than 1 % of the administered dose is removed by dialysis.

Guidelines recommend using CsA with caution in people with CKD; in those with significant reduction in renal function (CKD stage 3 or more)³¹², CsA nephrotoxicity may lead to further critical reduction in function.

Methotrexate


MTX is not generally considered nephrotoxic when used at low doses for inflammatory disease, although renal impairment is reported³¹³, and may be an under-recognized event. MTX and 7-hydroxymethotrexate are mainly excreted through the kidneys, via glomerular filtration and active transport. Methotrexate clearance is therefore reduced (and thus risk of toxicity increased) in the context of CKD, depending on the stage. In a cohort of 77 patients with RA and various stages of CKD, the elimination half-life of a single dose of intramuscular MTX (7.5-15 mg) was directly related to GFR, with a decrease in MTX of 44.7 % in the category of patients with the poorest renal function (i. e., creatinine clearance < 45 ml/min, roughly equivalent to stage 3b)³¹⁴. Pooling data from RCTs of MTX for RA also indicates that presence of renal impairment



(creatinine clearance < 79 ml/min) increases the OR for severe and pulmonary toxicity by four compared to those with a creatinine clearance > 99.8 ml/min (reference group)³¹⁵. There are no studies evaluating use of MTX for psoriasis with CKD. US guidelines⁴⁴ consider renal impairment a relative contra-indication to MTX, and all recent RCTs with a MTX arm exclude patients with 'significant' renal impairment. There are several case reports of life threatening toxicity following MTX use in people on dialysis (reviewed in³¹⁶). Guidelines in the rheumatology literature, largely consequent on the two studies referenced above, recommend avoiding MTX in people with creatinine clearance of < 20 ml/min, and halving the dose in those between 20 and 50 ml/min (summarized in³¹⁷).

Biological therapy

To date, nephrotoxicity has not been reported as an AE in relation to all groups of biologic agents (TNFi, IL-17A/IL-17RA antagonists, IL-12/23p40 antagonists, and IL-23p19 antagonists). Clearance of biological therapies should not be affected in case of CKD (of any stage).

We recommend ensuring an accurate assessment of renal function in any psoriasis patient with known or suspected chronic kidney disease prior to therapy.	↑↑	
We recommend working in collaboration with the nephrologist when prescribing systemic therapy in any psoriasis patient with chronic kidney disease of stage 3 (eGFR <60 mL/min/1.73 m ²) or more.	↑↑	
We suggest acitretin*, apremilast, fumarates*, methotrexate* may be used in psoriasis patients with mild to moderate renal impairment (eGFR ≥30 mL/min/1.73m ²). *(carefull dosing/dose adjustment may be needed)	↑	STRONG CONSENSUS ¹  EXPERT CONSENSUS
We suggest using biologics in psoriasis patients with chronic kidney disease and all stages of renal impairment.	↑	
We recommend against using ciclosporin, fumarates, or methotrexate in psoriasis patients with chronic kidney disease and severe renal impairment (eGFR <30 mL/min/1.73m ²).	↓↓	

¹ due to personal-financial conflict of interest 3 abstentions



3.8. Neurological diseases: Which treatments are appropriate for psoriasis patients with neurological diseases?

Narrative review of the existing literature was conducted.

Results/Answer:

Standard systemic therapy

Ciclosporin

Neurotoxicity is a well-established complication of CsA although it receives surprisingly little attention in literature. A comprehensive review ³¹⁸ referencing data from (primarily) the transplant population, estimated that 10 and 28 % of patients receiving calcineurin-inhibitors experience neurotoxic side effects ranging from mild paraesthesia and peripheral neuropathy through to centrally mediated complications such as altered cognition, visual disturbances and seizures. Of these tremor and paraesthesia are the commonest, and in the early trials in psoriasis, affected 40 and 25 % of participants receiving 5mg/kg respectively ³¹⁹. Calcineurin is major component of neural tissue, and plays a key role in the regulation of nerve cell function, and neurotransmission ^{320,321}; toxicity is dose-dependent and largely reversible. Ciclosporin does not readily cross the blood-brain barrier, however, conditions that disrupt the integrity of this, such as neurodegenerative disease, systemic infections, or hypertension, may perhaps also make patients more prone to the neurotoxic effects of CsA ³²⁰. Additional factors such as CsA-related hypomagnesaemia ³²² may also contribute. No studies were identified specifically reporting on outcomes in people with pre-existing neurological disease treated with CsA for psoriasis. Existing guidelines and the SmPC do not stipulate neurological disease to be a contra-indication to treatment.

Fumarates

Dimethyl fumarate (DMF) has more recently been licensed and developed for use in psoriasis and is also a licensed treatment for MS (reviewed in ³²³) at doses of 240 mg BID. Fumarates may be a preferred option for the treatment of psoriasis in people with established MS. There have been a total of nine reports of confirmed progressive multifocal leukoencephalopathy (PML) in patients with psoriasis treated with fumarates; six with Fumaderm[®], two with Psorinovo[®] (a slow release DMF formulation) and one with compounded fumaric acid esters ³²⁴⁻³³². In all cases, a degree of lymphopenia and/or other contributory factors for PML are thought to have been of direct etiological relevance.



Methotrexate

CNS toxicity is a well-recognized AE of high dose MTX, especially with intra-theal administration. Low dose oral and s/c MTX have rarely been reported to cause a reversible leukoencephalopathy (see ^{333,334} for recent reports and reviews). The SmPC cites drowsiness, ataxia, blurred vision, transient subtle cognitive dysfunction, mood alteration, and unusual cranial sensations as occasionally reported with low-dose MTX. No studies were identified specifically reporting on outcomes in people with pre-existing neurological disease treated with MTX for psoriasis. Existing guidelines and the SmPC do not stipulate neurological disease to be a contra-indication to treatment.

Biological therapy

TNFi

In vitro, murine and human data suggest that TNF has an important role in the pathogenesis of inflammatory demyelinating disease (reviewed in ³³⁵). However, an early report of increased lesion activity in two MS patients receiving infliximab ³³⁶ as well as the withdrawal of Lenercept (a soluble p55 receptor developed for the treatment of MS) due to increasing severity and duration of symptoms in clinical trial subjects led to heightened awareness of potential risk of TNFi therapy in the context of MS. More recently ³³⁷, the single nucleotide polymorphism (SNP) rs1800693 in the TNFRSF1A gene associated with MS but not psoriasis (or other autoimmune conditions) has been shown to direct expression of a novel, soluble form of TNFR1 that can block TNF, hence lending further biological plausibility to a causal relationship between TNF-antagonism and demyelination.

All five TNFi have been associated with aggravation of MS and/or new onset central demyelination, which have been reviewed by Mahil *et al* and Bosch *et al* ^{338,339}. Case reports in more recently licensed TNFi golimumab ^{340,341} and certolizumab ³⁴² have been described. Of 84 cases of central demyelination reported in patients with psoriasis, the majority occurred within the first year of therapy; 33% (25/76) achieved complete recovery after cessation of TNFi +/- adjunctive therapy, 72% (55/76) did not achieve complete clinical recovery after cessation of TNFi therapy. There were fourteen cases of worsening neurological disease despite cessation of TNFi therapy and several reports of new, clinically silent lesions detected on follow-up imaging ^{338,341-352}.

A case control study in rheumatoid arthritis using Canadian administrative claims and an electronic medical records database showed a trend towards an increased rate of



demyelination in 891 patients with no risk factors (for demyelination). The authors suggested that TNFi therapy may increase the risk of truly incident demyelinating events by ~30 %, although this result failed to meet statistical significance (adjusted rate ratio 1.31 [95% CI 0.68 to 2.50])³⁵³. [More recent data from UK and Scandinavian registries do not show convincing evidence for incident demyelination with TNFi, and if there is an effect, one estimate suggests this is less than 1/1000 patient-years exposure. Thus, to date, it remains the case that](#) trial and pharmacovigilance registry data have not shown any [convincing](#) increased risk, although this may relate to a low overall incidence [of events and/or](#) exclusion of people at particular risk³⁵⁴⁻³⁵⁶.

With respect to peripheral disease, all forms of demyelinating neuropathies, including Guillain-Barré syndrome, Miller-Fisher syndrome, multifocal motor neuropathy with conduction blocks, Lewis-Sumner syndrome, and chronic polyradiculoneuritis have been reported in association with TNFi therapy, although the number of case reports in the literature are fewer when compared to central demyelination^{339,357,358}. One report of five patients providing longer term data (up 3-4 years) indicated that once triggered, chronic demyelinating neuropathy may persist or recur irrespective of whether the TNFi is discontinued³⁵⁸. Isolated cases of axonal neuropathy and vasculitis neuropathy are also reported³³⁹. US, UK and German psoriasis guidelines all advise avoidance of or caution with TNFi in people with demyelination and caution in those at risk. Prescribers and patients should also be made aware of symptoms of demyelination when prescribing TNFi to ensure early identification and drug discontinuation.

IL12/23 pathway inhibitors

The IL (interleukin) 12 p40 family of cytokines (IL-12 and IL-23) has been strongly implicated in the pathogenesis of both MS and experimental autoimmune encephalomyelitis (EAE), an animal model that mimics many clinical and histological characteristics of MS. This prompted a phase II study evaluating the role of ustekinumab in patients with relapsing and remitting MS. Patients were randomly assigned 1:1:1:1 to placebo or 27 mg, 90 mg, or 180 mg ustekinumab every four weeks or 90 mg ustekinumab every eight weeks up to week 23. A total of 200 patients received at least one dose of ustekinumab and whilst there was no evidence of benefit, there was no evidence of worsening neurological disease or increase in AEs when compared to placebo. To date, there has been one case report of primary progressive MS in a patient taking ustekinumab for refractory Crohn's disease³⁵⁹ with the first neurological symptoms occurring around one year into therapy. She had received TNFi therapy (infliximab, adalimumab, and



certolizumab) prior to ustekinumab. With respect to peripheral demyelinating disease, a single case of Guillain Barré has been reported in a 23-year-old male with refractory Crohn's disease one year after commencing treatment with ustekinumab, having previously been treated with adalimumab ³⁶⁰. A further isolated case of peripheral neuropathy of unspecified etiology after three doses of ustekinumab was reported in an observational, retrospective 5-year follow-up study of ustekinumab in psoriasis ³⁶¹. Furthermore, the first case of reversible posterior leukoencephalopathy syndrome (RPLS) in a 65-year-old woman who received ustekinumab for over 2.5 years for psoriasis has been reported. She presented with mild hypertension, confusion, headache, nausea, vomiting, multiple seizures. Computed tomographic scans and magnetic resonance images of her head revealed characteristic findings of RPLS. Complete clinical recovery and reversal of the radiologic findings occurred, which is also considered typical of RPLS ³⁶². [One case report of an axonal polyneuropathy following guselkumab has been reported which recovered on cessation of drug ³⁶³](#). No further data on the newer p19 inhibitors were identified.

IL-17 inhibitors

The IL 17A/F pathway is implicated in both psoriasis and multiple sclerosis, with elevated levels of IL-17A and IL-17F levels detected in both diseases ³⁶⁴. Phase II randomised controlled data has shown encouraging results with secukinumab associated with a reduction in both the number of active and new MRI brain lesions in patients relapsing-remitting MS which were reduced by 49% and 67% respectively ³⁶⁵; but this is yet to be replicated in further studies. There are five cases in the literature of patients receiving Secukinumab for immune-mediated inflammatory diseases with concomitant MS. 80% (4/5) of patients with MS remained stable with no progression of disease and achieved remission of psoriasis/psoriatic arthritis/ankylosing spondylitis. 20% (1/5) had a relapse of MS and required treatment with rituximab ³⁶⁶⁻³⁶⁹. There are no reported de novo cases of central demyelination with secukinumab, however longer-term safety data is required. No published data on other IL17 agents (ixekizumab, bimekizumab and brodalumab) were identified.

Summary and synthesis of recommendations

With the exception of TNFi, any of the standard or biologic treatments can be used in people with co-existing neurological disease. Although neurotoxicity is reported with CsA, and (rarely) with MTX, there is no evidence that those with pre-existing neurological disease are more at risk. The causal association between TNFi and demyelination remains yet to be proven, although



accumulating anecdotal reports, biological plausibility and expert consensus indicate that this class of drugs should be avoided in patients with a clear history of central demyelination. Given evidence for a genetic basis to MS ³⁷⁰, and that asymptomatic first- degree relatives may have morphological evidence of subclinical disease and/or CSF oligoclonal bands (reviewed in ³⁷¹), it would seem prudent to use TNFi with caution in this group too. Dimethyl fumarate is licensed for use in MS, and so may be a preferred first line option, however, surveillance monitoring of peripheral leukocyte counts is strongly recommended in order to minimise the risk of PML. Ustekinumab p19 and anti - IL 17 represent alternative treatment options.

We suggest using fumarates in psoriasis patients with multiple sclerosis.	↑	<p>STRONG CONSENSUS¹</p> <p style="text-align: center;">100% Agreement</p> <p>EXPERT CONSENSUS</p>
We recommend against using TNFi therapy in psoriasis patients with a diagnosis of multiple sclerosis or other demyelinating disease.	↓↓↓	
In psoriasis patients with a first-degree relative with multiple sclerosis or other demyelinating disease, we suggest against the use of TNFi therapy if other suitable treatment options are available.	↓	

¹ due to personal-financial conflict of interest 3 abstentions



3.9. Viral hepatitis: When and how should psoriasis patients be screened for viral hepatitis and how should patients who test positive be managed?

The chapter is currently under review.




3.10. Tuberculosis: How to screen for tuberculosis before and during biologic treatment?

This chapter is based on the corresponding chapter in the previous versions of the guideline.

^{17,18,160}. A search was conducted, details of which can be found in the individual chapter, see website.

Results/Answer:

Current guidelines and recommendations for screening for tuberculosis (TB) vary between countries and specialties. There are variations in the recommended diagnostic tests, cut off values, follow up and preventive therapy regimens. A uniform approach for the diagnostic procedures and the interpretation of the test results for (latent) tuberculosis infection (LTBI) screening may reduce the cases of (re)activation/worsening, but binding pan-European recommendations are partly hampered by different regional regulations. For recommendations for which treatment TB screening is recommended, please see respective drug chapters.

We recommend screening for tuberculosis according to local regulations.	↑↑	
For pre-screening, we recommend taking a thorough patient history including tuberculosis history; a chest X-ray; TST and/or IGRA.	↑↑	STRONG CONSENSUS ¹ 
We recommend remaining alert to the possibility of tuberculosis infection during therapy. This includes taking medical history and might include tuberculosis testing.	↑↑	EXPERT CONSENSUS

¹ due to personal-financial conflict of interest 4 abstentions



Tuberculosis screening

Diagnostic for TB, regardless Bacillus Calmette-Guérin (BCG) vaccination, prior to and during follow up with biologic. One must be alert for TB infections before, during biologic treatment and up to six months after discontinuation. During treatment, rescreening for LTBI is recommended and frequency should be based on: patient history, risk of exposure, as well as tuberculin skin test (TST) and interferon gamma release assay (IGRA) results.

1. Patient history:

- Symptoms suspicious for TB
- History of TB, adequate treatment
- Exposure to TB
- Origin from or recently stayed for a long time in an endemic area
- High risk patient
- BCG vaccination

2. Physical examination, to consider:

- Auscultation of the lungs if symptomatic (not-specific for TB diagnosis)
- Scar (left) upper arm (may indicate a BCG vaccination)
- Enlarged lymph nodes, abscess scars

3. Chest X-ray: **If a chest X-ray has been conducted in the past, the decision to repeat the X-ray should be based on the psoriasis treatment selected, time since the last x-ray, the patient's risk profile, potential exposure or local guidelines.**

- Suspicious for active, LTBI or history of TB?
→ Consult pulmonologist if abnormalities

4. TST* and/or IGRA

- If IGRA and TST are **both** performed, the IGRA can best be drawn right after the TST is assessed. If drawing is done more than three days after the TST, the TST can booster the IGRA and result in a false-positive response.
- The recommendation to perform IGRA testing rather than TST testing is strong for those who have received the BCG vaccination.

* It is necessary to follow the local recommendations, as the threshold for the TST is different among countries and even among regions within the same country. In most of the countries ≥ 5 mm is considered positive.



TST*	IGRA	Diagnosis	Policy
< 5 mm	negative	Depends on patient history	<ul style="list-style-type: none"> - If no TB suspicious patient history or symptoms, no history of TB, no TB exposure, no living in or travel to endemic area, and no high-risk patient, a biologic can be given. - If yes: Consult pulmonologist for any further diagnosis and treatment - TB infection can still be present in HIV-infected patients with a low CD-4 count
≥ 5 mm < 10 mm	negative	LTBI or active TB with false negative IGRA, or false positive TST	Consult pulmonologist for any further diagnosis and treatment
> 10 mm	negative	Strongly consider LTBI or active TB with false negative IGRA, or false positive TST	Consult pulmonologist for treatment
Every result	QFT-G 0.2-0.35 U/ml	Consider LTBI or active TB, or IGRA false positive	Consult pulmonologist for any further diagnosis and treatment
Every result	Positive (QFT-G > 0.35 U/ml)	Strongly consider LTBI or active TB	Consult pulmonologist for treatment

* It is necessary to follow the local recommendations, as the threshold for the TST is different among countries and even among regions within the same country. In most of the countries ≥ 5 mm is considered positive.

Tuberculin skin test (TST)

False negative TST include those related to the protein purified derivative (PPD) (PPD expiration, experience or loss of antigen [e.g. subcutaneous administration]), and those related to the situation of the patient (HIV infection, recent infections and vaccinations, malignancy, metabolic diseases, immuno-suppressant therapy, or extreme ages [newborn, elderly]). False positive TST include those related to the administration and PPD lecture (inexperience, high amount of antigen), and cross-reactions (BCG vaccination, and most environmental nontuberculous mycobacteria). Although a BCG-vaccination or an atypical mycobacterial infection may cross-react with the TST, causing a false positive result, the tuberculin reaction would usually be much higher if active TB is truly present. The BCG vaccination may fade over time and no cross-reaction would occur. Regardless the BCG vaccination, in general, an assessment of ≥ 5 mm induration



will be considered as positive. A patient may then be referred directly to a pulmonologist. In patients with a history of BCG vaccination, IGRA testing is preferred over TST.

IGRA

IGRA is a specific blood test. After a *Mycobacterium Tuberculosis* infection, T cells will release interferon-gamma (IFN- γ) in response to contact with the TB antigens. Two measurements for interferon-gamma are known; the QuantiFERON[®]-TB Gold-test (QFT-G), based on the amount of IFN- γ that is released in response to the antigens, and the T-SPOT[®] TB test (T-SPOT), counting the number of T cells that produce IFN- γ in a sample of blood. The IGRA is not affected by prior BCG vaccination, however the interpretation of results (borderline results) might be limited due to issues in the cut-off values, shifting conversions and reversion rates over time, and varying test reproducibility. Neither TST nor IGRA allow to distinguish between active or latent TB³⁷². A suppressed immune system reduces the sensitivity of tests based on T cell responses. Only positive results will be convincing in that case, while negative results cannot rule out a TB infection. A negative IGRA, following a positive TST, can still suggest a LTBI. Besides, the IGRA can be unreliable (false negative) if other immunosuppressive medications were applied in advance. An IGRA is also recommended if the TST was less than 5 mm in induration. Negative results of TST or IGRA of HIV-infected patients with a low CD-4 count cannot rule out a TB infection.

Screening during biologic treatment

Physicians have to be aware that there is still a risk of active tuberculosis under biologic therapy, even if LTBI was correctly treated. Therefore, LTBI rescreening is preferable during biologic treatment. The frequency should take risk exposure into consideration. Besides medical history, both TST and IGRA are recommended, because of the influence that the biologic may have (false-negative) on these tests. A high index of suspicion should also be maintained for six months following discontinuation.



3.11. Tuberculosis: How to manage psoriasis in patients with positive tuberculosis test results?

This chapter is based on the corresponding chapter in the previous versions of the guideline.^{17,18,160} A search was conducted, details of which can be found in the individual chapter, see website.

Results/Answer:

Comment: Depending on the prevalence of TB and on the health care situation, dermatologists may be in a position to interpret positive findings, to make further management decisions themselves or to directly refer patients to infectious disease specialists where interdisciplinary cooperation is common.

Interpretation of positive findings in IGRA/TST

Patients with active and latent tuberculosis (TB) can be identified using either the interferon gamma release assay (IGRA) or tuberculin skin test (TST). However, neither test can distinguish between the latent and active states of the disease³⁷²

IGRA is a specific blood test. The interpretation of IGRA test results (especially borderline results) can be limited due to issues in the cut-off values, shifting conversions and reversion rates over time, and varying test reproducibility. In case of borderline results, repeating the test may be advisable³⁷².

The sensitivity of **TST** for latent tuberculosis infection (LTBI) has been described as 74 % and the specificity of 89 % in a meta-analysis^{373,374}. The positive predictive value for TB infection by the TST depends on the prevalence of TB within a given region/population and the possibility of cross-reactions.

False positive TST include those related to the administration of purified protein derivative (PPD) and its lecture (inexperience, high amount of antigen), and cross-reactions (BCG vaccination, and most environmental non-tuberculous mycobacteria). Although the TST would usually be, much higher if active TB is truly present.

Means to distinguish between active and latent TB commonly used in the guidelines group experts' setting include medical history (exposure risk), signs and symptoms (e.g. current cough, fever, weight loss, night sweats), chest x-ray³⁷⁵ and urinalysis (pyuria)³⁷⁶⁻³⁷⁸. For details of differential diagnosis of latent versus active TB, please see respective guidelines and reviews

^{372,375,379}



We **recommend** discussing the decision to initiate immuno-suppressive therapies in patients with signs of latent tuberculosis with an infectious disease specialist (case-by-case basis).

↑↑

STRONG CONSENSUS¹

As a commonly used procedure in case of latent TB, a treatment with isoniazid can be **recommended** with treatment initiation one month before the start of the immunosuppressive therapy and should be continued for 6 months (for alternatives see Table 48).

↑↑

EXPERT CONSENSUS

100% Agreement

¹ due to personal-financial conflict of interest 4 abstentions

Different treatment regimens are available for LTBI with duration depending on monotherapy or combinations. In clinical practice, the most widely accepted treatment are isoniazid (INH) for six months and INH + rifampicin (RIF) for three months, see Table 48³⁸⁰. Patients should have regular check-ups during chemoprophylaxis treatment to detect any drug-related adverse events (e.g. hepatotoxicity) and to monitor for symptoms of TB during treatment with biologics, as reactivation has been reported even after screening and chemoprophylaxis for LTBI has been completed¹⁶⁷.

Table 48: Therapeutic regimens for LTBI

Drug	Dose	Treatment duration
INH alone (daily)	5 mg/kg; max dose: 300 mg	6-9 months
RIF alone (daily)	10mg/kg; max dose: 600 mg	3-4 months
INH + RIF (daily)	INH: 5 mg/kg; max dose: 300 mg RIF: 10mg/kg; max dose: 600 mg	3-4 months

INH = Isoniazide; RIF Rifampicin, Treatments with pyrazinamide should be avoided (high risk of hepatotoxicity). Based on WHO: Latent tuberculosis infection: updated and consolidated guidelines for programmatic management, 2018.

Risk of TBC reactivation with different treatments

The search conducted for this update did not provide robust evidence that would justify an adjustment of the current recommendations regarding TB management. Further research is needed to determine whether there are differences in risk of tuberculosis infection/ reactivation between the different classes of immunosuppressive agents (i.e. whether risks associated with IL17 and IL12/23 inhibition are equivalent to the established risks associated with TNFi).

Conventional treatments/Small molecules

Data on the reactivation risk with acitretin, ciclosporin (CsA), fumarates, methotrexate (MTX) and apremilast is scarce. Most published guidelines have, thus far, not recommended TB screening for these drugs (except MTX and CsA)³⁸¹. Screening before treatment with MTX is



recommended in the summary of products characteristics (SmPC). The sensitivity of IGRA and TST may be influenced by conventional immunosuppressive treatments, so doing IGRA initially may be beneficial if a later switch, especially from MTX to other drug categories appears likely.³⁸²

Biologics

A higher risk of latent TB reactivation under treatment with infliximab or adalimumab has been identified, with a lower risk of reactivation with etanercept. Cases of latent TB reactivation with ustekinumab have been reported in a long-term study of up to 5 years²⁸². The risk of latent TB reactivation seems to be lowest during treatment with anti-IL 17 and anti-IL 23 targeted treatments^{167,383}.

In a systematic review by Snast et al., 78 patients who developed active TB during biologic treatment were analysed. Eighty percent of all cases were treated with adalimumab or infliximab, 12% were treated with etanercept. No case of active TB was identified with the anti-interleukin-17 agents (ixekizumab, secukinumab, and brodalumab); however, the total patient exposure years for these at the time of analysis were much shorter than for the TNFi. All patients in this review had initially been screened for TB. In the majority of cases of reactivation, patients presented with extra-pulmonary disease within the first six months of biologic therapy.³⁸⁴

Table 49 provides an overview of the screening practice based on reactivation risk during antipsoriatic treatments. The risk assessment may be biased due to the different time periods when the cases occurred. At the time of TNF alpha introduction, TBC screening was not always done, leading to less testing and higher numbers of patients with latent TB being exposed to the respective drugs. In addition to the reported cases of TB reactivation, pathophysiological considerations of the immune response to TB favor the group of anti-IL-17 and anti-IL-23 as treatment options. IL-12 has been reported to play a role in the anti TB immune response.


Table 49: LTBI screening indication based on different systemic treatments

Systemic treatments		Screening recommendation as provided in SmPC	Comments
Conventional systemic agents	Acitretin	No	No cases of reactivation have been reported ³⁸⁵
	Ciclosporin	No	Cases have been reported in organ transplant patients with high doses of CsA ³⁸⁵
	Fumarates	No	No cases of reactivation have been reported ^{386,387}



	Methotrexate	Yes	Cases of reactivation have been reported ³⁸⁸
Phosphodiesterase 4 inhibitor	Apremilast	No	Increased risk has not been reported ³⁸⁹
Tyrosine-kinase 2 inhibitor	Deucravacitinib	Yes	Uncertain risk of reactivation. No data available yet.
TNFi	Etanercept	Yes	Increased risk of reactivation has been reported ^{390,391}
	Infliximab	Yes	Increased risk of reactivation has been reported ^{390,391}
	Adalimumab	Yes	Increased risk of reactivation has been reported ^{390,391}
	Certolizumab	Yes	Increased risk of reactivation has been reported ^{385,390}
Anti-IL 12/23	Ustekinumab	Yes	Uncertain risk of reactivation (cases have been reported) ^{385,392,393}
Anti-IL 17	Secukinumab	Yes	Increased risk has not been reported in clinical trials ^{392,394}
	Ixekizumab	Yes	Increased risk has not been reported in clinical trials ³⁹²
	Brodalumab	Yes	Increased risk has not been reported in clinical trials ³⁹²
Anti-IL 23	Guselkumab	Yes	Increased risk has not been reported in clinical trials ³⁹⁵
	Tildrakizumab	Yes	Increased risk has not been reported in clinical trials ⁸⁶
	Risankizumab	Yes	Increased risk has not been reported in clinical trials ³⁹⁶
Reported cases need to be seen in correlation to approval date, especially with years and numbers of psoriasis patients exposed to the drug.			



<p>We recommend against TNFi as a treatment for patients with latent TB unless there are no other suitable treatment options.</p>	<p>↓↓</p>	
<p>We recommend remaining alert to signs and symptoms of tuberculosis activation or re-infection during therapy.</p>	<p>↑↑</p>	<p>STRONG CONSENSUS¹</p> <div style="text-align: center;">  </div>
<p>We suggest acitretin, apremilast or fumarates or a treatment from the anti-IL-17 and anti-IL-23 group for patients with latent TB that require a systemic antipsoriatic treatment.</p>	<p>↑</p>	<p>EXPERT CONSENSUS</p>

¹ due to personal-financial conflict of interest 4 abstentions



3.12. Wish for child / pregnancy: How should psoriasis patients with a wish for pregnancy in the near future or who are pregnant be managed? (under review; last update: 10/2021)

This chapter is based on the previous chapter ^{17,18}. A search was conducted.

Results/Answer:

Psoriasis commonly affects men and women planning conception and women who are pregnant, so understanding the risks of therapy during conception and pregnancy is crucial. Psoriasis is not known to have a significant impact on either male or female fertility. Although pregnancy has an unpredictable effect on psoriasis, limited evidence suggests that psoriasis usually improves; around 55% improve during pregnancy, 25% report no change, and 25% worsen ^{397,398}. Conversely in the post-partum period, psoriasis is more likely to flare; around 65% worsen, 25% demonstrate no change and 10% improve.

Maternal and fetal health outcomes are vital considerations when deciding on the optimal treatment for individuals with psoriasis who are planning conception or are pregnant. Although data are limited and not always consistent across studies ³⁹⁹, untreated severe psoriasis in the mother may be detrimental for fetal well-being and pregnancy outcomes, for example it has been shown to be associated with preterm birth and low birthweight babies ^{400,401}. The risk of untreated psoriasis of the mother in pregnancy must therefore be weighed against any potential harm through drug exposure of the fetus. Other factors that may impact pregnancy outcomes include alcohol consumption, smoking and comorbidities such as obesity and depression (which are more prevalent in greater disease severity) ⁴⁰². Despite the rapidly increasing number of medications available for the treatment of psoriasis, knowledge on their safety in pregnancy remains limited.

Non-biologic systemic drugs

Acitretin

Acitretin is teratogenic and is contraindicated in women of child-bearing potential, those planning pregnancy, breastfeeding or not capable of using contraception until three years after cessation of therapy ⁴⁰³.



Apremilast

There are limited data about the use of the small molecule apremilast during pregnancy. Previous studies on animals did not show an increase in malformations with apremilast, but have shown dose-related fetal loss and reduced birth weight. Apremilast is therefore contraindicated during pregnancy⁴⁰⁴. Women of child-bearing potential should use effective contraception to prevent pregnancy and continue this until at least four weeks after cessation of apremilast treatment⁴⁰⁴.

Apremilast was detected in the milk of lactating mice at levels approximately 1.5-fold that of blood plasma samples^{405,406}. It is unknown whether apremilast or its metabolites are excreted in breast milk in humans, therefore apremilast should not be used whilst breastfeeding^{404,406}. No data are available regarding the influence of apremilast on fertility in humans⁴⁰⁴.

Ciclosporin

Ciclosporin crosses the placenta, but there is no evidence for teratogenicity⁴⁰⁷. Experience with solid organ transplant recipients indicates that ciclosporin increases the chance of pregnancy-specific complications such as pre-eclampsia and low birthweight. In pregnant women with plaque psoriasis receiving ciclosporin, the advantages and disadvantages of continuing ciclosporin should be considered. Ciclosporin should not be used during pregnancy unless the potential benefit to the mother justifies the potential risk to the fetus⁴⁰⁷. The ethanol content of the Sandimmun Neoral formulations should also be taken into account in pregnant women. If necessary, ciclosporin treatment can be continued with close follow-up, preferably together with an obstetrician^{40,407}. Ciclosporin is transferred into breast milk, therefore ciclosporin use is contraindicated during breastfeeding. There is limited data on the effect of ciclosporin on human fertility.

Dimethyl fumarate

Dimethyl fumarate is contra-indicated in women of child-bearing potential who are not using appropriate contraception⁴⁰⁸. Dimethyl fumarate should not be taken by women who are pregnant, breast-feeding or attempting conception. There are no published reports of patients becoming pregnant while on dimethyl fumarate⁴⁰⁹. No data are available on the effects of dimethyl fumarate on female fertility⁴⁰⁸. In patients with diarrhea during treatment with dimethyl fumarate, the effect of oral contraceptives can be reduced. Additional use of barrier methods of contraception is therefore recommended⁴⁰⁸.



It is unknown whether fumarates or their metabolites are excreted in breast milk, therefore the use of fumarates is contraindicated during breastfeeding ⁴⁰⁸.

Methotrexate

Methotrexate is a folic acid antagonist known to be teratogenic in humans. In a recent review, statistically significant higher proportions of microcephaly, craniosynostosis, tetralogy of Fallot, pulmonary valve atresia, limb reduction defects and syndactyly were found in newborns after maternal use of methotrexate in pregnancy ⁴¹⁰. Spontaneous abortions were observed more frequently in pregnant women receiving methotrexate (less than 30 mg/week) compared to women with comparable diseases treated with other medications (42.5% versus 22.5%) ⁴¹¹.

Therefore, where relevant, women should be counselled about pregnancy and breastfeeding, and should not conceive whilst taking methotrexate ⁴¹¹. Recent EMA guidelines recommend discontinuing methotrexate for 6 months before attempting conception, which is a change from the previous recommendations of 3 months ⁴¹². No evidence pertaining to the standard dose of methotrexate (5-30mg/week) for inflammatory diseases is cited for this change of recommendation. The practice of the guideline group differs from this in favor of a shorter period of discontinuation (3 months).

It is recommended that sexually active women have a pregnancy test prior to starting therapy and use two methods of contraception throughout the period of methotrexate treatment. In the event of pregnancy during methotrexate therapy, immediate referral to an obstetrician is required ⁴¹³. Methotrexate influences oogenesis and possibly can reduce fertility, especially in high doses. In most patients this is reversible after stopping methotrexate ⁴¹¹. Methotrexate is excreted into breast milk and so should not be used when breastfeeding.

Recommendations (non-biologic systemic drugs):

When providing advice on use of systemic therapies in women planning conception or who are pregnant, prescribers are advised to use these recommendations with reference to the individual drug SmPC.



We suggest ciclosporin as a first line convention agent in women planning conception and when it is necessary to start systemic therapy during the 2 nd and 3 rd trimester of pregnancy	↑	<p>STRONG CONSENSUS¹</p> <p>100% Agreement</p> <p>EXPERT CONSENSUS</p>
Methotrexate and acitretin are contra-indicated in women planning conception. We recommend against using these.	↓↓	
Fumarates and apremilast are contra-indicated in women planning conception. We suggest against using these.	↓	
We recommend consultation and information sharing across specialties, including with an obstetrician with expertise in caring for pregnant women with medical problems.	↑↑	
We recommend the collection of maternal exposure to medications and pregnancy outcome data in national safety registries where available.	↑↑	

¹ due to personal-financial conflict of interest 3 abstentions

Biologic drugs

Data from studies reporting pregnancy outcomes in women exposed to biologic treatments during conception and/or pregnancy were recently comprehensively reviewed as part of the British Association of Dermatologists guidelines for biologics use in psoriasis ⁴¹⁴. All of the biologic agents that are currently licensed for psoriasis except certolizumab pegol contain a human IgG1 Fc region and are actively transported across the placenta via neonatal Fc receptors ^{415,416}. Active placental transfer is thought to be very low during the first trimester when organogenesis takes place, hence the theoretical risk of teratogenicity of biologics is low. Active transfer can, however, occur at around 13 weeks' gestation and increases significantly after 20 weeks' gestation. This increasing exposure to biologics during the second and third trimesters is hypothesised to adversely affect fetal development, leading to potential risk of neonatal immunosuppression and greater risk of neonatal infections ⁴¹⁷. Biologic therapies typically disappear from an infant's serum within the first six months of life.

In contrast, certolizumab pegol is the only PEGylated humanised antigen-binding fragment of a TNF antagonist and it lacks a Fc domain ⁴¹⁸. Certolizumab pegol therefore does not bind to the human neonatal Fc receptor and it is not actively transferred across the placenta. This was underscored by an analysis of 31 pregnancies exposed to infliximab, adalimumab and certolizumab pegol (for inflammatory bowel disease), in which the median levels of infliximab,



adalimumab and certolizumab pegol in the cord blood of infants compared with that of mother were 160%, 153%, and 3.9%, respectively ⁴¹⁹. Infliximab and adalimumab could be detected in the infants for as long as 6 months. Post-marketing prospective pharmacokinetic research has confirmed no/minimal transfer of certolizumab pegol via the placenta (CRIB study, n=16 ⁴²⁰) and into breast milk (CRADLE study, n=19 ⁴²¹).

Population-based cohort studies that report pregnancy outcomes in women exposed to biologics during conception and/or pregnancy are limited to TNF antagonist exposure only ⁴²²⁻⁴³⁴ (see respective table). No evidence was identified on the use of IL-12/IL-23p40, IL-17 or IL-23p19 inhibitor biologics. Overall, the available studies identified no clear evidence of drug-specific harm to the fetus following TNF antagonist exposure with respect to congenital malformations, live births, pre-term births or neonatal infections ⁴²²⁻⁴³⁴. One study (in inflammatory bowel disease) addressed maternal infection, indicating a potential increased risk to the mother following TNF antagonist exposure ⁴²⁶.

The evidence is overall limited since most studies involved small cohorts that may be underpowered to demonstrate small but significant risks associated with the treatments. Most of the evidence also relates to women with other chronic inflammatory conditions such as inflammatory bowel disease or arthritis rather than psoriasis specifically. Several of the outcomes were poorly defined and heterogeneous, making it difficult to ascertain whether or not a pattern of specific birth defects was occurring. There is also a paucity of information on long-term outcomes for children born to women receiving biologics.

Recommendations (biologic drugs):

When providing advice on use of systemic therapies in women planning conception or who are pregnant, prescribers are advised to use these recommendations with reference to the individual drug SmPC.

All biologic drugs currently licensed for psoriasis (with the exception of certolizumab pegol) are actively transferred to the fetus during the second and third trimester, and the impact of this on neonatal development and risk of infection (to both mother and baby) has not been adequately studied.



<p>We suggest certolizumab pegol as a first line choice when starting biologic therapy in women planning conception (when a biologic is considered essential to use in pregnancy) and when it is necessary to start a systemic therapy during the second or third trimester.</p>	<p>↑</p>	<p>STRONG CONSENSUS¹</p> <div style="display: flex; align-items: center; justify-content: center;"> <div style="border: 1px solid black; border-radius: 50%; width: 20px; height: 20px; background-color: #90EE90; margin-right: 5px;"></div> 100% Agreement </div> <p>EXPERT CONSENSUS</p>
<p>We suggest stopping biologic therapy in the second and third trimester (except certolizumab pegol) to minimise fetal exposure and limit potential infection risk to the neonate.</p>	<p>↑</p>	
<p>We suggest against using live or live attenuated vaccines in infants (up to 6 months of age) whose mothers received biologic therapy beyond 16 weeks gestation, unless the benefit of the vaccination clearly outweighs the theoretical risk of administration.</p>	<p>↓</p>	
<p>We recommend consultation and information sharing across specialties, including with an obstetrician with expertise in caring for pregnant women with medical problems</p>	<p>↑↑</p>	
<p>We recommend the collection of maternal exposure to medications and pregnancy outcome data in national safety registries where available.</p>	<p>↑↑</p>	

¹ due to personal-financial conflict of interest 3 abstentions

Necessity for continuing contraception immediately following biologic treatment cessation

There is no consensus on how long contraception needs to be continued after stopping treatment with a biologic. **Table 50** gives an overview of the recommended minimum time lag between stopping a biologic treatment and conception, as stated in the respective SmPCs. For treatments with a good safety profile during pregnancy, continuation of contraception immediately following treatment cessation may not be as relevant as for treatments with an unknown or less favourable safety profile. It is worth noting, that active placental transfer of biologics starts to occur around 13 weeks' gestation and increases significantly after 20 weeks' gestation. The specific half-lives of the respective drugs impact the remaining drug level at these time points.



Table 50: Overview of minimum time between stop of treatment and conception as given by respective SmPC (under review, last update 10/2021)

Infliximab	Adalimumab	Etanercept	Ustekinumab	Secukinumab	Apremilast*
6 months ¹³³	5 months ³²	3 weeks ³⁸²	15 weeks ⁸⁸	20 weeks ⁸⁰	No information provided in SmPC, 28 days advised by Celgene

Ixekizumab	Certolizumab	Bimekizumab	Brodalumab	Tildrakizumab	Guselkumab	Risankizumab
10 weeks	5 months*	17 weeks	12 weeks	17 weeks	12 weeks	21 weeks

* Note: Certolizumab is the suggested biologic treatment option, for women who are planning conception or are pregnant and require a systemic therapy, see also respective chapters

Paternal use

In men who are planning conception, the effects of systemic medications on both fertility and fetal development are important considerations. However, there is very limited data on the impact of paternal exposure to systemic medications, particularly with respect to teratogenicity and longer term sequelae.

Acitretin

Acitretin has no known effect on male fertility⁴³⁵. Traces of acitretin have been reported in the semen of men, however there is no evidence of teratogenicity at conception as the main at risk period is 4–6 weeks later⁴³⁶. Although ongoing exposure via direct contact with semen during unprotected sexual intercourse after conception is of low risk, the barrier method of contraception post-conception may be considered⁴⁰⁵.

Apremilast

There are no available data for the impact of paternal exposure to apremilast on male fertility or pregnancy outcomes. In animal studies in mice, no adverse effects on fertility were observed in males at exposure levels threefold clinical exposure¹⁸.

Ciclosporin

There is no evidence that paternal use of ciclosporin affects male fertility, however there are a paucity of studies on this^{405,437,438}. Recent systematic reviews of cohort study data showed no impact on pregnancy outcomes^{405,437}. This includes data from a Danish registry study of 247 children conceived during paternal use of ciclosporin, which found no association between paternal exposure to ciclosporin and increased risk of congenital abnormalities⁴³⁹.



Fumarates

A recent European consensus meeting concluded that contraception for males receiving fumarates is not required, although there is a paucity of evidence ⁴⁰⁸

Methotrexate

Fertility

A recent systematic review identified 48 male exposures to methotrexate ⁴³⁷, of which there were two isolated case reports of oligospermia (one reversible and one irreversible) ^{440,441}. Another five publications comprising the remaining 46 exposures concluded that there was no impact of methotrexate on male fertility ⁴³⁷. A case series of 26 men receiving methotrexate who had their semen examined using radioactive phosphorus for testicular histology and spermatogenic function showed no negative impact on fertility ⁴⁴². Another study compared semen parameters from ten men treated with methotrexate for severe psoriasis with those of ten men using topical steroids, and found that those taking methotrexate were significantly more likely to have normal semen parameters ⁴⁴³.

Pregnancy outcomes

Paternal methotrexate use has not been shown to cause teratogenicity or adverse pregnancy outcomes. A recent systematic review which reported 1511 peri-conception paternal methotrexate exposures concluded that there was no link between paternal methotrexate exposure and adverse pregnancy outcomes or congenital malformations ⁴³⁷. The largest cohort studies, comprising national registry data ^{439,444,445} and longer term outcomes ⁴⁴⁶, showed no increased risk of paternal methotrexate exposure on pregnancy outcomes.

Although the above data do not support the need for any washout period for methotrexate, further evidence is required before this can be recommended. Recent EMA guidelines recommend discontinuing methotrexate for six months before attempting conception, which is a change from the previous recommendations of three months ⁴¹². No evidence pertaining to the standard dose of methotrexate (5-30mg/week) for inflammatory diseases is cited for this change of recommendation. The practice of the guideline group differs from this in favor of a shorter period of discontinuation (3 months).

Biologics

Although there is limited available data, cohort studies of TNF antagonists found no evidence for impairment in fertility during paternal use ^{405,438}. A systematic review highlighted that sperm motility and vitality may even improve under TNF antagonist therapy, possibly due to a decrease



in disease activity ⁴⁴⁷. Cohort studies (total of 60 exposures with outcome events documented in 28 cases) involving a range of TNF antagonists (adalimumab, certolizumab pegol, etanercept, infliximab) also demonstrated no evidence for an association between impaired pregnancy outcomes and paternal use of TNF antagonist therapy at the time of conception ^{405,437,447}.

There are no studies which have assessed the potential impact of paternal exposure to other biologic agents including IL-12/IL-23p40 inhibitors, IL-17 inhibitors or IL-23p19 inhibitors on male fertility or pregnancy outcomes.

<p>It is recommended that men discontinue methotrexate 3 months before attempting conception. *</p> <p>*EMA recommends 6 months as a means of precaution, the practice of the guideline group differs from this.</p>	<p>↑↑</p>	<p>STRONG CONSENSUS¹</p>
<p>As a precaution, it is suggested that men taking acitretin use barrier forms of contraception post-conception to limit exposure via direct contact with semen during pregnancy.</p>	<p>↑</p>	<p>100% Agreement</p> <p>EXPERT CONSENSUS</p>
<p>We recommend the collection of paternal exposure to medications during conception and pregnancy outcome data in national safety registries where available.</p>	<p>↑↑</p>	

¹ due to personal-financial conflict of interest 3 abstentions



3.13. Vaccinations: How should vaccinations in psoriasis patients on systemic treatment be managed?

A narrative literature review was conducted.

Results/Answer:

Psoriasis per se is not considered a reason to deviate from standard vaccination recommendations/national vaccination policy.

Patients who are planning to start systemic immune-modifying therapy for psoriasis:

- The optimal timing for vaccination is prior to starting systemic immune-modifying therapy.
- Check vaccination status and complete appropriate vaccinations in line with national vaccination policy prior to starting systemic immune-modifying therapy where possible.
- Check the drug specific summary of product characteristics (SmPC) for the recommended timeframe for starting systemic immune-modifying medication following vaccination.

Patients who are receiving systemic immune-modifying therapy for psoriasis:

- The immune response to vaccination is influenced by multiple factors including the type and dose of systemic immune-modifying therapy, the type of vaccine (live attenuated or non-live attenuated), intrinsic host factors (e.g. age, comorbidities) and extrinsic factors (e.g. preexisting immunity from prior exposure to antigen) ⁴⁴⁸.
- Check national vaccination policy for vaccination requirements during therapy.
- Check the drug specific SmPC for the recommended timeframe for taking systemic immune-modifying treatment following vaccination.
- In general, non-live attenuated vaccines can be safely used in patients receiving systemic immune-modifying therapy, however vaccine immunogenicity may be reduced. Live attenuated vaccines should be avoided in patients receiving systemic immune-modifying therapy, in line with drug specific SmPCs. Live attenuated vaccines should also be avoided in infants (up to six months of age) whose mothers received biologic therapy beyond 16 weeks gestation (see drug specific SmPCs and chapter on pregnancy).
- A complete course of COVID-19 vaccination including an additional (third) primary dose and booster doses in line with national vaccination policy is recommended since individuals receiving immune-modifying therapy may have attenuated humoral and cellular responses to the COVID-19 vaccine compared with healthy controls ⁴⁴⁹⁻⁴⁵². A 2-



week interruption of methotrexate following vaccination should be considered where possible since it may improve vaccine immunogenicity, although the impact on vaccine clinical effectiveness is unknown^{453,454}. There is no consensus on correlates of protection against infection, symptomatic disease or severe COVID-19.



3.14. Immunogenicity of targeted therapies in psoriasis (last update: 10/2021)

Narrative review of the existing literature was conducted.

Results/Answer:

A lack of fully comparable information on the formation of anti-drug antibodies against targeted therapies in psoriasis has been identified in the course of the guideline's development. Within the scope of this version of the guideline, a thorough systematic search of the available evidence has not been feasible and a consensus on consequent measures has not been achieved. The author group acknowledges that there is evidence of a beneficial effect of the combination of methotrexate with adalimumab from psoriasis patients and MTX with infliximab in rheumatoid arthritis or Crohn's disease patients to reduce the formation in ADA.

The guideline group encourages researches to pursue further investigations into the field of anti-drug antibodies and to generate data that allows comparison between different drugs and that can lead clinically relevant recommendations.

The authors encourage further opinion papers, narrative or preferably systematic reviews to further advance the discussion on immunogenicity. ⁴⁵⁵⁻⁴⁵⁷



XI. Strengths and limitations

The general recommendations and treatment algorithm are evidence- and consensus-based and they were developed in cooperation with Sbidian et al., which meant that the most-up-to-date systematic review and network meta-analysis was used and that the methods applied in the development of this review were rigorous – as detailed in the Cochrane Handbook - and peer reviewed independently through the Cochrane Skin Group.

While this allowed for an inclusion of newer treatment options, one limitation of this guideline is the absence of recommendations beyond induction treatment, as this was not covered by the review.

Another focus of this guideline is the explicit reporting on management and monitoring recommendations for patients receiving the different treatments. However, while these were developed taking the SmPCs and clinical practice in many European countries into account, the recommendations are often not evidence-based as there typically is no evidence available.



XII. References

1. Higgins JPT, Green S, (editors). *Cochrane Handbook for Systematic Reviews of Interventions*. vol Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011.
2. Augustin M, Alvaro-Gracia JM, Bagot M, et al. A framework for improving the quality of care for people with psoriasis. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Jul 2012;26 Suppl 4:1-16. doi:10.1111/j.1468-3083.2012.04576.x
3. Campanati A, Ganzetti G, Giuliadori K, Molinelli E, Offidani A. Biologic Therapy in Psoriasis: Safety Profile. *Current drug safety*. 2016;11(1):4-11. doi:10.2174/1574886310666151014115532
4. International Federation of Psoriasis Association. Position Statement of biosimilars - IFPA. 2021. p. p. 2.
5. Association IFoP. Strengthening Global Commitments to UHC Psoriatic Disease. 2023.
6. Dubertret L, Mrowietz U, Ranki A, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. *The British journal of dermatology*. Oct 2006;155(4):729-36. doi:10.1111/j.1365-2133.2006.07405.x
7. Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. *J Am Acad Dermatol*. Apr 2006;54(4):685-704. doi:10.1016/j.jaad.2005.10.008
8. Löfvendahl S. *Burden of Disease in Psoriasis and Psoriatic Arthritis. Occurrence, Healthcare Use, Costs and Health Outcome*. 2016.
9. Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. *Dermatologica*. 1978;157(4):238-44. doi:10.1159/000250839
10. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. *Clinical and experimental dermatology*. May 1994;19(3):210-6.
11. Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. *Archives of dermatological research*. Jan 2011;303(1):1-10. doi:10.1007/s00403-010-1080-1
12. Khilji FA, Gonzalez M, Finlay AY. Clinical meaning of change in Dermatology Life Quality Index scores. *The British journal of dermatology*. 2002;147 Suppl 62:50.
13. Augustin M, Kruger K, Radtke MA, Schwippl I, Reich K. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. *Dermatology*. 2008;216(4):366-72.
14. Katugampola RP, Lewis VJ, Finlay AY. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis. *The British journal of dermatology*. May 2007;156(5):945-50.
15. Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. *J Am Acad Dermatol*. Jan 2020;82(1):117-122. doi:10.1016/j.jaad.2019.08.026
16. Dauden E, Puig L, Ferrandiz C, Sanchez-Carazo JL, Hernanz-Hermosa JM. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Mar 2016;30 Suppl 2:1-18. doi:10.1111/jdv.13542
17. Nast A, Gisondi P, Ormerod AD, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Dec 2015;29(12):2277-94. doi:10.1111/jdv.13354
18. Nast A, Spuls PI, van der Kraaij G, et al. European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with



- EADV and IPC. *Journal of the European Academy of Dermatology and Venereology: JEADV*. 2017;12 2017;31(12):1951-1963. doi:10.1111/jdv.14454
19. Mrowietz U, de Jong EM, Kragballe K, et al. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Apr 2014;28(4):438-53. doi:10.1111/jdv.12118
20. Torres T, Puig L. Treatment goals for psoriasis: Should PASI 90 become the standard of care? *Actas dermo-sifiliograficas*. Apr 2015;106(3):155-7. doi:10.1016/j.ad.2014.10.001
21. Mahil SK, Wilson N, Dand N, et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). *The British journal of dermatology*. May 2020;182(5):1158-1166. doi:10.1111/bjd.18333
22. Seston EM, Ashcroft DM, Griffiths CEM. Balancing the Benefits and Risks of Drug Treatment: A Stated-Preference, Discrete Choice Experiment With Patients With Psoriasis. *Archives of dermatology*. 2007;143(9):1175-1179. doi:10.1001/archderm.143.9.1175
23. Egeberg A, Andersen YMF, Halling-Overgaard AS, et al. Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Jan 2020;34(1):39-46. doi:10.1111/jdv.15920
24. Nast A, Sporbeck B, Rosumeck S, et al. Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action. *The Journal of investigative dermatology*. Aug 2013;133(8):1963-70. doi:10.1038/jid.2013.78
25. Pham PA, Dressler C, Eisert L, Nast A, Werner RN. Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals. *Rheumatol Int*. Apr 2019;39(4):605-618. doi:10.1007/s00296-019-04244-5
26. Nast A, Dilleen M, Liyanage W, Aikman L, Szczypa P, Dressler C. Time, Psoriasis Area and Severity Index and Dermatology Life Quality Index of patients with psoriasis who drop out of clinical trials on etanercept because of lack of efficacy: a pooled analysis from 10 clinical trials. *The British journal of dermatology*. Feb 2018;178(2):400-405. doi:10.1111/bjd.15864
27. Zidane M, Dressler C, Gaskins M, Nast A. Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis. *JAMA dermatology*. Oct 16 2019;doi:10.1001/jamadermatol.2019.2941
28. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. *Journal of clinical epidemiology*. Apr 2011;64(4):383-94. doi:10.1016/j.jclinepi.2010.04.026
29. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. *Journal of clinical epidemiology*. Apr 2011;64(4):380-2. doi:10.1016/j.jclinepi.2010.09.011
30. The GRADE Working Group. Accessed July 10, 2018. <http://www.gradeworkinggroup.org/>
31. Werner RN, Nikkels AF, Marinovic B, et al. European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 1: Diagnosis. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Jan 2017;31(1):9-19. doi:10.1111/jdv.13995
32. Werner RN, Nikkels AF, Marinovic B, et al. European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2:



- Treatment. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Jan 2017;31(1):20-29. doi:10.1111/jdv.13957
33. Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. *The Cochrane database of systematic reviews*. May 23 2022;5(5):Cd011535. doi:10.1002/14651858.CD011535.pub5
34. Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of evidence from a network meta-analysis. *PLoS One*. 2014;9(7):e99682. doi:10.1371/journal.pone.0099682
35. *CINeMA 2017 [Computer program] Institute of Social and Preventive Medicine, University of Bern CINeMA: Confidence in Network Meta-Analysis. Bern: Institute of Social and Preventive Medicine, University of Bern, 2017.*
36. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Oct 2009;23 Suppl 2:1-70. doi:10.1111/j.1468-3083.2009.03389.x
37. Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. *Journal of the European Academy of Dermatology and Venereology : JEADV*. May 2017;31(5):774-790. doi:10.1111/jdv.14114
38. Kragballe K, Jansen CT, Geiger JM, et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study. *Acta dermato-venereologica*. 1989;69(1):35-40.
39. Samarasekera E, Sawyer L, Parnham J, Smith CH. Assessment and management of psoriasis: summary of NICE guidance. *Bmj*. Oct 24 2012;345:e6712. doi:10.1136/bmj.e6712
40. van der Kraaij GE, Balak DMW, Busard CI, et al. Highlights of the updated Dutch evidence- and consensus-based guideline on psoriasis 2017. *The British journal of dermatology*. Jan 2019;180(1):31-42. doi:10.1111/bjd.17198
41. Amatore F, Villani AP, Tauber M, Viguier M, Guillot B. French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Mar 2019;33(3):464-483. doi:10.1111/jdv.15340
42. Carretero G, Ribera M, Belinchon I, et al. Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the Spanish Academy of Dermatology and Venereology. *Actas dermo-sifiliograficas*. Sep 2013;104(7):598-616. doi:10.1016/j.adengl.2013.01.001
43. Munera-Campos M, Vilar-Alejo J, Rivera R, et al. The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry. *The Journal of dermatological treatment*. Jun 2022;33(4):2110-2117. doi:10.1080/09546634.2021.1922572
44. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. *J Am Acad Dermatol*. Sep 2009;61(3):451-85. doi:10.1016/j.jaad.2009.03.027
45. Mrowietz U, Morrison PJ, Suhrkamp I, Kumanova M, Clement B. The Pharmacokinetics of Fumaric Acid Esters Reveal Their In Vivo Effects. *Trends in pharmacological sciences*. Jan 2018;39(1):1-12. doi:10.1016/j.tips.2017.11.002
46. van de Meeberg MM, Hebing RCF, Nurmohamed MT, et al. A meta-analysis of methotrexate polyglutamates in relation to efficacy and toxicity of methotrexate in inflammatory arthritis, colitis and dermatitis. *British journal of clinical pharmacology*. Jan 2023;89(1):61-79. doi:10.1111/bcp.15579



47. van Huizen AM, Menting SP, Gyulai R, et al. International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. *JAMA dermatology*. May 1 2022;158(5):561-572. doi:10.1001/jamadermatol.2022.0434
48. Malaviya AN. Methotrexate intolerance in the treatment of rheumatoid arthritis (RA): effect of adding caffeine to the management regimen. *Clinical rheumatology*. Feb 2017;36(2):279-285. doi:10.1007/s10067-016-3398-3
49. Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. *J Am Acad Dermatol*. Mar 1993;28(3):466-9.
50. Ortiz Z, Shea B, Suarez Almazor M, Moher D, Wells G, Tugwell P. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. *The Cochrane database of systematic reviews*. 2000;(2):CD000951.
51. van Ede AE, Laan RF, Rood MJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. *Arthritis and rheumatism*. Jul 2001;44(7):1515-24.
52. Haque Hussain SS, Wallace M, Belham M, et al. Infective endocarditis complicating adalimumab therapy for psoriasis. *Clinical and experimental dermatology*. Jun 2014;39(4):555-6. doi:10.1111/ced.12312
53. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. *Annals of the rheumatic diseases*. Apr 2013;72(4):517-24. doi:10.1136/annrheumdis-2011-201244
54. Alwawi EA, Mehlis SL, Gordon KB. Treating psoriasis with adalimumab. *Therapeutics and clinical risk management*. Apr 2008;4(2):345-51.
55. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. *Pharmacology & therapeutics*. Feb 2008;117(2):244-79.
56. Traczewski P, Rudnicka L. Adalimumab in dermatology. *British journal of clinical pharmacology*. Jul 11 2008;
57. Esposito M, Giunta A, Mazzotta A, et al. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study. *Dermatology*. 2012;225(4):312-9. doi:10.1159/000345623
58. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. *Arthritis and rheumatism*. Jul 15 2008;59(7):996-1001. doi:10.1002/art.23835
59. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. *The Journal of dermatological treatment*. 2009;20(2):100-8. doi:10.1080/09546630802441234
60. Melo FJ, Magina S. Clinical management of Anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review. *International journal of dermatology*. Dec 2018;57(12):1521-1532. doi:10.1111/ijd.14072
61. Pappas DA, Giles JT. Do antitumor necrosis factor agents increase the risk of postoperative orthopedic infections? *Current opinion in rheumatology*. Jul 2008;20(4):450-6. doi:10.1097/BOR.0b013e3282fcc345
62. den Broeder AA, Creemers MC, Fransen J, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special



- attention for anti-tumor necrosis factor: a large retrospective study. *J Rheumatol*. Apr 2007;34(4):689-95.
63. Busard C, Zweegers J, Limpens J, Langendam M, Spuls PI. Combined use of systemic agents for psoriasis: a systematic review. *JAMA dermatology*. Nov 2014;150(11):1213-20. doi:10.1001/jamadermatol.2014.1111
64. Davila-Seijo P, Dauden E, Descalzo MA, et al. Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry. *The Journal of investigative dermatology*. Feb 2017;137(2):313-321. doi:10.1016/j.jid.2016.08.034
65. European Medicines Agency. Humira [Humira: EPAR - Product Information]. Updated 18 December 2014. Accessed 31 March 2015, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000481/WC500050870.pdf
66. Mrowietz U, Barker J, Conrad C, et al. Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: Results from the EMBRACE randomized trial. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Oct 27 2022;doi:10.1111/jdv.18689
67. Persson R, Cordey M, Paris M, Jick S. Safety of Apremilast in Patients with Psoriasis and Psoriatic Arthritis: Findings from the UK Clinical Practice Research Datalink. *Drug Saf*. Nov 2022;45(11):1403-1411. doi:10.1007/s40264-022-01235-7
68. European Medicines Agency. Otezla - Summary of product characteristics (Annex I). 08/07/2016 Otezla -EMA/H/C/003746 -PSUSA/10338/201506. Updated 19/07/2016. Accessed Nov 28, 2016, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003746/WC500182627.pdf
69. Viswanath V, Joshi P, Lawate P, et al. An Open-Label, Randomized, Prospective, Comparative, Three-Arm Clinical Trial to Evaluate the Safety and Effectiveness of Apremilast with Three Different Titration Methods in Patients with Chronic Plaque Psoriasis in India. *Psoriasis (Auckl)*. 2022;12:53-61. doi:10.2147/ptt.S357184
70. Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. *Lancet*. Aug 25 2012;380(9843):738-46. doi:[http://dx.doi.org/10.1016/S0140-6736\(12\)60642-4](http://dx.doi.org/10.1016/S0140-6736(12)60642-4)
71. Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). *J Am Acad Dermatol*. Jul 2015;73(1):37-49. doi:<http://dx.doi.org/10.1016/j.jaad.2015.03.049>
72. Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Journal Article. *The British journal of dermatology*. Dec 2015;173(6):1387-99. doi:10.1111/bjd.14164
73. Papp KA, Kaufmann R, Thaci D, Hu C, Sutherland D, Rohane P. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. *Journal of the European Academy of Dermatology & Venereology*. Mar 2013;27(3):e376-83. doi:<http://dx.doi.org/10.1111/j.1468-3083.2012.04716.x>
74. Liu Y, Zhou S, Wan Y, Wu A, Palmisano M. The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. *British journal of clinical pharmacology*. Nov 2014;78(5):1050-7. doi:10.1111/bcp.12448



75. Gordon KB, Langley RG, Warren RB, et al. Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials. *JAMA dermatology*. Jul 1 2022;158(7):735-744. doi:10.1001/jamadermatol.2022.1185
76. Blauvelt A, Chiricozzi A. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. *Clin Rev Allergy Immunol*. Dec 2018;55(3):379-390. doi:10.1007/s12016-018-8702-3
77. Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. *Annals of the rheumatic diseases*. Apr 2018;77(4):523-532. doi:10.1136/annrheumdis-2017-212127
78. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. *New England Journal of Medicine*. Jul 24 2014;371(4):326-38. doi:<http://dx.doi.org/10.1056/NEJMoa1314258>
79. Whibley N, Tritto E, Traggiai E, et al. Antibody blockade of IL-17 family cytokines in immunity to acute murine oral mucosal candidiasis. *J Leukoc Biol*. Jun 2016;99(6):1153-64. doi:10.1189/jlb.4A0915-428R
80. Saunte DM, Mrowietz U, Puig L, Zachariae C. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. *The British journal of dermatology*. Jul 2017;177(1):47-62. doi:10.1111/bjd.15015
81. Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. *Clin Infect Dis*. Feb 15 2016;62(4):e1-50. doi:10.1093/cid/civ933
82. Edwards SK, Bunker CB, van der Snoek EM, van der Meijden WI. 2022 European guideline for the management of balanoposthitis. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Jun 2023;37(6):1104-1117. doi:10.1111/jdv.18954
83. Puig L, Lebwohl M, Bachelez H, Sobell J, Jacobson AA. Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial. *J Am Acad Dermatol*. Jun 5 2019;doi:10.1016/j.jaad.2019.05.095
84. Lebwohl MG, Blauvelt A, Menter A, et al. Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study. *American journal of clinical dermatology*. Sep 6 2019;doi:10.1007/s40257-019-00466-2
85. Lebwohl M, Strober B, Menter A, et al. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. *The New England journal of medicine*. Oct 2015;373(14):1318-28. doi:10.1056/NEJMoa1503824
86. Lebwohl MG, Papp KA, Marangell LB, et al. Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials. *J Am Acad Dermatol*. Jan 2018;78(1):81-89.e5. doi:10.1016/j.jaad.2017.08.024
87. European Medicines Agency. Summary of product characteristics Brodalumab https://www.ema.europa.eu/en/documents/product-information/kyntheum-epar-product-information_en.pdf (last accessed 28-10-2019)
88. Hashim PW, Chen T, Lebwohl MG, Marangell LB, Kircik LH. What Lies Beneath the Face Value of a BOX WARNING: A Deeper Look at Brodalumab. *Journal of drugs in dermatology : JDD*. Aug 1 2018;17(8):s29-s34.
89. Lebwohl M, Leonardi C, Armstrong A, et al. Three-year U.S. pharmacovigilance report of brodalumab. *Dermatologic therapy*. Nov 2021;34(6):e15105. doi:10.1111/dth.15105



90. Yeroushalmi S, Chung M, Bartholomew E, Hakimi M, Koo J. Examining worldwide postmarketing suicides from biologics used for psoriasis with a focus on brodalumab: A cross-sectional analysis using the Food and Drug Administration Adverse Event Reporting System (FAERS). *JAAD Int*. Dec 2022;9:119-121. doi:10.1016/j.jdin.2022.08.010
91. Targan SR, Feagan B, Vermeire S, et al. A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease. *The American journal of gastroenterology*. Nov 2016;111(11):1599-1607. doi:10.1038/ajg.2016.298
92. Gottlieb AB, Blauvelt A, Thaci D, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). *J Am Acad Dermatol*. Aug 2018;79(2):302-314.e6. doi:10.1016/j.jaad.2018.04.012
93. Lebwohl M, Blauvelt A, Paul C, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). *J Am Acad Dermatol*. Aug 2018;79(2):266-276.e5. doi:10.1016/j.jaad.2018.04.013
94. Wang X, Liu Q, Wu L, Nie Z, Mei Z. Risk of non-melanoma skin cancer in patients with psoriasis: An updated evidence from systematic review with meta-analysis. *Journal of Cancer*. 2020;11(5):1047-1055. doi:10.7150/jca.37015
95. Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. 2023;(1097-6787 (Electronic))
96. Strober B, Thaçi D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. *J Am Acad Dermatol*. Jan 2023;88(1):40-51. doi:10.1016/j.jaad.2022.08.061
97. Bristol Myers Squibb. SOTYKTU™ (deucravacitinib) tablets, for oral use: US prescribing information. Accessed 01 Feb 2023, https://packageinserts.bms.com/pi/pi_sotyktu.pdf
98. Warren RB, Sofen H, Imafuku S. Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program. presented at: Presented at European Academy of Dermatology and Venereology (EADV) Spring Symposium; May 12–14, 2022 2022; Ljubljana, Slovenia.
99. Chimalakonda A, Burke J, Cheng L, et al. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors. *Dermatology and therapy*. Oct 2021;11(5):1763-1776. doi:10.1007/s13555-021-00596-8
100. Goodman SM, Springer BD, Chen AF, et al. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. *Arthritis care & research*. Sep 2022;74(9):1399-1408. doi:10.1002/acr.24893
101. Catlett IM, Aras U, Hansen L, et al. First-in-human study of deucravacitinib: A selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2. *Clin Transl Sci*. Jan 2023;16(1):151-164. doi:10.1111/cts.13435
102. Tying S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. *Archives of dermatology*. Jun 2007;143(6):719-26. doi:10.1001/archderm.143.6.719



103. Papp KA, Poulin Y, Bissonnette R, et al. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. *J Am Acad Dermatol*. Feb 2012;66(2):e33-45. doi:10.1016/j.jaad.2010.07.026
104. Wyeth Europa Ltd. Fachinformation Enbrel 50 mg Fertigspritze. Accessed January 12, 2015, <http://www.fachinfo.de/data/fi/jsearch?praep>
105. European Medicines Agency. Taltz [Taltz: EPAR - Product Information]. https://www.ema.europa.eu/en/documents/product-information/taltz-epar-product-information_en.pdf
106. Chabra S, Gill BJ, Gallo G, et al. Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials. *Adv Ther*. Jun 2022;39(6):2862-2872. doi:10.1007/s12325-022-02126-0
107. Griffiths CEM, Gooderham M, Colombel JF, et al. Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure. *Dermatology and therapy*. Jun 2022;12(6):1431-1446. doi:10.1007/s13555-022-00743-9
108. Deodhar AA, Combe B, Accioly AP, et al. Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure. *Annals of the rheumatic diseases*. Jul 2022;81(7):944-950. doi:10.1136/annrheumdis-2021-222027
109. European Medicines Agency. Summary of product characteristics Ixekizumab. Accessed 3 November 2019, https://www.ema.europa.eu/en/documents/product-information/taltz-epar-product-information_en.pdf
110. Menter A, Warren RB, Langley RG, et al. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). *Journal of the European Academy of Dermatology and Venereology : JEADV*. Oct 2017;31(10):1686-1692. doi:10.1111/jdv.14237
111. Blauvelt A, Gooderham M, Iversen L, et al. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). *J Am Acad Dermatol*. Nov 2017;77(5):855-862. doi:10.1016/j.jaad.2017.06.153
112. Lebwohl MG, Gordon KB, Gallo G, Zhang L, Paul C. Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Sep 3 2019;doi:10.1111/jdv.15921
113. Papp K, Maari C, Cauthen A, et al. An indirect comparison of long-term efficacy of every-two-week dosing versus recommended dosing of ixekizumab in patients who had sPGA>1 at week 12. *The British journal of dermatology*. Sep 23 2019;doi:10.1111/bjd.18550
114. European Medicines Agency. Skyrizi - EMEA/H/C/004759 - IA/0006. Accessed September 2019, <https://www.ema.europa.eu/en/medicines/human/EPAR/skyrizi#product-information-section>
115. Woods RH. Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA Adverse Event Reporting System (FAERS). *British journal of clinical pharmacology*. Nov 2 2022;doi:10.1111/bcp.15581
116. Khatri A, Cheng L, Camez A, Ignatenko S, Pang Y, Othman AA. Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis. *Clinical pharmacokinetics*. Jun 2019;58(6):805-814. doi:10.1007/s40262-018-0730-x
117. Gottlieb AB, Deodhar A, McInnes IB, et al. Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing



- Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data. *Acta dermato-venereologica*. Apr 27 2022;102:adv00698. doi:10.2340/actadv.v102.563
118. Zheng Y, Guo X, Chen C, et al. Toxicity signals associated with secukinumab: A pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database. *British journal of clinical pharmacology*. Sep 15 2022;doi:10.1111/bcp.15535
119. European Medicines Agency. Cosentyx - Summary of product characteristics (Annex I). 01/04/2016 Cosentyx -EMA/H/C/003729 -II/0008. Updated 02/05/2016 Accessed Nov 28, 2016, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003729/WC500183129.pdf
120. Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. *Arthritis research & therapy*. May 2 2019;21(1):111. doi:10.1186/s13075-019-1882-2
121. Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. *Gut*. Dec 2012;61(12):1693-700. doi:10.1136/gutjnl-2011-301668
122. Novartis Pharmaceuticals Corporation. Secukinumab (AIN457) - ADVISORY COMMITTEE BRIEFING MATERIAL: AVAILABLE FOR PUBLIC RELEASE Accessed Nov 30, 2016, <http://www.fda.gov/downloads/AdvisoryCommittees/UCM419023.pdf>
123. Swiss Specialist Information Ilumetri. 2018. www.swissmedicinfo.ch
124. Reich K, Warren RB, Iversen L, et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. *The British journal of dermatology*. Jun 19 2019;doi:10.1111/bjd.18232
125. European Medicines Agency. IlumetriTM (Tildrakizumab) Summary of product characteristics. Accessed September 2019, https://www.ema.europa.eu/documents/product-information/ilumetri-epar-product-information_en.pdf
126. Cerrone M, Wang X, Neary M, et al. Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals. *Clin Infect Dis*. Jan 18 2019;68(3):446-452. doi:<https://dx.doi.org/10.1093/cid/ciy491>
127. European Medicines Agency. Questions and answers on biosimilar medicines (similar biological medicinal products). WWW document. Accessed 13 June 2014, http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500020062.pdf
128. Gerdes S, Thaci D, Griffiths CEM, et al. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Mar 2018;32(3):420-427. doi:10.1111/jdv.14605
129. Moots RJ, Curiale C, Petersel D, Rolland C, Jones H, Mysler E. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review. *BioDrugs*. Jun 2018;32(3):193-199. doi:10.1007/s40259-018-0283-4
130. García-Beloso N, Altabás-González I, Samartín-Ucha M, et al. Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: A



- systematic literature review. *British journal of clinical pharmacology*. Feb 2022;88(4):1529-1550. doi:10.1111/bcp.15101
131. FDA Accepts BLA for Alvotech Ustekinumab Biosimilar. AJMC - The center for Biosimilars. 09.02.2023, Accessed 09.02.2023, <https://www.centerforbiosimilars.com/view/fda-accepts-bla-for-alvotech-ustekinumab-biosimilar>
132. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. *Annals of the rheumatic diseases*. Jun 2020;79(6):700-712. doi:10.1136/annrheumdis-2020-217159
133. Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. *Nat Rev Rheumatol*. Aug 2022;18(8):465-479. doi:10.1038/s41584-022-00798-0
134. Elmamoun M, Chandran V. Role of Methotrexate in the Management of Psoriatic Arthritis. *Drugs*. Apr 2018;78(6):611-619. doi:10.1007/s40265-018-0898-2
135. McInnes IB, Nash P, Ritchlin C, et al. Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis. *Journal of comparative effectiveness research*. Nov 2018;7(11):1107-1123. doi:10.2217/cer-2018-0075
136. Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. *Annals of the rheumatic diseases*. Jan 2020;79(1):123-131. doi:10.1136/annrheumdis-2019-215386
137. Nash P, McInnes IB, Mease PJ, et al. Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison. *Rheumatology and therapy*. Jun 2018;5(1):99-122. doi:10.1007/s40744-018-0106-6
138. Dressler C, Eisert L, Pham PA, Nast A. Efficacy and safety of systemic treatments in psoriatic arthritis: a systematic review, meta-analysis and GRADE evaluation. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Jul 2019;33(7):1249-1260. doi:10.1111/jdv.15482
139. Murashima A, Watanabe N, Ozawa N, Saito H, Yamaguchi K. Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant's serum. *Annals of the rheumatic diseases*. Nov 2009;68(11):1793-4. doi:10.1136/ard.2008.105924
140. Samanta J, Naidu G, Chattopadhyay A, et al. Comparison between methotrexate and apremilast in psoriatic arthritis-a single blinded randomized controlled trial (apremepsa study). Journal: Conference Abstract. *Annals of the rheumatic diseases*. 2021;80(SUPPL 1):1305-1306. doi:10.1136/annrheumdis-2021-eular.1850
141. Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. *Annals of the rheumatic diseases*. Jan 2012;71(1):4-12. doi:10.1136/annrheumdis-2011-200350
142. Nast A, Amelunxen L, Augustin M, et al. S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 2 - Special patient populations and treatment situations. *Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG*. Jun 2018;16(6):806-813. doi:10.1111/ddg.13538
143. Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. *J Am Acad Dermatol*. Apr 2019;80(4):1073-1113. doi:10.1016/j.jaad.2018.11.058



144. Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schafer I. Epidemiology and comorbidity of psoriasis in children. *The British journal of dermatology*. Mar 2010;162(3):633-6. doi:10.1111/j.1365-2133.2009.09593.x
145. Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany. *Acta dermato-venereologica*. Mar 2010;90(2):147-51. doi:10.2340/00015555-0770
146. Armstrong A, Paul C, Puig L, et al. Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. *Dermatology and therapy*. Nov 20 2019;doi:10.1007/s13555-019-00340-3
147. Feagan BG, Sandborn WJ, D'Haens G, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. *Lancet*. Apr 29 2017;389(10080):1699-1709. doi:10.1016/s0140-6736(17)30570-6
148. Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. *Lancet*. Sep 7 2019;394(10201):831-839. doi:10.1016/s0140-6736(19)31773-8
149. Whitlock SM, Enos CW, Armstrong AW, et al. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. *J Am Acad Dermatol*. Feb 2018;78(2):383-394. doi:10.1016/j.jaad.2017.06.043
150. Feagan BG, Panes J, Ferrante M, et al. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. *The lancet Gastroenterology & hepatology*. Oct 2018;3(10):671-680. doi:10.1016/s2468-1253(18)30233-4
151. Visvanathan S, Baum P, Salas A, et al. Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn's Disease: Results From a Randomised Phase II Biopsy Sub-study. *Journal of Crohn's & colitis*. Nov 9 2018;12(10):1170-1179. doi:10.1093/ecco-jcc/jjy099
152. Grossberg LB. A Case Report of Successful Treatment of Crohn's Disease and Psoriasis With Guselkumab. *Inflammatory bowel diseases*. Jun 18 2019;25(7):e84. doi:10.1093/ibd/izz033
153. Berman HS, Villa NM, Shi VY, Hsiao JL. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease. *The Journal of dermatological treatment*. Aug 25 2019;1-3. doi:10.1080/09546634.2019.1654067
154. Danese S, Neurath M, Kopon A, et al. OP006 Apremilast for active ulcerative colitis: a phase 2, randomised, double-blind, placebo-controlled induction study. *Journal of Crohn's and Colitis*. 01/16 2018;12:S004-S004. doi:10.1093/ecco-jcc/jjx180.004
155. Patel V, Wang Y, MacDonald JK, McDonald JW, Chande N. Methotrexate for maintenance of remission in Crohn's disease. *The Cochrane database of systematic reviews*. Aug 26 2014;(8):Cd006884. doi:10.1002/14651858.CD006884.pub3
156. McDonald JW, Wang Y, Tsoulis DJ, MacDonald JK, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. *The Cochrane database of systematic reviews*. Aug 6 2014;(8):Cd003459. doi:10.1002/14651858.CD003459.pub4
157. Chande N, Wang Y, MacDonald JK, McDonald JW. Methotrexate for induction of remission in ulcerative colitis. *The Cochrane database of systematic reviews*. Aug 27 2014;(8):Cd006618. doi:10.1002/14651858.CD006618.pub3
158. Herfarth H, Barnes EL, Valentine JF, et al. Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis. *Gastroenterology*. Oct 2018;155(4):1098-1108.e9. doi:10.1053/j.gastro.2018.06.046



159. Laharie D, Bourreille A, Branche J, et al. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. *Gut*. Feb 2018;67(2):237-243. doi:10.1136/gutjnl-2016-313060
160. Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Feb 2021;35(2):281-317. doi:10.1111/jdv.16926
161. Dhana A, Yen H, Yen H, Cho E. All-cause and cause-specific mortality in psoriasis: A systematic review and meta-analysis. *J Am Acad Dermatol*. May 2019;80(5):1332-1343. doi:10.1016/j.jaad.2018.12.037
162. Vaengebjerg S, Skov L, Egeberg A, Loft ND. Prevalence, Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-analysis. *JAMA dermatology*. Feb 19 2020;doi:10.1001/jamadermatol.2020.0024
163. Peleva E, Exton LS, Kelley K, Kleyn CE, Mason KJ, Smith CH. Risk of cancer in patients with psoriasis on biological therapies: a systematic review. *The British journal of dermatology*. Jan 2018;178(1):103-113. doi:10.1111/bjd.15830
164. Lebwohl M, Deodhar A, Griffiths CEM, et al. The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up. *The British journal of dermatology*. Apr 8 2021;doi:10.1111/bjd.20136
165. Thaci D, Piaserico S, Warren RB, et al. Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). *The British journal of dermatology*. Aug 2021;185(2):323-334. doi:10.1111/bjd.19866
166. Garcia-Doval I, Hernandez MV, Vanaclocha F, Sellas A, de la Cueva P, Montero D. Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts. *The British journal of dermatology*. Mar 2017;176(3):643-649. doi:10.1111/bjd.14776
167. Holroyd CR, Seth R, Bukhari M, et al. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. *Rheumatology*. Feb 1 2019;58(2):e3-e42. doi:10.1093/rheumatology/key208
168. Luo X, Deng C, Fei Y, et al. Malignancy development risk in psoriatic arthritis patients undergoing treatment: A systematic review and meta-analysis. *Seminars in arthritis and rheumatism*. Feb 2019;48(4):626-631. doi:10.1016/j.semarthrit.2018.05.009
169. Kim SC, Schneeweiss S, Liu J, et al. Biologic Disease-Modifying Antirheumatic Drugs and Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Rheumatoid Arthritis: A Cohort Study. *Arthritis & rheumatology (Hoboken, NJ)*. Sep 2016;68(9):2106-13. doi:10.1002/art.39689
170. Mercer LK, Low AS, Galloway JB, et al. Anti-TNF therapy in women with rheumatoid arthritis with a history of carcinoma in situ of the cervix. *Annals of the rheumatic diseases*. Jan 2013;72(1):143-4. doi:10.1136/annrheumdis-2012-201814
171. Micic D, Komaki Y, Alavanja A, Rubin DT, Sakuraba A. Risk of Cancer Recurrence Among Individuals Exposed to Antitumor Necrosis Factor Therapy: A Systematic Review and Meta-Analysis of Observational Studies. *Journal of clinical gastroenterology*. Jan 2019;53(1):e1-e11. doi:10.1097/mcg.0000000000000865
172. Scott FI, Mamtani R, Brensinger CM, et al. Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History



- of Autoimmune Disease and Nonmelanoma Skin Cancer. *JAMA dermatology*. Feb 2016;152(2):164-72. doi:10.1001/jamadermatol.2015.3029
173. Shelton E, Laharie D, Scott FI, et al. Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. *Gastroenterology*. Jul 2016;151(1):97-109.e4. doi:10.1053/j.gastro.2016.03.037
174. Cohen BE, Martires KJ, Ho RS. Psoriasis and the Risk of Depression in the US Population: National Health and Nutrition Examination Survey 2009-2012. *JAMA dermatology*. Jan 2016;152(1):73-9. doi:10.1001/jamadermatol.2015.3605
175. Egeberg A, Thyssen JP, Wu JJ, Skov L. Risk of first-time and recurrent depression in patients with psoriasis: a population-based cohort study. *The British journal of dermatology*. Jan 2019;180(1):116-121. doi:10.1111/bjd.17208
176. Fleming P, Roubille C, Richer V, et al. Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Jun 2015;29(6):1063-70. doi:10.1111/jdv.12909
177. Tribo MJ, Turroja M, Castano-Vinyals G, et al. Patients with Moderate to Severe Psoriasis Associate with Higher Risk of Depression and Anxiety Symptoms: Results of a Multivariate Study of 300 Spanish Individuals with Psoriasis. *Acta dermato-venereologica*. Apr 1 2019;99(4):417-422. doi:10.2340/00015555-3114
178. Abbott R, Whear R, Nikolaou V, et al. Tumour necrosis factor-alpha inhibitor therapy in chronic physical illness: A systematic review and meta-analysis of the effect on depression and anxiety. *J Psychosom Res*. Sep 2015;79(3):175-84. doi:10.1016/j.jpsychores.2015.04.008
179. Carrascosa JM, Rebollo F, Gomez S, De-la-Cueva P. Effects of etanercept on the patient-perceived results (PROs) in patients with moderate-to-severe plaque psoriasis: systematic review of the literature and meta-analysis. *The Journal of dermatological treatment*. Dec 2018;29(8):806-811. doi:10.1080/09546634.2018.1467536
180. Gordon KB, Armstrong AW, Han C, et al. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Nov 2018;32(11):1940-1949. doi:10.1111/jdv.15012
181. Griffiths CEM, Fava M, Miller AH, et al. Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies. *Psychother Psychosom*. 2017;86(5):260-267. doi:10.1159/000479163
182. Schmieder A, Poppe M, Hametner C, et al. Impact of fumaric acid esters on cardiovascular risk factors and depression in psoriasis: a prospective pilot study. *Archives of dermatological research*. Jul 2015;307(5):413-24. doi:10.1007/s00403-015-1541-7
183. Kim SJ, Park MY, Pak K, et al. Improvement of depressive symptoms in patients with moderate-to-severe psoriasis treated with ustekinumab: an open label trial validated using beck depression inventory, Hamilton depression rating scale measures and (18)fluorodeoxyglucose (FDG) positron emission tomography (PET). *The Journal of dermatological treatment*. Dec 2018;29(8):761-768. doi:10.1080/09546634.2018.1466021
184. Augustin M, Lambert J, Zema C, et al. Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials. *JAMA dermatology*. Dec 1 2020;156(12):1344-1353. doi:10.1001/jamadermatol.2020.3617
185. Strober B, Gooderham M, de Jong E, et al. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). *J Am Acad Dermatol*. Jan 2018;78(1):70-80. doi:10.1016/j.jaad.2017.08.051



186. Arican O, Sasmaz S, Ozbulut O. Increased suicidal tendency in a case of psoriasis vulgaris under acitretin treatment. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Apr 2006;20(4):464-5. doi:10.1111/j.1468-3083.2006.01447.x
187. Henderson CA, Highet AS. Depression induced by etretinate. *Bmj*. Apr 8 1989;298(6678):964. doi:10.1136/bmj.298.6678.964
188. Hayes J, Koo J. Depression and acitretin: a true association or a class labeling? *Journal of drugs in dermatology : JDD*. Apr 2011;10(4):409-12.
189. Starling J, 3rd, Koo J. Evidence based or theoretical concern? Pseudotumor cerebri and depression as acitretin side effects. *Journal of drugs in dermatology : JDD*. Nov-Dec 2005;4(6):690-6.
190. European Medicines Agency. Retinoid-containing medicinal products. <https://www.ema.europa.eu/en/medicines/human/referrals/retinoid-containing-medicinal-products>
191. European Medicines Agency. Acitretin SmPC and Patient Leaflet. The electronic medicines compendium. <https://www.medicines.org.uk/emc/product/10247/smpc>
192. Lebwohl M, Strober B, Menter A, et al. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. *New Engl J Med*. Oct 1 2015;373(14):1318-1328. doi:10.1056/NEJMoa1503824
193. Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. *The British journal of dermatology*. Aug 2016;175(2):273-86. doi:10.1111/bjd.14493
194. Beck KM, Koo J. Brodalumab for the treatment of plaque psoriasis: up-to-date. *Expert Opin Biol Ther*. Apr 2019;19(4):287-292. doi:10.1080/14712598.2019.1579794
195. European Medicines Agency. Kyntheum SmPC and Patient Leaflet. The electronic medicines compendium.
196. Crowley J, Thaci D, Joly P, et al. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥ 156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). *J Am Acad Dermatol*. Aug 2017;77(2):310-317 e1. doi:10.1016/j.jaad.2017.01.052
197. Kavanaugh A, Gladman DD, Edwards CJ, et al. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis. *Arthritis research & therapy*. May 10 2019;21(1):118. doi:10.1186/s13075-019-1901-3
198. Otezla (apremilast): New important advice regarding suicidal ideation and behaviour. Celgene Europe Limited; 2016.
199. European Medicines Agency. Summary of Risk Management Plan for Otezla (apremilast). Updated 21/07/2022. Accessed Mar 27, 2023, https://www.ema.europa.eu/en/documents/rmp-summary/otezla-epar-risk-management-plan-summary_en.pdf
200. European Medicines Agency. Otezla SmPC and Patient Leaflet. The electronic medicines compendium. <https://www.medicines.org.uk/emc/files/pil.10709.pdf>
201. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. *JAMA dermatology*. 01/ 2013;149(1):84-91.
202. Mamizadeh M, Tardeh Z, Azami M. The association between psoriasis and diabetes mellitus: A systematic review and meta-analysis. *Diabetes & metabolic syndrome*. Mar - Apr 2019;13(2):1405-1412. doi:10.1016/j.dsx.2019.01.009
203. Coto-Segura P, Eiris-Salvado N, Gonzalez-Lara L, et al. Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis. *The British journal of dermatology*. Oct 2013;169(4):783-93. doi:10.1111/bjd.12473



204. Lee MS, Lin RY, Lai MS. Increased risk of diabetes mellitus in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort study. *J Am Acad Dermatol*. Apr 2014;70(4):691-8. doi:10.1016/j.jaad.2013.11.023
205. Dregan A, Charlton J, Chowienczyk P, Gulliford MC. Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study. *Circulation*. Sep 2 2014;130(10):837-44. doi:10.1161/CIRCULATIONAHA.114.009990
206. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. *Nutr Diabetes*. / 2012;2
207. Dehpouri T, Rokni GR, Narenjbon NA, et al. Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study. *Dermatology reports*. Jan 23 2019;11(1):7965. doi:10.4081/dr.2019.7965
208. Owczarczyk-Saczonek A, Drozdowski M, Maciejewska-Radomska A, Choszcz D, Placek W. The effect of subcutaneous methotrexate on markers of metabolic syndrome in psoriatic patients - preliminary report. *Postepy dermatologii i alergologii*. Feb 2018;35(1):53-59. doi:10.5114/ada.2017.71358
209. Wu JJ, Liu L, Asgari MM, et al. Initiation of TNF inhibitor therapy and change in physiologic measures in psoriasis. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Oct 2014;28(10):1380-7. doi:10.1111/jdv.12296
210. Rosenberg P, Urwitz H, Johannesson A, et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. *J Hepatol*. 06/ 2007;46(6):1111-1118.
211. Singh JA, Guyatt G, Ogdie A, et al. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. *Arthritis care & research*. Jan 2019;71(1):2-29. doi:10.1002/acr.23789
212. Rattanakaemakorn P, Pinyowiwat P, Iamsung W, Chanprapaph K, Suchonwanit P. Incidence and Risk Factors of Hepatic Fibrosis in Psoriatic Patients Receiving Methotrexate with Concomitant Acitretin Therapy and Methotrexate Monotherapy. *Drug Des Devel Ther*. 2021;15:2299-2307. doi:<https://dx.doi.org/10.2147/DDDT.S304168>
213. Gisondi P, Cazzaniga S, Chimenti S, et al. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry. *Journal of the European Academy of Dermatology and Venereology : JEADV*. 01/ 2013;27(1):30-41.
214. Cotovio P, Neves M, Rodrigues L, et al. New-onset diabetes after transplantation: assessment of risk factors and clinical outcomes. *Transplant Proc*. 04/ 2013;45(3):1079-1083.
215. Sato T, Inagaki A, Uchida K, et al. Diabetes mellitus after transplant: relationship to pretransplant glucose metabolism and tacrolimus or cyclosporine A-based therapy. *Transplantation*. Nov 15 2003;76(9):1320-6. doi:10.1097/01.TP.0000084295.67371.11
216. Lestre S, Diamantino F, Veloso L, Fidalgo A, Ferreira A. Effects of etanercept treatment on lipid profile in patients with moderate-to-severe chronic plaque psoriasis: a retrospective cohort study. *Eur J Dermatol*. / 2011;21(6):916-920.
217. Gisondi P, Cotena C, Tessari G, Girolomoni G. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. *Journal of the European Academy of Dermatology and Venereology : JEADV*. 03/ 2008;22(3):341-344.
218. Renzo LD, Saraceno R, Schipani C, et al. Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-alpha treatment. *Dermatologic therapy*. Jul-Aug 2011;24(4):446-51. doi:10.1111/j.1529-8019.2011.01439.x



219. Gisondi P, Conti A, Galdo G, Piaserico S, De Simone C, Girolomoni G. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. *The British journal of dermatology*. 05/ 2013;168(5):1124-1127.
220. Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. *J Am Acad Dermatol*. Jan 2019;80(1):27-40. doi:10.1016/j.jaad.2018.06.057
221. da Silva BS, Bonfa E, de Moraes JC, et al. Effects of anti-TNF therapy on glucose metabolism in patients with ankylosing spondylitis, psoriatic arthritis or juvenile idiopathic arthritis. *Biologicals : journal of the International Association of Biological Standardization*. Sep 2010;38(5):567-9. doi:10.1016/j.biologicals.2010.05.003
222. Costa L, Caso F, Atteno M, et al. Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. *Clinical rheumatology*. Jun 2014;33(6):833-9. doi:10.1007/s10067-013-2369-1
223. Martinez-Abundis E, Reynoso-von Drateln C, Hernandez-Salazar E, Gonzalez-Ortiz M. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus. *Archives of dermatological research*. Nov 2007;299(9):461-5. doi:10.1007/s00403-007-0784-3
224. Kofoed K, Clemmensen A, Mikkelsen UR, Simonsen L, Andersen O, Gniadecki R. Effects of anti-tumor necrosis factor therapy on body composition and insulin sensitivity in patients with psoriasis. *Archives of dermatology*. 09/ 2012;148(9):1089-1091.
225. Campanati A, Ganzetti G, Di Sario A, et al. The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. *Journal of gastroenterology*. Jul 2013;48(7):839-46. doi:10.1007/s00535-012-0678-9
226. Marra M, Campanati A, Testa R, et al. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. *Int J Immunopathol Pharmacol*. / 2007;20(4):731-736.
227. Pina T, Armesto S, Lopez-Mejias R, et al. Anti-TNF-alpha therapy improves insulin sensitivity in non-diabetic patients with psoriasis: a 6-month prospective study. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Jul 2015;29(7):1325-30. doi:10.1111/jdv.12814
228. Al-Mutairi N, Shabaan D. Effects of tumor necrosis factor alpha inhibitors extend beyond psoriasis: insulin sensitivity in psoriasis patients with type 2 diabetes mellitus. *Cutis*. Mar 2016;97(3):235-41.
229. Gerdes S, Pinter A, Papavassiliis C, Reinhardt M. Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Oct 10 2019;doi:10.1111/jdv.16004
230. Gisondi P, Del Giglio M, Di Francesco V, Zamboni M, Girolomoni G. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. *Am J Clin Nutr*. 11/ 2008;88(5):1242-1247.
231. Jensen P, Zachariae C, Christensen R, et al. Effect of weight loss on the severity of psoriasis: a randomized clinical study. *JAMA dermatology*. 07/ 2013;149(7):795-801.
232. Naldi L, Conti A, Cazzaniga S, et al. Diet and physical exercise in psoriasis: a randomized controlled trial. *The British journal of dermatology*. Mar 2014;170(3):634-42. doi:10.1111/bjd.12735
233. Ford AR, Siegel M, Bagel J, et al. Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic Review. *JAMA dermatology*. Aug 1 2018;154(8):934-950. doi:10.1001/jamadermatol.2018.1412



234. Koenig AS, Szumski A, Pedersen R, Robertson D. Impact of Etanercept Therapy on Glycemic Control in a Cohort of Psoriatic Patients: The PRISTINE Trial. 2010.
235. Balato N, Patruno C, Napolitano M, Patri A, Ayala F, Scarpa R. Managing moderate-to-severe psoriasis in the elderly. *Drugs & aging*. Apr 2014;31(4):233-8. doi:10.1007/s40266-014-0156-6
236. Spuls PI, Witkamp L, Bossuyt PM, Bos JD. A systematic review of five systemic treatments for severe psoriasis. *The British journal of dermatology*. Dec 1997;137(6):943-9.
237. Hong JR, Lee YW, Choe YB, Ahn KJ. Risk factors for increased serum creatinine level in patients with psoriasis treated with cyclosporine in a real-world practice. *Dermatologic therapy*. May 2019;32(3):e12875. doi:10.1111/dth.12875
238. Enos CW, Ramos VL, McLean RR, et al. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry. *J Am Acad Dermatol*. January 2022;86(1):68-76. doi:<https://dx.doi.org/10.1016/j.jaad.2021.06.883>
239. Enos CW, Ramos VL, McLean RR, et al. Proportions of Biologic Discontinuation Among Psoriasis Patients With Metabolic Comorbidities. *Journal of Psoriasis and Psoriatic Arthritis*. 2022;doi:<https://dx.doi.org/10.1177/24755303221131257>
240. Van Muijen ME, Thomas SE, Vellinga D, et al. Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis. Note. *Acta dermato-venereologica*. 2022;102 (no pagination)adv00755. doi:<https://dx.doi.org/10.2340/actadv.v102.685>
241. Mendes-Bastos P, Morais P, Ferreira P, et al. Persistence, effectiveness, and real-world outcomes in psoriasis patients treated with secukinumab in Portugal. *Dermatologic therapy*. Jul 2022;35(7):e15510. doi:<https://dx.doi.org/10.1111/dth.15510>
242. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *European heart journal*. Jan 14 2020;41(3):407-477. doi:10.1093/eurheartj/ehz425
243. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *European heart journal*. Aug 1 2016;37(29):2315-2381. doi:10.1093/eurheartj/ehw106
244. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *European heart journal*. Jan 1 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455
245. Boehncke W-H, Gladman DD, Chandran V. Cardiovascular comorbidities in psoriasis and psoriatic arthritis: pathogenesis, consequences for patient management, and future research agenda: a report from the GRAPPA 2009 annual meeting. *J Rheumatol*. 03/ 2011;38(3):567-571.
246. Kimball AB, Szapary P, Mrowietz U, et al. Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. *J Am Acad Dermatol*. 07/ 2012;67(1):76-85.
247. Wakkee M, Herings RM, Nijsten T. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. *The Journal of investigative dermatology*. Apr 2010;130(4):962-7. doi:10.1038/jid.2009.321
248. Stern RS, Huibregtse A. Very severe psoriasis is associated with increased noncardiovascular mortality but not with increased cardiovascular risk. *The Journal of investigative dermatology*. May 2011;131(5):1159-66. doi:10.1038/jid.2010.399



249. Samarasekera EJ, Neilson JM, Warren RB, Parnham J, Smith CH. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. *The Journal of investigative dermatology*. Oct 2013;133(10):2340-6. doi:10.1038/jid.2013.149
250. Gaeta M, Castelvechio S, Ricci C, Pigatto P, Pellissero G, Cappato R. Role of psoriasis as independent predictor of cardiovascular disease: a meta-regression analysis. *International journal of cardiology*. Oct 3 2013;168(3):2282-8. doi:10.1016/j.ijcard.2013.01.197
251. Kaiser H, Abdulla J, Henningsen KMA, Skov L, Hansen PR. Coronary Artery Disease Assessed by Computed Tomography in Patients with Psoriasis: A Systematic Review and Meta-Analysis. *Dermatology*. 2019;235(6):478-487. doi:10.1159/000502138
252. Davidovici BB, Sattar N, Prinz JC, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. *The Journal of investigative dermatology*. 07/ 2010;130(7):1785-1796.
253. Ghazizadeh R, Shimizu H, Tosa M, Ghazizadeh M. Pathogenic mechanisms shared between psoriasis and cardiovascular disease. *Int J Med Sci*. / 2010;7(5):284-289.
254. Chappe SG, Roenigk HH, Miller AJ, Beeff DE, Tyrpin L. The effect of photochemotherapy on the cardiovascular system. *J Am Acad Dermatol*. 05/ 1981;4(5):561-566.
255. Hugh J, Van Voorhees AS, Nijhawan RI, et al. From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. *J Am Acad Dermatol*. Jan 2014;70(1):168-77. doi:10.1016/j.jaad.2013.09.020
256. Katz HI, Waalen J, Leach EE. Acitretin in psoriasis: an overview of adverse effects. *J Am Acad Dermatol*. 09/ 1999;41(3 Pt 2):7.
257. Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. *The Cochrane database of systematic reviews*. 2010;(1):CD007893. doi:10.1002/14651858.CD007893.pub2
258. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. *Lancet*. 04/06 2002;359(9313):1173-1177.
259. Prodanovich S, Prodanowich S, Ma F, et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. *J Am Acad Dermatol*. 2005;52(2):262-267.
260. Westlake SL, Colebatch AN, Baird J, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. *Rheumatology*. Feb 2010;49(2):295-307. doi:10.1093/rheumatology/kep366
261. Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. *Annals of the rheumatic diseases*. Mar 2015;74(3):480-9. doi:10.1136/annrheumdis-2014-206624
262. Ahlehoff O, Skov L, Gislasen G, et al. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Jun 2015;29(6):1128-34. doi:10.1111/jdv.12768
263. Martinez-Lopez A, Blasco-Morente G, Perez-Lopez I, Tercedor-Sanchez J, Arias-Santiago S. Studying the effect of systemic and biological drugs on intima-media thickness in patients suffering from moderate and severe psoriasis. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Sep 2018;32(9):1492-1498. doi:10.1111/jdv.14841



264. Imam F, Al-Harbi NO, Al-Harbi MM, et al. Apremilast prevent doxorubicin-induced apoptosis and inflammation in heart through inhibition of oxidative stress mediated activation of NF-kappaB signaling pathways. *Pharmacological reports : PR*. Oct 2018;70(5):993-1000. doi:10.1016/j.pharep.2018.03.009
265. Peters MJL, Watt P, Cherry L, et al. Lack of effect of TNFalpha blockade therapy on circulating adiponectin levels in patients with autoimmune disease: results from two independent prospective studies. *Annals of the rheumatic diseases*. 2010;69(9):1687-1690.
266. Strober B, Teller C, Yamauchi P, et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. *The British journal of dermatology*. 08/ 2008;159(2):322-330.
267. Gisondi P, Lora V, Bonauguri C, Russo A, Lippi G, Girolomoni G. Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab. *The British journal of dermatology*. Apr 2013;168(4):749-55. doi:10.1111/bjd.12118
268. Eder L, Joshi AA, Dey AK, et al. Association of Tumor Necrosis Factor Inhibitor Treatment With Reduced Indices of Subclinical Atherosclerosis in Patients With Psoriatic Disease. *Arthritis & rheumatology (Hoboken, NJ)*. Mar 2018;70(3):408-416. doi:10.1002/art.40366
269. Gelfand JM, Shin DB, Alavi A, et al. A Phase IV, Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U Trial). *The Journal of investigative dermatology*. Jan 2020;140(1):85-93.e2. doi:10.1016/j.jid.2019.07.679
270. Gonzalez-Cantero A, Ortega-Quijano D, Alvarez-Diaz N, et al. Impact of Biological Agents on Imaging and Biomarkers of Cardiovascular Disease in Patients with Psoriasis: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. *Journal of Investigative Dermatology*. 10 2021;141(10):2402-2411. doi:<https://dx.doi.org/10.1016/j.jid.2021.03.024>
271. Bilsborough W, Keen H, Taylor A, O'Driscoll GJ, Arnolda L, Green DJ. Anti-tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. *Rheumatol Int*. 10/ 2006;26(12):1125-1131.
272. Tam LS, Li EK, Shang Q, et al. Tumour necrosis factor alpha blockade is associated with sustained regression of carotid intima-media thickness for patients with active psoriatic arthritis: a 2-year pilot study. *Annals of the rheumatic diseases*. Apr 2011;70(4):705-6. doi:10.1136/ard.2010.131359
273. Pina T, Corrales A, Lopez-Mejias R, et al. Anti-tumor necrosis factor-alpha therapy improves endothelial function and arterial stiffness in patients with moderate to severe psoriasis: A 6-month prospective study. *The Journal of dermatology*. Nov 2016;43(11):1267-1272. doi:10.1111/1346-8138.13398
274. von Stebut E, Reich K, Thaci D, et al. Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks. *The Journal of investigative dermatology*. May 2019;139(5):1054-1062. doi:10.1016/j.jid.2018.10.042
275. Abuabara K, Lee H, Kimball AB. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. *The British journal of dermatology*. Nov 2011;165(5):1066-73. doi:10.1111/j.1365-2133.2011.10525.x
276. Leisner MZ, Lindorff Riis J, Gniadecki R, Iversen L, Olsen M. Psoriasis and risk of myocardial infarction before and during an era with biological therapy: a population-based follow-up study. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Dec 2018;32(12):2185-2190. doi:10.1111/jdv.15021



277. Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. *JAMA*. 08/24 2011;306(8):864-871.
278. Wu JJ, Poon K-YT, Channal JC, Shen AY-J. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. *Archives of dermatology*. 11/ 2012;148(11):1244-1250.
279. Ahlehoff O, Skov L, Gislasen G, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. *J Intern Med*. 02/ 2013;273(2):197-204.
280. Wu JJ, Guerin A, Sundaram M, Dea K, Cloutier M, Mulani P. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus methotrexate. *J Am Acad Dermatol*. Jan 2017;76(1):81-90. doi:10.1016/j.jaad.2016.07.042
281. Reich K, Langley RG, Lebwohl M, et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. *The British journal of dermatology*. 04/ 2011;164(4):862-872.
282. Papp KA, Griffiths CE, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. *The British journal of dermatology*. Apr 2013;168(4):844-54. doi:10.1111/bjd.12214
283. Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM. Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. *The British journal of dermatology*. Apr 2017;176(4):890-901. doi:10.1111/bjd.14964
284. Champs B, Degboe Y, Barnetche T, Cantagrel A, Ruysen-Witrand A, Constantin A. Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trials. *RMD open*. 2019;5(1):e000763. doi:10.1136/rmdopen-2018-000763
285. Rungapiromnan W, Mason KJ, Lunt M, et al. Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Oct 21 2019;doi:10.1111/jdv.16018
286. Lee MP, Desai RJ, Jin Y, Brill G, Ogdie A, Kim SC. Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis. *JAMA dermatology*. Jun 1 2019;155(6):700-707. doi:10.1001/jamadermatol.2019.0001
287. Hu S, Lin C, Cai X, et al. The Biological Disease-Modifying Antirheumatic Drugs and the Risk of Cardiovascular Events: A Systematic Review and Meta-Analysis. *Mediators of inflammation*. 2021;2021:7712587. doi:<https://dx.doi.org/10.1155/2021/7712587>
288. Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. 2015;(1468-2060 (Electronic))
289. Eder L, Wu Y, Chandran V, Cook R, Gladman DD. Incidence and predictors for cardiovascular events in patients with psoriatic arthritis. *Annals of the rheumatic diseases*. Sep 2016;75(9):1680-6. doi:10.1136/annrheumdis-2015-207980
290. Li L, Hagberg KW, Peng M, Shah K, Paris M, Jick S. Rates of Cardiovascular Disease and Major Adverse Cardiovascular Events in Patients With Psoriatic Arthritis Compared to Patients Without Psoriatic Arthritis. *J Clin Rheumatol*. Dec 2015;21(8):405-10. doi:10.1097/rhu.0000000000000306



291. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. *Revista espanola de cardiologia (English ed)*. Dec 2016;69(12):1167. doi:10.1016/j.rec.2016.11.005
292. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. *The Journal of clinical investigation*. Nov 1993;92(5):2303-12. doi:10.1172/JCI116834
293. Torre-Amione G, Bozkurt B, Deswal A, Mann DL. An overview of tumor necrosis factor alpha and the failing human heart. *Current opinion in cardiology*. May 1999;14(3):206-10.
294. Deswal A, Bozkurt B, Seta Y, et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. *Circulation*. Jun 29 1999;99(25):3224-6.
295. Coletta AP, Clark AL, Banarjee P, Cleland JG. Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH. *European journal of heart failure*. Aug 2002;4(4):559-61.
296. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, Anti TNFTACHFI. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. *Circulation*. Jul 1 2003;107(25):3133-40. doi:10.1161/01.CIR.0000077913.60364.D2
297. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. *The Cochrane database of systematic reviews*. 2011;(2):CD008794. doi:10.1002/14651858.CD008794.pub2
298. Schonmann Y, Mansfield KE, Mulick A, et al. Inflammatory skin diseases and the risk of chronic kidney disease: population-based case-control and cohort analyses. *The British journal of dermatology*. Oct 2021;185(4):772-780. doi:10.1111/bjd.20067
299. Garcia-Doval I, Carretero G, Vanaclocha F, et al. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. *Archives of dermatology*. Apr 2012;148(4):463-70. doi:10.1001/archdermatol.2011.2768
300. Friedland R, Kridin K, Cohen AD, Landau D, Ben-Amitai D. Psoriasis and Renal Disorders: A Large-Scale Population-Based Study in Children and Adults. *Dermatology*. 2022;238(5):904-909. doi:10.1159/000522228
301. Higaki A, Mahmoud AUM, Paradis P, Schiffrin EL. Role of interleukin-23/interleukin-17 axis in T-cell-mediated actions in hypertension. *Cardiovasc Res*. Apr 23 2021;117(5):1274-1283. doi:10.1093/cvr/cvaa257
302. Ormerod AD, Campalani E, Goodfield MJ, Unit BADCS. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. *The British journal of dermatology*. May 2010;162(5):952-63. doi:10.1111/j.1365-2133.2010.09755.x
303. Bath-Hextall F, Leonardi-Bee J, Somchand N, Webster A, Delitt J, Perkins W. Interventions for preventing non-melanoma skin cancers in high-risk groups. *The Cochrane database of systematic reviews*. 2007;4(4):CD005414. doi:10.1002/14651858.CD005414.pub2
304. Stuck AE, Brindley CJ, Busslinger A, Frey FJ. Pharmacokinetics of acitretin and its 13-cis metabolite in patients on haemodialysis. *British journal of clinical pharmacology*. Mar 1989;27(3):301-4.
305. Chimenti MS, Gramiccia T, Saraceno R, et al. Apremilast for the treatment of psoriasis. *Expert opinion on pharmacotherapy*. 2015;16(13):2083-94. doi:10.1517/14656566.2015.1076794
306. European Medicines Agency. Otezla SmPC and Patient Leaflet. The electronic medicines compendium. <https://www.medicines.org.uk/emc/product/10709/smpc>



307. Cada DJ, Levien TL, Baker DE. Dimethyl fumarate. *Hospital pharmacy*. Sep 2013;48(8):668-79. doi:10.1310/hpj4808-668
308. Rostami-Yazdi M, Clement B, Mrowietz U. Pharmacokinetics of anti-psoriatic fumaric acid esters in psoriasis patients. *Archives of dermatological research*. Sep 2010;302(7):531-8. doi:10.1007/s00403-010-1061-4
309. Rostami-Yazdi M, Clement B, Schmidt TJ, Schinor D, Mrowietz U. Detection of metabolites of fumaric acid esters in human urine: implications for their mode of action. *The Journal of investigative dermatology*. Jan 2009;129(1):231-4. doi:10.1038/jid.2008.197
310. Maza A, Montaudie H, Sbidian E, et al. Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. *Journal of the European Academy of Dermatology and Venereology : JEADV*. May 2011;25 Suppl 2:19-27. doi:10.1111/j.1468-3083.2011.03992.x
311. Issa N, Kukla A, Ibrahim HN. Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence. *American journal of nephrology*. 2013;37(6):602-12. doi:10.1159/000351648
312. Chadban SJ, Barraclough KA, Campbell SB, et al. KHA-CARI guideline: KHA-CARI adaptation of the KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. *Nephrology*. Mar 2012;17(3):204-14. doi:10.1111/j.1440-1797.2011.01559.x
313. Kremer JM, Pettilo GF, Hamilton RA. Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. *J Rheumatol*. Jan 1995;22(1):38-40.
314. Bressolle F, Bologna C, Kinowski JM, Sany J, Combe B. Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. *Annals of the rheumatic diseases*. Feb 1998;57(2):110-3. doi:10.1136/ard.57.2.110
315. Rheumatoid Arthritis Clinical Trial Archive Group. The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. *J Rheumatol*. Feb 1995;22(2):218-23.
316. Willner N, Storch S, Tadmor T, Schiff E. Almost a tragedy: severe methotrexate toxicity in a hemodialysis patient treated for ectopic pregnancy. *European journal of clinical pharmacology*. Mar 2014;70(3):261-3. doi:10.1007/s00228-013-1608-3
317. Le Boedec M, Marhadour T, Devauchelle-Pensec V, et al. Baseline laboratory test abnormalities are common in early arthritis but rarely contraindicate methotrexate: study of three cohorts (ESPOIR, VErA, and Brittany). *Seminars in arthritis and rheumatism*. Apr 2013;42(5):474-81. doi:10.1016/j.semarthrit.2012.08.001
318. Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. *Transplant international : official journal of the European Society for Organ Transplantation*. 2000;13(5):313-26. doi:10.1111/j.1432-2277.2000.tb01004.x
319. Ellis CN, Fradin MS, Messina JM, et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. *The New England journal of medicine*. Jan 31 1991;324(5):277-84. doi:10.1056/NEJM199101313240501
320. Tan TC, Robinson PJ. Mechanisms of calcineurin inhibitor-induced neurotoxicity. *Transplantation Reviews*. 2006;20(1):49-60. doi:<http://dx.doi.org/10.1016/j.trre.2006.02.005>
321. Arnold R, Pussell BA, Pianta TJ, Lin CS, Kiernan MC, Krishnan AV. Association between calcineurin inhibitor treatment and peripheral nerve dysfunction in renal transplant recipients. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. Sep 2013;13(9):2426-32. doi:10.1111/ajt.12324



322. Thompson CB, Sullivan KM, June CH, Thomas ED. Association between Cyclosporin Neurotoxicity and Hypomagnesemia. *Lancet*. 1984;2(8412):1116-1120.
doi:[http://dx.doi.org/10.1016/S0140-6736\(84\)91556-3](http://dx.doi.org/10.1016/S0140-6736(84)91556-3)
323. Venci JV, Gandhi MA. Dimethyl fumarate (Tecfidera): a new oral agent for multiple sclerosis. *The Annals of pharmacotherapy*. Dec 2013;47(12):1697-702.
doi:10.1177/1060028013509232
324. van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. *The New England journal of medicine*. Apr 25 2013;368(17):1658-9. doi:10.1056/NEJMc1215357
325. Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. *The New England journal of medicine*. Apr 25 2013;368(17):1657-8. doi:10.1056/NEJMc1211805
326. Stoppe M, Thoma E, Liebert UG, et al. Cerebellar manifestation of PML under fumarate and after efalizumab treatment of psoriasis. *Journal of neurology*. May 2014;261(5):1021-4.
doi:10.1007/s00415-014-7311-1
327. Sweetser MT, Dawson KT, Bozic C. Manufacturer's response to case reports of PML. *The New England journal of medicine*. Apr 25 2013;368(17):1659-61.
doi:10.1056/NEJMc1300283
328. Buttman M, Stoll G. Case reports of PML in patients treated for psoriasis. *The New England journal of medicine*. Sep 12 2013;369(11):1081. doi:10.1056/NEJMc1307680
329. Bartsch T, Rempe T, Wrede A, et al. Progressive neurologic dysfunction in a psoriasis patient treated with dimethyl fumarate. *Ann Neurol*. Oct 2015;78(4):501-14.
doi:10.1002/ana.24471
330. Nieuwkamp DJ, Murk JL, van Oosten BW, et al. PML in a patient without severe lymphocytopenia receiving dimethyl fumarate. *The New England journal of medicine*. Apr 9 2015;372(15):1474-6. doi:10.1056/NEJMc1413724
331. Dammeier N, Schubert V, Hauser TK, Bornemann A, Bischof F. Case report of a patient with progressive multifocal leukoencephalopathy under treatment with dimethyl fumarate. *BMC Neurol*. Jul 8 2015;15:108. doi:10.1186/s12883-015-0363-8
332. Hoepner R, Faissner S, Klasing A, et al. Progressive multifocal leukoencephalopathy during fumarate monotherapy of psoriasis. *Neurol Neuroimmunol Neuroinflamm*. Jun 2015;2(3):e85. doi:10.1212/nxi.0000000000000085
333. Paudyal B, Viets R, Skliut M. A case of low-dose oral methotrexate-induced reversible neurotoxicity. *AJNR American journal of neuroradiology*. Oct 2010;31(9):E77.
doi:10.3174/ajnr.A2191
334. Sommer WH, Ganiere V, Gachoud D, et al. Neurological and pulmonary adverse effects of subcutaneous methotrexate therapy. *Scandinavian journal of rheumatology*. Jul-Aug 2008;37(4):306-9. doi:10.1080/03009740801908001
335. Kaltsonoudis E, Voulgari PV, Konitsiotis S, Drosos AA. Demyelination and other neurological adverse events after anti-TNF therapy. *Autoimmunity reviews*. Jan 2014;13(1):54-8. doi:10.1016/j.autrev.2013.09.002
336. van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. *Neurology*. Dec 1996;47(6):1531-4.
337. Gregory AP, Dendrou CA, Attfield KE, et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. 10.1038/nature11307. *Nature*. Aug 23 2012;488(7412):508-11. doi:10.1038/nature11307
338. Mahil SK, Andrews TC, Brierley C, Barker JN, Smith CH. Demyelination during tumour necrosis factor antagonist therapy for psoriasis: a case report and review of the literature. *The*



Journal of dermatological treatment. Feb 2013;24(1):38-49.

doi:10.3109/09546634.2012.660520

339. Bosch X, Saiz A, Ramos-Casals M, Group BS. Monoclonal antibody therapy-associated neurological disorders. *10.1038/nrneurol.2011.1. Nature reviews Neurology.* Mar 2011;7(3):165-72. doi:10.1038/nrneurol.2011.1
340. Kay J, Fleischmann R, Keystone E, et al. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. *Annals of the rheumatic diseases.* Mar 2015;74(3):538-46. doi:10.1136/annrheumdis-2013-204195
341. Maillart E, Papeix C, Mellerio C, Bertrand A, Lubetzki C, Louapre C. Extensive and severe CNS demyelination associated with golimumab therapy. *Journal of neurology.* Sep 2016;263(9):1869-71. doi:10.1007/s00415-016-8238-5
342. Barreras P, Mealy MA, Pardo CA. TNF-alpha inhibitor associated myelopathies: A neurological complication in patients with rheumatologic disorders. *J Neurol Sci.* Feb 15 2017;373:303-306. doi:10.1016/j.jns.2017.01.023
343. Hare NC, Hunt DP, Venugopal K, et al. Multiple sclerosis in the context of TNF blockade and inflammatory bowel disease. *Qjm.* Jan 2014;107(1):51-5. doi:10.1093/qjmed/hcr237
344. Lommers E, Depierreux F, Hansen I, Dive D, Maquet P. NMOSD with anti-MOG antibodies following anti-TNFalpha therapy: A case report. *Mult Scler Relat Disord.* Nov 2018;26:37-39. doi:10.1016/j.msard.2018.08.029
345. Boggs JME, Barnes L. Demyelination during anti-tumour necrosis factor therapy for psoriasis. *Clinical and experimental dermatology.* Jul 2018;43(5):577-578. doi:10.1111/ced.13412
346. Honda Y, Otsuka A, Egawa G, et al. Multiple neurological abnormalities, including pontine hemorrhage, multiple sclerosis and aseptic meningitis, during anti-TNF-alpha therapy in psoriatic arthritis. *Eur J Dermatol.* Sep-Oct 2015;25(5):487-8. doi:10.1684/ejd.2015.2558
347. Motuzova Y, Di Sapio A, Capobianco M, et al. Peculiar Cytological Cerebrospinal Fluid Pattern in a Case of Encephalomyelitis During Anti-Tumor Necrosis Factor-alpha Therapy. *Neurol Ther.* Jun 2015;4(1):53-60. doi:10.1007/s40120-015-0027-z
348. Theibich A, Dreyer L, Magyari M, Loch H. Demyelinating neurological disease after treatment with tumor necrosis factor alpha-inhibiting agents in a rheumatological outpatient clinic: description of six cases. *Clinical rheumatology.* May 2014;33(5):719-23. doi:10.1007/s10067-013-2419-8
349. Escalas J, Knopf N, Martin-Santiago A, Calles C. Acute transverse myelitis during treatment with etanercept for severe plaque psoriasis. *J Am Acad Dermatol.* Jan 2014;70(1):e17-8. doi:10.1016/j.jaad.2013.08.047
350. Sarathchandran P, Alboudi A, AlSuwaidi R, Almadani AA. Iatrogenic transverse myelitis in a patient with rheumatoid arthritis. *BMJ Case Reports.* 2019;12(3):e227584. doi:10.1136/bcr-2018-227584
351. Baumer FM, Ouahed J, Verhave M, Rivkin MJ. Fatal Central Nervous System Disease Following First Infliximab Infusion in a Child With Inflammatory Bowel Disease. *Pediatr Neurol.* Apr 2016;57:91-4. doi:10.1016/j.pediatrneurol.2015.12.017
352. Signore SC, Brauns B, Schutze G, et al. Infliximab-Associated Chronic Inflammatory Central Nervous System Disease and Peroneal Nerve Injury in a Psoriatic Patient Refractory to Treatment: Case Report with 10-Year Follow-Up. *Case Rep Neurol.* Jan-Apr 2018;10(1):12-17. doi:10.1159/000485499



353. Bernatsky S, Renoux C, Suissa S. Demyelinating events in rheumatoid arthritis after drug exposures. *Annals of the rheumatic diseases*. Sep 2010;69(9):1691-3. doi:10.1136/ard.2009.111500
354. Kunchok A, Aksamit AJ, Jr., Davis JM, 3rd, et al. Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events. *JAMA Neurol*. Aug 1 2020;77(8):937-946. doi:10.1001/jamaneurol.2020.1162
355. Kopp TI, Delcoigne B, Arkema EV, et al. Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden. *Annals of the rheumatic diseases*. May 2020;79(5):566-572. doi:10.1136/annrheumdis-2019-216693
356. Taylor TRP, Galloway J, Davies R, Hyrich K, Dobson R. Demyelinating Events Following Initiation of Anti-TNF α Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis. *Neurol Neuroimmunol Neuroinflamm*. May 2021;8(3)doi:10.1212/nxi.0000000000000992
357. Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. *Annals of the rheumatic diseases*. Mar 2014;73(3):529-35. doi:10.1136/annrheumdis-2013-204575
358. Lozeron P, Denier C, Lacroix C, Adams D. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. *Archives of neurology*. Apr 2009;66(4):490-7. doi:10.1001/archneurol.2009.11
359. Badat Y, Meissner WG, Laharie D. Demyelination in a patient receiving ustekinumab for refractory Crohn's disease. *Journal of Crohn's & colitis*. Sep 1 2014;8(9):1138-9. doi:10.1016/j.crohns.2014.02.004
360. Fukushima T, Nakajima K, Nozawa H, et al. [A case of Crohn's disease complicated by Guillain-Barre syndrome during ustekinumab therapy]. *Nihon Shokakibyō Gakkai Zasshi*. 2019;116(4):324-329. doi:10.11405/nisshoshi.116.324
361. Acer E, Igrek A, Erdogan HK, Saracoglu ZN. Ustekinumab in psoriasis: Five-year real life experience from a single tertiary centre. *Dermatologic therapy*. Jan 9 2020:e13224. doi:10.1111/dth.13224
362. Gratton D, Szapary P, Goyal K, Fakhrazadeh S, Germain V, Saltiel P. Reversible posterior leukoencephalopathy syndrome in a patient treated with ustekinumab: case report and review of the literature. *Archives of dermatology*. Oct 2011;147(10):1197-202. doi:10.1001/archdermatol.2011.161
363. Hamadah I, Chisti MA. Axonal sensorimotor polyneuropathy after starting guselkumab. *The Journal of dermatological treatment*. Jun 2022;33(4):2371-2372. doi:10.1080/09546634.2021.1914304
364. Kolbinger F, Huppertz C, Mir A, Padova FD. IL-17A and Multiple Sclerosis: Signaling Pathways, Producing Cells and Target Cells in the Central Nervous System. *Curr Drug Targets*. 2016;17(16):1882-1893. doi:10.2174/1389450117666160307144027
365. Havrdova E, Belova A, Goloborodko A, et al. Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. *Journal of neurology*. Jul 2016;263(7):1287-95. doi:10.1007/s00415-016-8128-x
366. Diebold M, Muller S, Derfuss T, Decard BF. A case of concomitant psoriasis and multiple sclerosis: Secukinumab and rituximab exert dichotomous effects in two autoimmune conditions. *Mult Scler Relat Disord*. Jun 2019;31:38-40. doi:10.1016/j.msard.2019.03.009
367. Assefa GT, Kaneko S, Oguro H, Morita E. Treatment of psoriasis and psoriatic arthritis with secukinumab after unsatisfactory response to ustekinumab in multiple sclerosis patient. *The Journal of dermatology*. Mar 2019;46(3):e112-e113. doi:10.1111/1346-8138.14619



368. Venturini M, Zanca A, Venturuzzo A, et al. Secukinumab for patients with plaque psoriasis affected by multiple sclerosis: a mini-review with a representative case report. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Oct 30 2019;doi:10.1111/jdv.16035
369. Cortese A, Lucchetti R, Altobelli A, et al. Secukinumab may be a valid treatment option in patients with CNS demyelination and concurrent ankylosing spondylitis: Report of two clinical cases. *Mult Scler Relat Disord*. Oct 2019;35:193-195. doi:10.1016/j.msard.2019.08.006
370. Ebers GC, Bulman DE, Sadovnick AD, et al. A population-based study of multiple sclerosis in twins. *The New England journal of medicine*. Dec 25 1986;315(26):1638-42. doi:10.1056/NEJM198612253152603
371. Siva A. Asymptomatic MS. *Clinical neurology and neurosurgery*. Dec 2013;115 Suppl 1(0):S1-5. doi:10.1016/j.clineuro.2013.09.012
372. Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. *Clin Infect Dis*. Jan 15 2017;64(2):111-115. doi:10.1093/cid/ciw778
373. Desai N, Raste Y, Cooke NT, Harland CC. QuantiFERON-TB Gold testing for tuberculosis in psoriasis patients commencing anti-tumour necrosis factor alpha therapy. *The British journal of dermatology*. May 2008;158(5):1137-8. doi:10.1111/j.1365-2133.2008.08457.x
374. Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? *Clin Infect Dis*. Aug 1 2005;41 Suppl 3:S199-203. doi:10.1086/429998
375. World Health Organization. WHO Guidelines Approved by the Guidelines Review Committee. *Latent tuberculosis infection: updated and consolidated guidelines for programmatic management*. World Health Organization (c) World Health Organization 2018.; 2018.
376. Golden MP, Vikram HR. Extrapulmonary tuberculosis: an overview. *American family physician*. Nov 1 2005;72(9):1761-8.
377. Christensen WI. Genitourinary tuberculosis: review of 102 cases. *Medicine*. Sep 1974;53(5):377-90. doi:10.1097/00005792-197409000-00004
378. Simon HB, Weinstein AJ, Pasternak MS, Swartz MN, Kunz LJ. Genitourinary tuberculosis. Clinical features in a general hospital population. *The American journal of medicine*. Sep 1977;63(3):410-20. doi:10.1016/0002-9343(77)90279-0
379. National Collaborating Centre for Chronic C, Centre for Clinical Practice at, Nice,,. National Institute for Health and Clinical Excellence: Guidance. *Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for Its Prevention and Control*. National Institute for Health and Clinical Excellence (UK) Royal College of Physicians of London. Updated text, Copyright (c) 2011, National Institute for Health and Clinical Excellence.; 2011.
380. Schaberg T, Bauer T, Brinkmann F, et al. [Tuberculosis Guideline for Adults - Guideline for Diagnosis and Treatment of Tuberculosis including LTBI Testing and Treatment of the German Central Committee (DZK) and the German Respiratory Society (DGP)]. *Pneumologie (Stuttgart, Germany)*. Jun 2017;71(6):325-397. S2k-Leitlinie: Tuberkulose im Erwachsenenalter. doi:10.1055/s-0043-105954
381. Doherty SD, Van Voorhees A, Lebwohl MG, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. *J Am Acad Dermatol*. Aug 2008;59(2):209-17. doi:10.1016/j.jaad.2008.03.023



382. Arias-Guillen M, Sanchez Menendez MM, Alperi M, et al. High rates of tuberculin skin test positivity due to methotrexate therapy: False positive results? *Seminars in arthritis and rheumatism*. Dec 2018;48(3):538-546. doi:10.1016/j.semarthrit.2018.03.018
383. Cantini F, Nannini C, Niccoli L, Petrone L, Ippolito G, Goletti D. Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics. *Mediators of inflammation*. 2017;2017:8909834. doi:10.1155/2017/8909834
384. Snast I, Bercovici E, Solomon-Cohen E, et al. Active Tuberculosis in Patients with Psoriasis Receiving Biologic Therapy: A Systematic Review. *American journal of clinical dermatology*. Aug 2019;20(4):483-491. doi:10.1007/s40257-019-00432-y
385. Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections. *J Am Acad Dermatol*. Jan 2019;80(1):43-53. doi:10.1016/j.jaad.2018.06.056
386. Epstein DJ, Dunn J, Deresinski S. Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management. *Open forum infectious diseases*. Aug 2018;5(8):ofy174. doi:10.1093/ofid/ofy174
387. Fox RJ, Kita M, Cohan SL, et al. BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety. *Current medical research and opinion*. Feb 2014;30(2):251-62. doi:10.1185/03007995.2013.849236
388. Cantini F, Niccoli L, Capone A, Petrone L, Goletti D. Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. *Expert opinion on drug safety*. May 2019;18(5):415-425. doi:10.1080/14740338.2019.1612872
389. Crowley J, Thaci D, Joly P, et al. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for >=156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). *Clinical Trial, Phase III Randomized Controlled Trial*. *J Am Acad Dermatol*. Aug 2017;77(2):310-317.e1. doi:<https://dx.doi.org/10.1016/j.jaad.2017.01.052>
390. Baddley JW, Cantini F, Goletti D, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-alpha agents). *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. Jun 2018;24 Suppl 2:S10-s20. doi:10.1016/j.cmi.2017.12.025
391. Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. Review. *J Rheumatol Suppl*. May 2014;91:47-55. doi:<https://dx.doi.org/10.3899/jrheum.140102>
392. Winthrop KL, Mariette X, Silva JT, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases*. Jun 2018;24 Suppl 2:S21-s40. doi:10.1016/j.cmi.2018.02.002
393. Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-



- term extension studies. *Rheumatology*. Oct 2014;53(10):1872-85.
doi:10.1093/rheumatology/keu172
394. Elewski BE, Baddley JW, Deodhar AA, et al. Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis. *JAMA dermatology*. 2021;157(1):43-51. doi:10.1001/jamadermatol.2020.3257
395. Crowley JJ, Warren RB, Cather JC. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. *Journal of the European Academy of Dermatology and Venereology : JEADV*. Sep 2019;33(9):1676-1684. doi:10.1111/jdv.15653
396. Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. *Lancet*. Aug 25 2018;392(10148):650-661. doi:10.1016/s0140-6736(18)31713-6
397. Boyd AS, Morris LF, Phillips CM, Menter MA. Psoriasis and pregnancy: hormone and immune system interaction. *International journal of dermatology*. 1996/03 1996;35(3):169-172. doi:10.1111/j.1365-4362.1996.tb01632.x
398. Murase JE, Chan KK, Garite TJ, Cooper DM, Weinstein GD. Hormonal effect on psoriasis in pregnancy and post partum. *Archives of dermatology*. 2005/05 2005;141(5):601-606. doi:10.1001/archderm.141.5.601
399. Bobotsis R, Gulliver WP, Monaghan K, Lynde C, Fleming P. Psoriasis and adverse pregnancy outcomes: a systematic review of observational studies. *The British journal of dermatology*. 2016/09 2016;175(3):464-472. doi:10.1111/bjd.14547
400. Yang Y-W, Chen C-S, Chen Y-H, Lin H-C. Psoriasis and pregnancy outcomes: a nationwide population-based study. *J Am Acad Dermatol*. 2011/01 2011;64(1):71-77. doi:10.1016/j.jaad.2010.02.005
401. Lima XT, Janakiraman V, Hughes MD, Kimball AB. The impact of psoriasis on pregnancy outcomes. *The Journal of investigative dermatology*. 2012/01 2012;132(1):85-91. doi:10.1038/jid.2011.271
402. Bandoli G, Johnson DL, Jones KL, et al. Potentially modifiable risk factors for adverse pregnancy outcomes in women with psoriasis. *The British journal of dermatology*. 2010/08 2010;163(2):334-339. doi:10.1111/j.1365-2133.2010.09899.x
403. European Medicines Agency. Acitretin 25mg Capsules - Summary of Product Characteristics (SmPC) - (emc). Accessed 2019/12/19, <https://www.medicines.org.uk/emc/product/5264/smpc>
404. European Medicines Agency. Otezla 30 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC) - (emc). Accessed 2019/12/19, <https://www.medicines.org.uk/emc/product/3648/smpc>
405. Rademaker M, Agnew K, Andrews M, et al. Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. *Australas J Dermatol*. 2018/05 2018;59(2):86-100. doi:10.1111/ajd.12641
406. Gerosa M, Argolini LM, Artusi C, Chighizola CB. The use of biologics and small molecules in pregnant patients with rheumatic diseases. *Expert Rev Clin Pharmacol*. 2018/10 2018;11(10):987-998. doi:10.1080/17512433.2018.1525293
407. European Medicines Agency. Neoral Soft Gelatin Capsules - Summary of Product Characteristics (SmPC) - (emc). Accessed 2019/12/19, <https://www.medicines.org.uk/emc/product/1034/smpc>
408. European Medicines Agency. Skilarence 30 mg Gastro-resistant Tablets - Summary of Product Characteristics (SmPC) - (emc). Accessed 2019/12/19, https://www.ema.europa.eu/en/documents/product-information/dimethyl-fumarate-polpharma-epar-product-information_en.pdf



409. Mrowietz U, Barker J, Boehncke WH, et al. Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus. *Journal of the European Academy of Dermatology and Venereology: JEADV*. 2018/10 2018;32 Suppl 3:3-14. doi:10.1111/jdv.15218
410. Verberne EA, de Haan E, van Tintelen JP, Lindhout D, van Haelst MM. Fetal methotrexate syndrome: A systematic review of case reports. *Reprod Toxicol*. 2019 2019;87:125-139. doi:10.1016/j.reprotox.2019.05.066
411. European Medicines Agency. Methotrexate 2.5mg Tablets - Summary of Product Characteristics (SmPC) - (emc). Accessed 19.12.2019, <https://www.medicines.org.uk/emc/product/511/smpc>
412. European Medicines Agency. Nordimet - EPAR. Accessed 17.02.2020, <https://www.ema.europa.eu/en/medicines/human/EPAR/nordimet>
413. Warren RB, Weatherhead SC, Smith CH, et al. British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. *The British journal of dermatology*. 2016/07 2016;175(1):23-44. doi:10.1111/bjd.14816
414. Smith CH, Jabbar-Lopez ZK, Yiu ZZ, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. *The British journal of dermatology*. Sep 2017;177(3):628-636. doi:10.1111/bjd.15665
415. Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. *The American journal of gastroenterology*. 2009/01 2009;104(1):228-233. doi:10.1038/ajg.2008.71
416. Malek A, Sager R, Kuhn P, Nicolaidis KH, Schneider H. Evolution of maternofetal transport of immunoglobulins during human pregnancy. *Am J Reprod Immunol*. 1996/11 1996;36(5):248-255. doi:10.1111/j.1600-0897.1996.tb00172.x
417. Pottinger E, Woolf RT, Exton LS, Burden AD, Nelson-Piercy C, Smith CH. Exposure to biological therapies during conception and pregnancy: a systematic review. *The British journal of dermatology*. 2018 2018;178(1):95-102. doi:10.1111/bjd.15802
418. Ferrante M, Vermeire S, Rutgeerts PJ. Drug safety evaluation of certolizumab pegol. *Expert opinion on drug safety*. 2014/02 2014;13(2):255-266. doi:10.1517/14740338.2014.851666
419. Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. *Clin Gastroenterol Hepatol*. 2013/03 2013;11(3):286-292; quiz e24. doi:10.1016/j.cgh.2012.11.011
420. Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. *Annals of the rheumatic diseases*. 2018 2018;77(2):228-233. doi:10.1136/annrheumdis-2017-212196
421. Clowse ME, Förger F, Hwang C, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. *Annals of the rheumatic diseases*. 2017/11 2017;76(11):1890-1896. doi:10.1136/annrheumdis-2017-211384
422. Carman WJ, Accortt NA, Anthony MS, Iles J, Enger C. Pregnancy and infant outcomes including major congenital malformations among women with chronic inflammatory arthritis or psoriasis, with and without etanercept use. *Pharmacoepidemiol Drug Saf*. 2017/09 2017;26(9):1109-1118. doi:10.1002/pds.4261
423. Burmester GR, Landewé R, Genovese MC, et al. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid



- arthritis. *Annals of the rheumatic diseases*. 2017/02 2017;76(2):414-417.
doi:10.1136/annrheumdis-2016-209322
424. Bröms G, Granath F, Stephansson O, Kieler H. Preterm birth in women with inflammatory bowel disease - the association with disease activity and drug treatment. *Scand J Gastroenterol*. 2016/12 2016;51(12):1462-1469. doi:10.1080/00365521.2016.1208269
425. Bröms G, Granath F, Ekblom A, et al. Low Risk of Birth Defects for Infants Whose Mothers Are Treated With Anti-Tumor Necrosis Factor Agents During Pregnancy. *Clin Gastroenterol Hepatol*. 2016/02 2016;14(2):234-241.e1-5. doi:10.1016/j.cgh.2015.08.039
426. Luu M, Benzenine E, Doret M, et al. Continuous Anti-TNF α Use Throughout Pregnancy: Possible Complications For the Mother But Not for the Fetus. A Retrospective Cohort on the French National Health Insurance Database (EVASION). *The American journal of gastroenterology*. 2018 2018;113(11):1669-1677. doi:10.1038/s41395-018-0176-7
427. Casanova MJ, Chaparro M, Domènech E, et al. Safety of thiopurines and anti-TNF- α drugs during pregnancy in patients with inflammatory bowel disease. *The American journal of gastroenterology*. 2013/03 2013;108(3):433-440. doi:10.1038/ajg.2012.430
428. Cooper WO, Cheetham TC, Li D-K, et al. Brief report: Risk of adverse fetal outcomes associated with immunosuppressive medications for chronic immune-mediated diseases in pregnancy. *Arthritis & rheumatology (Hoboken, NJ)*. 2014/02 2014;66(2):444-450. doi:10.1002/art.38262
429. Weber-Schoendorfer C, Oppermann M, Wacker E, et al. Pregnancy outcome after TNF- α inhibitor therapy during the first trimester: a prospective multicentre cohort study. *British journal of clinical pharmacology*. 2015/10 2015;80(4):727-739. doi:10.1111/bcp.12642
430. Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, Ornoy A. Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study. *Reprod Toxicol*. 2014/01 2014;43:78-84. doi:10.1016/j.reprotox.2013.11.004
431. Schnitzler F, Fidler H, Ferrante M, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. *Inflammatory bowel diseases*. 2011/09 2011;17(9):1846-1854. doi:10.1002/ibd.21583
432. Seirafi M, de Vroey B, Amiot A, et al. Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease. *Aliment Pharmacol Ther*. 2014/08 2014;40(4):363-373. doi:10.1111/apt.12833
433. Verstappen SMM, King Y, Watson KD, Symmons DPM, Hyrich KL, Bsrbr Control Centre Consortium BSRBR. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. *Annals of the rheumatic diseases*. 2011/05 2011;70(5):823-826. doi:10.1136/ard.2010.140822
434. Clowse MEB, Scheuerle AE, Chambers C, et al. Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database. *Arthritis & rheumatology (Hoboken, NJ)*. 2018 2018;70(9):1399-1407. doi:10.1002/art.40508
435. Parsch EM, Ruzicka T, Przybilla B, Schill WB. Andrological investigations in men treated with acitretin (Ro 10-1670). *Andrologia*. 1990/10 1990;22(5):479-482. doi:10.1111/j.1439-0272.1990.tb02034.x
436. Geiger JM, Walker M. Is there a reproductive safety risk in male patients treated with acitretin (neotigason/soriatane)? *Dermatology (Basel)*. 2002 2002;205(2):105-107. doi:10.1159/000063893
437. Mouyis M, Flint JD, Giles IP. Safety of anti-rheumatic drugs in men trying to conceive: A systematic review and analysis of published evidence. *Seminars in arthritis and rheumatism*. 2019 2019;48(5):911-920. doi:10.1016/j.semarthrit.2018.07.011



438. Semet M, Paci M, Saias-Magnan J, et al. The impact of drugs on male fertility: a review. *Andrology*. 2017 2017;5(4):640-663. doi:10.1111/andr.12366
439. Egeberg A, Gislason GH, Nast A. Birth Outcomes in Children Fathered by Men Treated with Immunosuppressant Drugs before Conception-A Danish Population-Based Cohort Study. *The Journal of investigative dermatology*. 2017 2017;137(8):1790-1792. doi:10.1016/j.jid.2017.03.030
440. Pandhi D, Gupta R, Singal A. Gynaecomastia with oligospermia: an unusual complication of low-dose methotrexate for pustular psoriasis. *Clinical and experimental dermatology*. 2006/01 2006;31(1):138-140. doi:10.1111/j.1365-2230.2005.01925.x
441. Sussman A, Leonard JM. Psoriasis, methotrexate, and oligospermia. *Archives of dermatology*. 1980/02 1980;116(2):215-217.
442. El-Beheiry A, El-Mansy E, Kamel N, Salama N. Methotrexate and fertility in men. *Arch Androl*. 1979 1979;3(2):177-179. doi:10.3109/01485017908985067
443. Grunnet E, Nyfors A, Hansen KB. Studies of human semen in topical corticosteroid-treated and in methotrexate-treated psoriatics. *Dermatologica*. 1977 1977;154(2):78-84. doi:10.1159/000251036
444. Eck LK, Jensen TB, Mastrogiannis D, et al. Risk of Adverse Pregnancy Outcome After Paternal Exposure to Methotrexate Within 90 Days Before Pregnancy. *Obstet Gynecol*. 2017 2017;129(4):707-714. doi:10.1097/AOG.0000000000001936
445. Winter RW, Larsen MD, Magnussen B, Friedman S, Kammerlander H, Nørgård BM. Birth outcomes after preconception paternal exposure to methotrexate: A nationwide cohort study. *Reprod Toxicol*. 2017 2017;74:219-223. doi:10.1016/j.reprotox.2017.10.004
446. Friedman S, Larsen MD, Magnussen B, Jølvig LR, de Silva P, Nørgård BM. Paternal use of azathioprine/6-mercaptopurine or methotrexate within 3 months before conception and long-term health outcomes in the offspring-A nationwide cohort study. *Reprod Toxicol*. 2017 2017;73:196-200. doi:10.1016/j.reprotox.2017.08.013
447. Puchner R, Danninger K, Puchner A, Pieringer H. Impact of TNF-blocking agents on male sperm characteristics and pregnancy outcomes in fathers exposed to TNF-blocking agents at time of conception. *Clin Exp Rheumatol*. 2012/10 2012;30(5):765-767.
448. Zimmermann P, Curtis N. Factors That Influence the Immune Response to Vaccination. *Clin Microbiol Rev*. Mar 20 2019;32(2)doi:10.1128/cmr.00084-18
449. Liew SY, Tree T, Smith CH, Mahil SK. The Impact of Immune-Modifying Treatments for Skin Diseases on the Immune Response to COVID-19 Vaccines: a Narrative Review. *Curr Dermatol Rep*. 2022;11(4):263-288. doi:10.1007/s13671-022-00376-3
450. Lee A, Wong SY, Chai LYA, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. *Bmj*. Mar 2 2022;376:e068632. doi:10.1136/bmj-2021-068632
451. Laudeman E. Revised IPC Statement on COVID-19. International Psoriasis Council. 09.03.2023, 09.03.2023. <https://www.psoriasisCouncil.org/covid-19/revised-statement-covid-19/>
452. Parker EPK, Desai S, Marti M, et al. Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid review. *Lancet Glob Health*. Mar 2022;10(3):e326-e328. doi:10.1016/s2214-109x(21)00593-3
453. Skaria TG, Sreepakash A, Umesh R, et al. Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised controlled trials. *Lancet Rheumatol*. Nov 2022;4(11):e755-e764. doi:10.1016/s2665-9913(22)00228-4
454. Abhishek A, Boyton RJ, Peckham N, et al. Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity



in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial. *Lancet Respir Med*. Sep 2022;10(9):840-850. doi:10.1016/s2213-2600(22)00186-2 455. Goss SL, Klein CE, Jin Z, et al. Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial. *Clin Ther*. Feb 2018;40(2):309-319. doi:10.1016/j.clinthera.2018.01.002 456. Strik AS, van den Brink GR, Ponsioen C, Mathot R, Lowenberg M, D'Haens GR. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. *Aliment Pharmacol Ther*. Apr 2017;45(8):1128-1134. doi:10.1111/apt.13994 457. Van der Kraaij GE, et al. EADV Congress Poster, FC02.06. 2019.



XIII. Abbreviations

AAD	American Academy of Dermatology
ADA	Anti-drug antibodies
ADR	Adverse drug reactions
AE	Adverse event
ANA	Antinuclear antibodies
BCG	Bacillus Calmette-Guérin
BID	Twice daily
BIW	Twice weekly
BSA	Body surface area
CHF	Congestive heart failure
CI	Confidence interval
CKD	Chronic kidney disease
CS	Consensus statement
CSF	Cerebrospinal fluid
CsA	Ciclosporin
CV	Cardiovascular
DMF	Dimethylfumarate
DLQI	Dermatology Life Quality Index
DMARD	Disease-modifying antirheumatic drugs
EDF	European Dermatology Forum
EMA	European Medicines Agency
EOW	Every other week
FUM	Fumarates
GFR	Glomerular filtration rate
GL	Guideline
GRADE	Grading of Recommendations Assessment, Development, and Evaluation
HAART	Highly active antiretroviral therapy
HBV	Hepatitis B virus
HCV	Hepatitis C virus
HDL	High-density lipoprotein
HPV	Human papilloma virus
HOMA	Homeostasis Model Assessment
HRQoL	Health-Related Quality of Life
IBD	Inflammatory bowel disease
IFPA	International Federation of Psoriasis Associations
IGRA	Interferon-gamma-release assay
IL	Interleukin
LDL	Low-density lipoprotein
LTBI	Latent tuberculosis infection
MACE	Major adverse cardiac event
MEF	Monoethylfumarate
MI	Myocardial infarction



MID	Minimal important difference
MS	Multiple sclerosis
MTX	Methotrexate
NMA	Network meta-analysis
NMSC	non-melanoma skin cancer
NSAID	Nonsteroidal anti-inflammatory drugs
NYHA	New York Heart Association
OR	Odds ratio
PASI	Psoriasis Area and Severity Index
PBO	Placebo
PGA	Physician's Global Assessment
PIIINP	Procollagen type III N-terminal peptide
PML	Progressive multifocal leukoencephalopathy
PRAC	Pharmacovigilance Risk Assessment Committee
PsA	Psoriatic arthritis
PUVA	Psoralen plus UV-A
PY	Person years
Q2W	Every 2 weeks
Q4W	Every 4 weeks
QD	Once daily
QUICKI	Quantitative Insulin Sensitivity Check Index
QW	Once weekly
RA	Rheumatoid arthritis
RCT	Randomized controlled trial
RPLS	Reversible posterior leukoencephalopathy syndrome
RR	Risk ratio
SAE	Serious adverse event
SmPC	Summary of product characteristics
SR	Systematic review
SUCRA	Surface under the cumulative ranking curve
TB	Tuberculosis
TNFi	TNF inhibitor
TST	Tuberculin skin test